SAMPLING AND MASS SPECTROMETRY APPROACHES FOR THE DETECTION OF DRUGS AND FOREIGN CONTAMINANTS IN BREATH FOR HOMELAND SECURITY APPLICATIONS by Martin, A N
LLNL-TH-410574
SAMPLING AND MASS
SPECTROMETRY APPROACHES FOR
THE DETECTION OF DRUGS AND
FOREIGN CONTAMINANTS IN BREATH
FOR HOMELAND SECURITY
APPLICATIONS
A. N. Martin
February 13, 2009
Disclaimer 
 
This document was prepared as an account of work sponsored by an agency of the United States 
government. Neither the United States government nor Lawrence Livermore National Security, LLC, 
nor any of their employees makes any warranty, expressed or implied, or assumes any legal liability or 
responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or 
process disclosed, or represents that its use would not infringe privately owned rights. Reference herein 
to any specific commercial product, process, or service by trade name, trademark, manufacturer, or 
otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the 
United States government or Lawrence Livermore National Security, LLC. The views and opinions of 
authors expressed herein do not necessarily state or reflect those of the United States government or 
Lawrence Livermore National Security, LLC, and shall not be used for advertising or product 
endorsement purposes. 
 
 
 
This work performed under the auspices of the U.S. Department of Energy by Lawrence Livermore 
National Laboratory under Contract DE-AC52-07NA27344. 
 
  
 
 
 
 
 
 
SAMPLING AND MASS SPECTROMETRY APPROACHES FOR THE 
DETECTION OF DRUGS AND FOREIGN CONTAMINANTS IN BREATH FOR 
HOMELAND SECURITY APPLICATIONS 
 
By 
 
Audrey Noreen Martin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A DISSERTATION 
 
Submitted to 
Michigan State University 
in partial fulfillment of the requirements 
for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
Chemistry 
 
2009  
  
ABSTRACT 
 
SAMPLING AND MASS SPECTROMETRY APPROACHES FOR THE DETECTION 
OF DRUGS AND FOREIGN CONTAMINANTS IN BREATH FOR HOMELAND 
SECURITY APPLICATIONS 
 
By 
 
Audrey Noreen Martin 
 
Homeland security relies heavily on analytical chemistry to identify suspicious materials 
and persons.  Traditionally this role has focused on attribution, determining the type and 
origin of an explosive, for example.  But as technology advances, analytical chemistry 
can and will play an important role in the prevention and preemption of terrorist attacks.  
More sensitive and selective detection techniques can allow suspicious materials and 
persons to be identified even before a final destructive product is made.  The work 
presented herein focuses on the use of commercial and novel detection techniques for 
application to the prevention of terrorist activities. 
Although drugs are not commonly thought of when discussing terrorism, narcoterrorism 
has become a significant threat in the 21st century.  The role of the drug trade in the 
funding of terrorist groups is prevalent; thus, reducing the trafficking of illegal drugs can 
play a role in the prevention of terrorism by cutting off much needed funding.  To do so, 
sensitive, specific, and robust analytical equipment is needed to quickly identify a 
suspected drug sample no matter what matrix it is in.  Single Particle Aerosol Mass 
Spectrometry (SPAMS) is a novel technique that has previously been applied to 
biological and chemical detection.  The current work applies SPAMS to drug analysis, 
identifying the active ingredients in single component, multi-component, and multi-tablet 
drug samples in a relatively non-destructive manner.  In order to do so, a sampling 
  
apparatus was created to allow particle generation from drug tablets with on-line 
introduction to the SPAMS instrument.  Rules trees were developed to automate the 
identification of drug samples on a single particle basis. 
A novel analytical scheme was also developed to identify suspect individuals based on 
chemical signatures in human breath.  Human breath was sampled using an RTube™ and 
the trace volatile organic compounds (VOCs) were preconcentrated using solid phase 
microextraction (SPME) and identified using gas chromatography – mass spectrometry 
(GC-MS).  Modifications to the sampling apparatus allowed for increased VOC 
collection efficiency, and reduced the time of sampling and analysis by over 25%.  The 
VOCs are present in breath due to either endogenous production, or exposure to an 
external source through absorption, inhalation, or ingestion.  Detection of these 
exogenous chemicals can provide information on the prior location and activities of the 
subject.  Breath samples collected before and after exposure in a hardware store and nail 
salon were analyzed to investigate the prior location of a subject; breath samples 
collected before and after oral exposure to terpenes and terpenoid compounds, 
pseudoephedrine, and inhalation exposure to hexamine and other explosive related 
compounds were analyzed to investigate the prior activity of a subject.  The elimination 
of such compounds from the body was also monitored.  In application, this technique 
may provide an early warning system to identify persons of interest in the prevention and 
preemption stages of homeland security. 
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CHAPTER 1: Introduction 
1-1: Motivations 
Protection of the public from threats of violence in the 21st century is based upon the 
principles of deterrence, prevention, preemption, crisis management, consequence 
management, attribution, and response.1  Deterrence of violence involves actions that 
prevent the terrorist from planning an attack.2  These actions can include fear of 
retribution, as seen in the nuclear arms race of the Cold War.  Prevention is needed when 
deterrence fails and a terrorist group moves ahead with an attack plan.  Prevention takes 
place at ports of entry, border checkpoints, and in many law enforcement actions that can 
stop or mitigate a planned attack.3  Preemption follows closely with prevention, and aims 
to stop an attack before it occurs.  This often includes an action, such as a raid by law 
enforcement, to disrupt the action of the terrorist.4  If an attack does occur, crisis and 
consequence management become key functions in the protection of public safety.  
Strong leadership is required to coordinate multiple agencies responding to a crisis and 
ensure information is shared.  Consequence management attempts to mitigate the effects 
of an attack.  This occurs simultaneously with crisis management, and for example, 
would involve the coordination and actions of public health personnel after a biological 
attack.  Attributing a terrorist attack involves identifying and confirming the parties who 
participated in the event.5  This involves not only the forensic analysis of the scene of the 
attack, but also analysis of money and paper trails that may identify silent partners.6  The 
ability to quickly and effectively attribute an attack also feeds back into deterrence, as 
being identified as the attackers may prevent an organization from planning an attack.  
Finally, response to violence is the final principle of protecting the public.  It includes not 
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only focusing on the current identified threat, but also preventing potential criminals and 
terrorists from engaging in future violent activity.  All of the principles rely on studying 
the aggressors, i.e., the social science of studying the psychology of terrorist groups, 
identifying the aggressors, i.e., law enforcement efforts, as well as the science and 
technology of understanding and identifying the threats. 
The science and technology necessary for protecting the public from violence relies 
heavily on analytical chemistry to identify suspicious materials and persons.  
Traditionally this role has been more in the attribution phase, determining the type and 
origin of an explosive, for example.  But, as technology has advanced and new 
techniques have been created, analytical chemistry can and will play an important role in 
the prevention and preemption of terrorist attacks.  More sensitive and selective detection 
techniques can allow suspicious materials to be identified even before a final destructive 
product is made.  The work presented herein focuses on the use of commercial and novel 
detection techniques for application to the prevention of terrorist activities. 
1-2: Overview 
Chapter 2 will discuss advances in the detection of drugs using Single Particle Aerosol 
Mass Spectrometry (SPAMS), which is a rapid, sensitive, and information-rich analytical 
tool.  Although drugs are not commonly thought of when discussing terrorism, 
narcoterrorism has become a significant threat in the 21st century.  The role of the illicit 
drug trade in the funding of terrorist groups is prevalent, thus, reducing the trafficking of 
illegal drugs can play a role in the prevention of terrorism by cutting off much needed 
funding.  To do so, sensitive, specific, and robust analytical equipment is needed to 
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quickly identify a suspected drug sample no matter what matrix it is in.  SPAMS is a 
novel technique that has previously been applied to biological and chemical detection; 
this chapter will discuss efforts to apply the technique to the identification of a variety of 
constituents in drug tablets. 
Chapters 3 and 4 will discuss a novel analytical scheme to identify potential terrorists and 
criminals using a commercial gas chromatography-mass spectrometry (GC-MS) system.  
Human breath is sampled, breath constituents are concentrated, and the sensitivity of the 
GC-MS allows for trace volatile organic compounds (VOCs) to be identified in the 
breath.  These VOCs are present in breath owing either to their production in vivo, or 
exposure to an external source of VOCs through absorption, inhalation, or ingestion.  
Those chemicals arising from exposure can provide information about the prior location 
and activities of the subject; thus, activities such as synthesis of explosive materials may 
be detected through analysis of substances in breath.  In application, this technique may 
provide an early warning system to identify persons of interest in the prevention and 
preemption stages of homeland security.  Chapter 3 will discuss the development of the 
analytical method, including instrument settings, breath sampling procedures and 
optimization, as well as repeatability of the analysis.  Chapter 4 will present findings 
from several experiments when a subject had a known chemical exposure.  Information 
on the uptake and decay of several VOCs is included in this chapter. 
Chapter 5 will summarize conclusions from this body of work, as well as milestones that 
have been achieved.  Information about the potential applications of the techniques 
developed in these studies will be included. 
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CHAPTER 2: Single Particle Aerosol Mass Spectrometry of Drug Samples 
2-1: Motivations and Introduction 
The manufacture, sale, and use of legal and illegal drugs are major issues in the world 
today.  The science of pharmaceutical development and quality control/quality assurance 
has consistently been a pursuit of the chemist.  Analytical techniques that can identify the 
active and inactive ingredients of legal drugs, including over-the-counter and prescription 
medications, are necessary as it critical to know the components in the drug formulation 
and optimize the efficacy of a treatment.  Counterfeit prescription drug synthesis and sale 
is increasingly becoming a major problem,7 especially with the increase in the number 
and availability of online pharmacies and rising drug prices.  For example, a study that 
analyzed anti-malarial formulations marketed as containing chloroquine as the active 
ingredient obtained from street vendors in Cameroon determined that 32% of the samples 
analyzed were counterfeit and contained no chloroquine.8  The lack of active ingredient 
in such drugs can cause the spread of diseases such as malaria, and well as create new 
health concerns. 
The motivation for the analysis of illegal drugs is more criminal in nature.  The active 
and inactive ingredients are still important to identify, but many byproducts, cutting 
agents, and contaminants are usually present in illegal drugs, as synthesis is often done 
with off the shelf ingredients and apparati, in clandestine locations.  These ingredients 
may confound the analysis, thus insensitivity to matrix effects is an important quality of 
an analytical technique.  Another aspect of detecting illicit drugs is that the criminal may 
attempt to destroy evidence before analysis, such as rinsing the drugs down the drain or 
destroying them in some manner.  Analysis of residual particles would then be 
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advantageous to determine what the prior contents of a bottle or distillation flask were, or 
the identity of a powder on the floor or table of a suspected drug house. 
Drug trade contributes to the threat of terrorism as profits from drug exportation and sale 
often fund organizations that commit violence against the public.  For example, the 
Revolutionary Armed Forces of Colombia, FARC, is accused of being a narcoterrorist 
organization, monetarily benefiting from the production and sale of cocaine.9  It is 
important to have an analytical technique that can identify illicit drugs with speed, 
sensitivity, and selectivity in any environment, including border crossings to prevent the 
importation of illegal drugs into the United States and combat the drug trade. 
This chapter will describe efforts made to use the Single Particle Aerosol Mass 
Spectrometer to detect and identify drugs.  For safety and regulatory reasons, over-the-
counter drugs are used in lieu of illicit drugs, but the results are transferable across 
different classes of drugs.  Several over-the-counter drugs such as pseudoephedrine are 
used as starting materials in the synthesis of illegal drugs, thus their identification is 
important for identifying processes used in clandestine synthesis of drugs.  Also, many 
over-the-counter drug formulations are used as cutting agents in counterfeit and illegal 
drugs, so their identification would aid investigators identify tablets and their sources. An 
anti-malarial drug is also analyzed as proof-of-concept for counterfeit drug detection. 
 
2-2: Background on Drug Analysis  
Sensitive and specific analysis of drug tablets has a broad range of applications including 
pharmaceutical quality control and forensic analysis of counterfeit drugs or illicit 
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substances.  In a pharmaceutical context, it is important to identify the drug ingredient as 
well as any impurities that affect quality control.  In forensic investigations, it is 
important to identify the drug ingredients and impurities while maintaining the physical 
integrity of a tablet.  Both industries depend on fast and accurate analytical methods in 
order to process a large sample load. 
Preliminary forensic tests of a tablet rely first on visual inspection to identify any 
differences in shape, color, or markings from an authentic pill, or similarities to other 
drug seizures for prosecution reasons.7, 10  Confirmatory testing requires that the active 
ingredient be identified and characterized.  In fact, the World Health Organization 
(WHO) states that “the principal requirement for a suitable screening procedure is the 
identification of the active drug substance”.10  To this end, forensic laboratories as well as 
pharmaceutical companies are faced with an ever increasing sample load, stressing the 
importance of fast high-throughput analysis.  Thus, a simple, fast detection system with 
little sample preparation that can identify the active ingredient in a tablet while 
preserving the integrity of its structure and visual identifiers would be advantageous. 
Several methods have been used to separate and/or detect drug samples alone, as 
mixtures, or in complex samples.  Capillary electrophoresis11, 12  and infrared (IR) 
spectroscopy have often been used for drug detection, although sample preparation can 
be time-consuming.13-15  To circumvent this issue, near IR reflectance spectroscopy has 
been used to directly analyze drug tablets.13, 15  While sensitive, the main limitation to IR 
is the training required for the interpretation of the complex spectra the technique yields.  
Gas and liquid chromatography (GC and LC)16-18 have both been used for drug analysis 
when coupled to mass spectrometry (MS). The most common technique currently in use 
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for drug analysis is GC-MS.  This technique has the advantage of providing orthogonal 
data from one analytical scheme which fulfills the Scientific Working Group for the 
Analysis of Seized Drugs (SWGDRUG) recommendations for forensic analysis of seized 
drugs.19  The main drawbacks of GC-MS are that an extraction step is required which 
lengthens the time of analysis, uses consumable reagents, destroys the physical integrity 
of the solid sample, many drugs require derivatization because of their low volatility, and 
the chromatography itself has an inherent time requirement that can lead to an individual 
analysis taking over ten minutes.16  Chromatography is also used to analyze drugs in 
complex samples.  Water samples16, 20, 21 and biological samples17, 18 have been analyzed 
using LC-MS/MS, high performance LC-MS, GC with a nitrogen-phosphorus detector, 
and GC-MS.  Antonic and Heath demonstrated the use of GC-MS in the determination of 
several drugs in river sediments after extraction and the addition of a derivatizing agent to 
increase the volatility of the drugs.16 
Because of the sample preparation time required for GC-MS, other options for sample 
introduction into a mass spectrometer have been explored.  The recently developed 
ionization methods direct analysis in real time (DART), desorption atmospheric pressure 
chemical ionization (DAPCI) and direct electrospray ionization (DESI) have been used in 
conjunction with mass spectrometry to identify active ingredients in prescription, non-
prescription and illicit drugs by placing the tablet in the ionization stream of the 
instrument.22-30  Although many groups break or scrape the tablets before analysis26, 27, 31 
in order to sample the contents of the center of a coated tablet, little to no sample 
preparation is necessary.  Molecular fragmentation is commonly minimal; the ions 
predominantly obtained are [M+H]+ or [M-H]- which allow for facile identification of the 
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active ingredients.22, 30 Van Berkel et al. have coupled DESI-MS to TLC separation of 
extracted drug ingredients creating an orthogonal approach to drug analysis.32  While 
these techniques are promising advances in drug analysis, they do not sample the 
heterogeneous body of a tablet, only the small area that interacts with the ion or droplet 
stream, which may allow a drug component to go undetected. 
Single Particle Aerosol Mass Spectrometry (SPAMS) is an on-line detection system that 
individually analyzes single micrometer-sized particles and provides real-time data 
including sizing and simultaneously obtained positive and negative ion mass spectra.33-35  
SPAMS has been applied in a variety of environments,33, 34 and is capable of low 
concentration detection of target particles in a high background environment.  It was 
hypothesized that SPAMS would also provide a fast, simple, sample preparation-free 
method of analyzing drugs in tablet form.  The application of SPAMS to the rapid 
detection of over-the-counter drug samples is described herein.  Although SPAMS has 
previously been applied primarily to aerosolized liquids, this work shows the direct 
analysis of solid particles without the need for solvent extraction, and demonstrates the 
applicability of SPAMS to drug detection and identification.  
 
2-3: Background of SPAMS 
Single Particle Aerosol Mass Spectrometry (SPAMS) is a technique based on the original 
work of Davis in the 1970s.36  Davis’ system allowed aerosol particles to impinge on a 
heated Rhenium ribbon causing ions to be formed and released for analysis in a magnetic 
sector mass analyzer; the maximum particle yield, defined as the number of particles 
producing ions as compared to the number of particles per cm3 of air, was reported as 
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0.3%.36  Over the past several decades, many modifications and improvements have been 
made to Davis’ original system, which have been reviewed by Noble and Prather,37 
resulting in the current commercially available aerosol mass spectrometer from TSI Inc. 
(Shoreview, MN).  This instrument incorporates two time of flight mass analyzers which 
simultaneously analyze both the positive and negative ions produced in the source 
region,33 with a particle sizing region that calculates particle size based on the timing of 
scattering effects of 2 continuous wave (CW) lasers through which each particle passes.  
Since the 1990s, work at Lawrence Livermore National Laboratory (LLNL) has focused 
on modifying and improving this commercial instrument to function as a sensitive and 
selective biological agent detection system under the name of Bioaerosol Mass 
Spectrometry (BAMS).  Through this work the particle sizing region on the front end of 
the instrument, as well as the operating software, was modified, incorporating up to 6 
CW lasers allowing a more accurate determination of the aerodynamic diameter of each 
particle.35  This added a degree of selectivity, because particles of a size of interest could 
be selectively ionized in the source region, preventing excessive amounts of non-useful 
data from taking up disk space as well as time to be thoroughly analyzed.  A laser 
induced fluorescence (LIF) region was also added, allowing the fluorescence of each 
particle excited at 266 nm to be determined.  Advances in data acquisition and storage 
have also been made.  In the past two years, an additional LIF stage was incorporated to 
also measure the fluorescence of each particle excited at 355 nm, as well as a stage to 
determine the charge on each particle.  These stages can be operated to pre-select 
particles of interest for mass spectrometric analysis.  In the current configuration, particle 
yield, when defined in the same manner as in Davis’ experiments of the 1970s, can be as 
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high as 90%.  The operating software for the LLNL system is very powerful.  After 
‘training’ the system on a particular target particle type by collecting many spectra of a 
standard sample, alarm files can be made and the instrument will record an alarm 
whenever a user-set threshold number of particles identified by the software as containing 
that specific compound described by the alarm file in a set period of time are detected.  
This allows the instrument to operate autonomously with little user interaction for air 
monitoring studies. 
Although originally applied to the detection of such defense threat analytes as Bacillus 
spores,38-44 viruses, 41 toxin simulants,41 fungi,39 and Mycobacteria,44 work at LLNL has 
expanded the application of the BAMS system to include explosives,45 chemical warfare 
agent simulants,46 and even stretched into medical applications.44, 47  Because of this 
broader sample application, the name BAMS was officially changed to SPAMS45 to 
present a more universal detection system. 
A significant advantage of SPAMS is its ability to analyze solid and liquid samples with 
no sample preparation.  Vapor phase samples can also be analyzed, but do require some 
sample preparation to create particles large enough to detect.48  It is also able to detect a 
small number of particles with a particular chemical signature in the midst of a large 
number of particles that do not share the same chemistry.  This ability is aided by the 
capacity to pre-select particles for mass spectrometric analysis using the fluorescence 
and/or charge stages. 
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2-4: SPAMS Description 
A schematic of the SPAMS instrument used at LLNL is shown in Figure 2- 1.39 
 
 
Figure 2- 1: Schematic of the Single Particle Aerosol Mass Spectrometer.  Particles are 
generated using the modified glass vial and transferred to the SPAMS via conductive 
tubing.  After passing through a pressure flow reducer with a relaxation chamber and 
aerodynamic focusing lens, the pressure is lowered and the beam is focused into a linear 
beam.  Particles are then tracked, where the aerodynamic velocity and size are 
determined.  Laser induced fluorescence at two wavelengths (266 and 355 nm) as well as 
particle charge is then determined before the particle enters the source region of the 
mass spectrometer.  The particle is desorbed and ionized by an Nd:YAG laser operating 
at 266 nm, and the positive and negative ions created are concurrently accelerated in 
linearly opposing directions into two reflectron time-of-flight mass analyzers, where two 
mass spectra are recorded for each particle. 
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Particles released from the analyte in the solid sampling vial (discussed below) are 
carried to the SPAMS via 3/8” conductive tubing and enter the pressure flow reducer 
which reduces the pressure of the analyte stream for introduction to the higher vacuum 
chambers by passing the particles into two facing conical apertures, thereby cutting the 
flow significantly.  On the other side of the apertures the particles lose their directionality 
in the relaxation chamber.  From this chamber, the particles pass into the aerodynamic 
focusing lens, which centers the particles into a thin stream by passing them through a 
series of nine consecutively thinner lenses with orifices of decreasing diameter.  The 
particles then pass into the tracking region of the SPAMS, where their aerodynamic 
diameter (dp,a) is determined.  As the particles travel through this region of the 
instrument, the larger particles move more slowly than the smaller particles; thus size can 
be extrapolated from a calculation of the particle’s speed.  The tracking region (~10-4 
Torr) contains up to 6 diode lasers (660 nm, continuous wave) each paired with a channel 
photomultiplier tube (CPMTs, part c962, Perkin Elmer Optoelectronics, Santa Clara, 
CA).  As the particle travels through the laser beams, the light is scattered from its normal 
path, and a change in laser light intensity is detected by the CPMTs.  The time of each 
scattering event is recorded, and the series of scattering events can be used to determine 
the particle’s velocity and therefore aerodynamic size using a field-programmable gate 
array. Incorporating 6 lasers provides several scattering events per particle that would 
allow for the deconvolution of velocities of two particles traveling through the tracking 
region simultaneously.  The size measurement is calibrated by analysis of spherical 
standards (polymeric beads, Bangs Laboratories, Inc., Fishers, IN, and Duke Scientific 
Corp, Fremont, CA) of known size.  Aerodynamic diameter, and not actual diameter, is 
14 
 
used to describe aerosol particles.  Aerodynamic diameter is the diameter of a unit-
density spherical object that moves with the same velocity through a fluid49 and relates to 
Stokes’ diameter, which assumes a particle is spherical, by Equation 2- 1: 
pSpap dd ,,   
 
where dp,a is the aerodynamic diameter of a particle, dp,S is the Stokes’ diameter of the 
particle, and δp is the density of the particle. 
 
After size is determined, the particle enters the source region of the mass spectrometer 
(~10-6 Torr).  The previously determined particle velocity is used to calculate the exact 
time the particle will be centered in the source region, and internal electronics trigger the 
desorption/ionization (D/I) laser to fire at this precise moment.  The laser, a Q-switched 
frequency-quadrupled Nd:YAG (Ultra CFR, Big Sky Laser Technologies, Inc., Bozeman, 
MT), operates at 266 nm with 7 ns FWHM pulses and can fire at up to 20 Hz with 
fluences between 0.05-8.4  nJ/µm2.  When fired, the laser imparts a significant amount of 
energy to the particle, desorbing and ionizing it to create both positive and negative ions.  
These ions are simultaneously accelerated by an electric field in linearly opposing 
directions into two linear reflectron time-of-flight (TOF) mass analyzers,50 each 536 mm 
in length.  The TOF mass analyzer operates by determining an ion’s mass/charge by 
measuring the time between acceleration and arrival at the detection plate as it travels 
through a field-free drift region.50, 51  The reflectron aspect of the TOF was developed to 
Equation 2- 1: Relationship between aerodynamic diameter and Stokes’ Diameter, 
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improve the resolution of the time of arrival of ions of equal masses which have slightly 
different flight times owing to the variation in their ionization time, initial position, and 
initial kinetic energy.51  It involves the addition of retarding plates at the end of the flight 
tube which deflect the ions and reverse their direction to pass back through the flight tube 
to ring microchannel plate detectors (MCP, Burle Technologies, Inc., Lancaster, PA) 
surrounding the exit from the source region.  Ions that were imparted with larger kinetic 
energies or were closer to the flight tube during ionization and acceleration travel deeper 
into the retarding field than do those with lower kinetic energies or those that were 
further from the flight tube; thus, the faster ions are slowed slightly, allowing both types 
of ions to reach the detector simultaneously.  Time is then related to the mass-to-charge 
ratio (m/z) by Equation 2- 2: 51 
2
2
2
mdt
zeVs
  
 
where m is the mass of the ion (kg), d is the distance the ion travels to the detector (m), z 
is the charge on the ion, e is the charge on an electron (C), and VS is the accelerating 
voltage (V).  The signal from the MCPs is digitized (Signatec, Inc., Newport Beach, CA, 
PDA1000) at 500 MHz,  8 bits with 256 arbitrary units (a.u.) on a 333 mV scale, yielding 
a mass spectrum from both polarities of ions, providing a significant amount of 
information on each single particle. 
 
Equation 2- 2: Relationship between time and mass-to-charge ratio in a time-of-flight 
mass analyzer,  
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2-5: Laser Optics 
Figure 2- 2 shows a schematic of the optics used to create the D/I laser beam in the 
source region.  
 
 
The Nd:YAG laser beam, originally 1064 nm in wavelength, is passed through 2 
frequency doublers to form a 266 nm beam.  The beam then passes through an aperture 
and a half-wave plate, which is manually rotatable to control the polarization of the beam.  
Only vertically polarized light is then passed through the vertical polarizer; thus, the half-
wave plate and polarizer together control the energy of the transmitted beam.  The beam 
passes through a 10 cm plano-convex lens which creates an image of the aperture that is 
reflected into the source region on 2 planar mirrors.  The position of the mirrors is 
Figure 2- 2: Diagram of the desorption/ionization laser optics.  A Nd:YAG laser is 
frequency quadrupled to generate a 266 nm beam which is then passed through an 
aperture, adjustable half-wave plate and vertical polarizer before being imaged by a 
plano-convex lens with a 10 cm focus length onto two planar mirrors which direct the 
image into the source region of the mass spectrometer. 
Mass Analyzer
Frequency Doublers
Plano-Convex 
Lens (10 cm)Adjustable
Half-Wave Plate
Mirrors
Nd:YAG
Vertical Polarizer
Aperture
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controlled by manual calipers which manipulate the position of the image on the x-y 
plane.  The resulting beam is ~ 330 µm in diameter in the center of the source region, and 
maintains a relatively flat-topped energy profile,41 although weaker areas do exist, 
particularly near the beam edges.  The energy of each laser pulse is measured at the back 
of the source region using a digital laser energy meter (Coherent, Inc., Santa Clara, CA, 
J25LP-MUV).  The laser energy is averaged over 50 particles to give statistically 
significant values for energy, with the pulse-to-pulse variation generally being <5%. 
Laser fluence is often reported, and is equivalent to the laser energy per beam area, which 
in the current system is 0.086 mm2. 
 
2-6: Solid Sampling Materials 
Figure 2- 3 shows the modified glass vial used to introduce solid samples, particularly 
drug tablets, to the SPAMS. 
Figure 2- 3: Diagram of modified glass vial used to generate particles from solid samples 
for analysis by SPAMS.  The plastic cap was modified using stainless steel tubing to 
create a port to transfer the sample to the SPAMS as well as a second port to which a 
HEPA filter was attached.  The solid sample is placed in the vial which is then shaken or 
vortexed; particles are generated by the collisions induced by the shaking. 
Stainless Steel 
Tubing Modified 
with a HEPA Filter
Stainless 
Steel Outlet 
to SPAMS
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A ~20 mL glass vial with a plastic cap was modified using stainless steel tubing to create 
a port to allow connection of 3/8” conductive tubing to connect to the SPAMS 
instrument.  A second piece of steel tubing was also modified into the plastic cap to allow 
connection of a HEPA filter to the vial.  Particles are created by manually shaking or 
vortexing the vial, causing collisions between the vial contents and the vial walls. 
 
2-7: Data Collection and Analysis 
Operation of the SPAMS system and recording of the data obtained is performed using a 
program developed at LLNL by Vincent Riot.  Data can be collected using all analysis 
stages or any combination thereof, with the minimum requirement that two tracking 
lasers are used for accurate velocity determination.  The current experiments used only 
the sizing (3 tracking lasers) and mass spectral regions, generating smaller data files.  The 
software can be set to acquire a specific number of mass spectral ‘hits;’ a ‘hit’ occurs 
when mass spectral data is obtained that surpasses a user-define threshold, typically ~120 
mV on the 333 mV scale.  Hundreds if not thousands of particles per sample are 
analyzed, typically collecting 1000 mass spectral ‘hits’.  Once the data is obtained, 
spectral analysis occurs using another program developed in house by Paul Steele, Gary 
Armstrong, and David Fergenson, ‘Irene,’ which was written in MatLAB.  By using 
‘Irene,’ spectra can be averaged, sorted by peak area at a particular m/z value, integrated, 
and statistically analyzed. 
The mass spectrum for each particle is analyzed using ‘Irene’ to determine its 
composition by comparison against user-generated alarm files.  The alarm files used with 
SPAMS are typically created using an algorithm based on pattern matching, where the 
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350-order vector of the mass spectrum of a single particle is compared to the average 
vector from the mass spectra of a known material contained in the alarm file.52, 53  Further 
refinement of the alarm files is then done by creating rules trees to further discriminate 
particles.  In a rules tree, each ‘branch’ is created by probing a specific mass vector to 
determine if it is greater than or less than a specific value.  If the particle passes onto a 
specific branch, another mass vector may be probed, i.e. a second ‘branch’, etc. until 
sufficient differentiation has occurred.  Rules trees analyze normalized vector values so 
that an increase in overall signal from the MCPs does not affect the classification.  
Contributions from mass vectors typically seen in all particles, such as m/z 23 and 39, 
due to sodium and potassium, respectively, are eliminated to facilitate comparisons of 
mass spectra. 
Analysis of the heterogeneous drug samples provided many particles that contained 
numerous active ingredients, as discussed below, precluding accurate pattern matching 
without creating alarm files and thus a training set requiring a standard mixture for every 
possible combination of drug ingredients.  Therefore, alarm files for this study were 
created using only rules trees, where specific m/z values, or mass vectors, could be used 
to categorize the components of the particle.  A rules tree was created to identify each 
drug using m/z values corresponding to characteristic peaks seen in the mass spectra of 
each compound.  Using a unique alarm file for each drug allowed detection of any 
combination of 1, 2, 3, 4, etc. of these compounds in a single particle, as well as reduced 
confounding by any filler materials and inactive ingredients.  When discriminated with a 
single alarm file, each particle is thus processed through all ‘branches’ of the rules tree, 
and is identified as containing that specific drug, or not containing that specific drug 
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(Null).  All particles are then subjected to the rules tree for the second drug, etc., until all 
alarms have been run, allowing a single particle to be identified by multiple alarm files.  
The rules trees used for the identification of ibuprofen is shown in Figure 2- 4, and 
subsequent rules trees for other drug components are included in Appendix A. 
 
 
It should be noted that although only mass vectors are used to create the alarm files in 
this work, particle size, fluorescence (266 nm and 355 nm excitation), and/or charge 
could be incorporated into the alarm file in the future to further enhance the confidence in 
identification after an alarm is reported to further the selectivity. 
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Figure 2- 4: Rules tree for classification of ibuprofen.  The mass vectors probed at each 
branch division are shown, with ‘Y’ indicating a positive response and ‘N’ indicating a 
negative response.  Circles labeled ‘I’ indicate a positive identification for ibuprofen; 
circles labeled ‘Null’ indicate a negative response. M/z 206 corresponds to the [M]+ ion, 
m/z -205 and -206 correspond to the [M]-and [M-H]- ion, m/z 161 corresponds to the [M-
COOH]+ ion, and m/z -161 corresponds to the [M-COOH]- ion. 
21 
 
2-8: Drug Material Preparation 
Single ingredient over-the-counter medications containing acetaminophen 
(analgesic/antipyretic), aspirin (NSAID), clemastine (antihistamine), diphenhydramine 
(antihistamine, sedative), ibuprofen (NSAID), loratadine (antihistamine), phenylephrine 
(decongestant), or pseudoephedrine (decongestant) were obtained as tablets from 
commercial grocery chains.  Tablets containing chloroquine (antimalarial) were obtained 
from a commercial pharmacy in Belize City, Belize.  Multi-ingredient medications were 
also obtained from commercial grocery chains: Tylenol Cold™ and Tylenol PM™, 
containing acetaminophen and diphenhydramine, Tylenol Severe Congestion™, 
containing acetaminophen, diphenhydramine, pseudoephedrine, and guaifenesin 
(expectorant), and Advil Cold and Sinus™, containing ibuprofen and pseudoephedrine. 
For the single tablet experiments, a single tablet was placed in the modified glass vial and 
attached to the SPAMS using 3/8” conductive tubing.  The glass vial was either manually 
shaken or placed on a vortexer (Fisher Scientific, Inc.); the collisions of the tablet with 
the sides of the glass vial created sufficient particles for analysis.  In fact, manual shaking 
typically generated and transferred more particles to the SPAMS instrument than could 
be analyzed at the 20 Hz frequency of the D/I laser.   Placing the vial on the vortexer at a 
low setting provided a steadier stream of particles to the instrument, without constant 
saturation of the sampling rate of the instrument.  For the multiple tablet experiments, 
several tablets were simultaneously placed in the vial, each containing a different active 
ingredient.  These tablets were then removed from the vial and the emptied vial again 
analyzed.  A fluence of 2.7 nJ/m2 (SD=0.1) was used for all samples.  The drugs studied 
are shown in Table 2- 1, including their molecular weights and chemical structures. 
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2-9: Drug Analysis Using SPAMS 
2-9-1: Bayer™ Aspirin 
The resulting dual-polarity mass spectrum obtained from a single Bayer™ tablet 
containing 325 mg of aspirin is shown in Figure 2- 5. 
NO
Drug Structure Drug Structure
Acetaminophen
MW 151.06
Diphenhydramine
MW 255.16
Aspirin
MW 180.16 Guaifenesin
MW 198.09
Chloroquine
MW 319.18
Ibuprofen
MW 206.28
Chlorpheniramine
MW 274.12
Loratadine
MW 382.15
Clemastine
MW 343.17
Phenylephrine
MW 167.21
Dextromethorphan
MW 271.19
Pseudoephedrine
MW 165.23
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Table 2- 1: Structures and molecular weights of drug compounds studied. 
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Figure 2- 5: (a) Average single particle aerosol mass spectra of 999 aspirin particles, 
and (b) five consecutively obtained aspirin particles (aerodynamic diameter displayed in 
upper right of each spectrum).  The single particle spectra contain all peaks used to 
identify aspirin.  The spectra from these particles were obtained in less than five seconds. 
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Figure 2- 5(a) shows the average mass spectrum of 999 particles generated from the 
tablet obtained at a rate of 1 spectrum every 1.26 seconds.  The average aerodynamic 
diameter of the particles was 1.54 µm (RSD 71.7%).  The large size distribution (0.59 – 
8.71 µm) was expected owing to the method of particle formation, and particle size did 
not affect the relative ion abundances.  The major ions observed in the positive and 
negative mass spectra are characteristic of the aspirin (acetylsalicylic acid) present in the 
tablet.  Peaks at m/z -179, -151, and -137, due to [M-H]-, [M-H-CO]-, and [M-CH3CO]-, 
respectively, and major peaks in the negative ion spectrum, and have been previously 
documented in solid tablet analysis using DESI in negative ion mode to analyze the 
broken surface of a tablet25, 26 The spectrum also contains several significant peaks 
hypothesized to arise from the formation and fragmentation of an acetylsalicylic acid 
dimer formed via hydrogen-bonding ([2M-CO2-C2H2O-H)]- and [2M-CO2-C2H2O2-H]-, at 
m/z -273, and -257, respectively) which can also aid in identification of the active 
ingredient.  The main peaks in the positive ion spectrum are present at m/z +121, +135, 
and +163 ([M-CH3COO]+, [M-COOH]+, and [M+H-H2O]+, respectively) the latter of 
which has been previously described using DART, DESI and DAPCI in positive ion 
mode to analyze the broken surface of a tablet.31  Small peaks attributed to the dimer are 
also seen in the positive ion spectrum at m/z +213, 241, 255, and 283, assigned as [2M-
CH3COO-CH3CO-COOH]+, [2M-2CH3COO-H]+, [2M-CH3COO-COOH-H]+, and [2M-
COOH-CH3-OH]+, respectively.  Figure 2- 5(b) shows the mass spectra obtained from 
five consecutive single particles of the aspirin tablet.  Note the presence of all identifying 
peaks in the single spectra as well as the consistency in the signal obtained, allowing the 
presence of aspirin in the table to be confirmed from a single particle.  The speed with 
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which the mass spectra are obtained is demonstrated by the fact that the spectra shown in 
the figure were obtained in less than five seconds.  Software developed in-house has the 
capability to identify a sample in real-time based on single spectra and could be trained to 
identify and alarm when a specific drug was detected.53 
 
2-9-2: Chloroquine Diphosphate 
Figure 2- 6a shows the average dual-polarity mass spectrum obtained from a single tablet 
containing 250 mg of an anti-malarial drug, chloroquine diphosphate. 1000 particles were 
analyzed in 182 s. 
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Figure 2- 6: a) average dual-polarity mass spectrum of 1000 particles dislodged from a 
single chloroquine phosphate tablet, b) mass spectra obtained from 5 individual particles 
of chloroquine phosphate dislodged from the tablet.  Particle size is notated. 
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The average aerodynamic diameter of the particles was 1.88 µm (RSD 43.7%).  Most 
peaks in the positive and negative polarities can be attributed to the parent or fragment 
ions of the drug compound (7-chloro-4-((4-(diethylamino)-1-methylbutyl)amino)-
quinoline = M, MW 319.18).  The [M+H]+ ion is the most abundant ion in the positive 
spectrum at m/z 320, followed by the [CH2N(C2H5)2]+ fragment at m/z 86.  Other 
fragments due to the loss of chlorine and addition of hydrogen (m/z 286), the loss of 
N(C2H5)2 (m/z 247), and [CH3CH(CH2)3N(C2H5)2]+ (m/z 142) are also seen in the 
positive spectrum. The final major fragment seen in the positive ion spectrum is due to 
the phosphate salt of the drug, [2H3PO4-OH]+ at m/z 179.  Several peaks are also seen in 
the negative ion spectrum that can be attributed to phosphate salts.  P2O6-, PO3-, [2H3PO4-
H]-, [2H3PO4-H3O]-, and H2PO4- are seen at m/z -158, -79, -195, -177, and -97, 
respectively.  Peaks indicative of chloroquine are also seen in the negative spectrum; loss 
of an ethyl group is seen at m/z -290.  All of these fragment ions are consistent with the 
presence of the active ingredient, chloroquine, in the sample.  Figure 2- 6b shows the 
dual-polarity mass spectra from five individual particles containing chloroquine.  
Although there is some variation in the intensity of the peaks, the characteristic peaks are 
present in all spectra, and chloroquine can be easily recognized as a component of the 
tablet. The high quality and reproducibility of these mass spectra allow accurate rules 
trees to be created, which, when used with the software developed in house, provide 
automated identification of the compound with none of the alarm files for the other drugs 
tests provided a positive alarm.   
 
  
28 
 
2-9-3: Clemastine Fumarate 
An allergy medication containing 1.34 mg of clemastine fumarate was then studied.  An 
equivalent value of 1 mg of clemastine free base was present in the tablet.  The average 
aerodynamic diameter of 999 particles was 1.82 µm (RSD 45.4%).  Figure 2- 7shows the 
dual-polarity mass spectrum obtained from a single particle of the tablet.  This particle 
was 2.09 µm in diameter. 
 
 
Many fragments are present, owing to the fragmentation of the bonds connecting the 3 
rings of the molecule.  A series of fragments attributed to the consecutive breakage of C-
C bonds on the alkane chain connecting the pyrrolidine ring to the molecule are present: 
[C4H7NCH3]+, [CH2C4H7NCH3]-, [M-(CH2)2C4H7NCH3]-, [O(CH2)2C4H7NCH3]+ and [M-
O(CH2)2C4H7NCH3]+ and [M-H-O(CH2)2C4H7NCH3]-, at m/z 84, -98, -231, 128, 215, 
and -215, respectively.  The fragment at m/z -71 is formed by the removal of both the 
aromatic rings and the pyrrolidine ring, [CH3CO(CH2)2]-.  The chlorine atom is also 
removed from the molecule, leading to fragment ions at m/z -35, Cl-, and m/z 308, 
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Figure 2- 7: Average mass spectrum of a single particle dislodged from a clemastine 
tablet (aerodynamic diameter 2.09 µm). 
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assigned as [M-Cl]+.  A peak assigned as a molecular ion is seen in the positive spectrum; 
however, limitations in the data acquisition range prevent accurate mass calibration in 
this region, so it is unknown whether the peak is at m/z 344, assigned as the [M]+ ion, or 
m/z 345, due to [M+H]+.  This peak, as well as all peaks due to ions containing the 
chlorine atom, shows a consistent and appropriate isotopic distribution.  A peak due to 
the fumarate salt is also seen in the negative ion spectrum: [F-H]- at m/z -115.  An 
additional peak at m/z -98 may be due to [F-H2O]-, although this is more probably due to 
the clemastine fragment described above. 
 
2-9-4: Benadryl™ (Diphenhydramine) 
Next, an antihistamine and sedative Benadryl™ tablet containing 25 mg 
diphenhydramine was studied using SPAMS.  The average aerodynamic diameter of 999 
particles was 1.81 µm (RSD 80.6%).  Figure 2- 8 shows the mass spectrum of an 
individual particle generated from a single tablet. 
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Figure 2- 8: Single particle aerosol mass spectrum of an individual diphenhydramine 
particle (aerodynamic diameter 1.14 µm). 
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Minimal structural information is present in the negative ion spectrum; only the fragment 
attributed to [CN]- is identified.  A peak attributed to HCl2- is also seen, with the 
corresponding chlorine isotope ratio at m/z -71, -73, and -75.  However, many peaks 
indicative of diphenhydramine are present in the positive ion spectrum.  The most 
prominent peaks are assigned as loss of the side-chain from the parent molecule: 
[(CH3)2N(CH2)2O]+, [(CH3)2N(CH2)2]+, and [(CH3)2NCH2]+ at m/z +88, +72, and +58, as 
well as [M-(CH3)2N(CH2)2O]+ (m/z +167); the latter three have been previously reported 
using GC-MS (+EI),54 and LC-MS-MS (+CID).55  Peaks corresponding to the addition of 
these fragments to the molecular species as well as the protonated intact molecule are 
also present: [M+(CH3)2NCH2]+ (m/z +313), [M+(CH3)2N(CH2)2]+ (m/z +327), 
[M+(C6H5)2CH]+ (m/z +422) and [M+H]+ (m/z +256).  Two peaks separated by 38 mass 
units are seen in the high mass region of the positive mass spectrum.  These peaks have 
been tentatively attributed to the protonated dimer and potassiated dimer, which would 
yield m/z +511 and +549, respectively, but the mass calibration at these high masses is 
unreliable, so final assignments cannot be made.  The peaks seen in the mass spectrum of 
diphenhydramine allow for the positive identification of diphenhydramine in the tablet. 
 
2-9-5: Loratadine 
An antihistamine tablet containing 10 mg of loratadine was analyzed using SPAMS.  The 
average aerodynamic diameter of 999 particles was 1.67 µm (RSD 80.9%). A mass 
spectrum of an individual particle generated from the single tablet is shown in Figure 2- 
9. 
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The negative ion spectrum shows several peaks characteristic of loratadine, including 
those assigned as the fragments [M-OCHOC2H5-C4H3N-Cl]-, and [CN]-, at m/z -221 and 
-26, respectively.  The positive ion spectrum also shows peaks due to several fragments, 
including [M-C4H8NO2]+ at m/z +280; however, more significantly, peaks at m/z +348 
and +383, assigned as [M+H-Cl]+ and [M+H]+ are seen.  The [M+H]+ has been 
previously reported.22, 25  The inset in Figure 2-9 shows the high mass region between 
m/z +680 and +780.  Although the intensity is low, significant peaks are seen with 
sufficient signal-to-noise ratios at m/z +695 and +730, possibly due to loratadine dimers 
[2M+H-2Cl]+ and [2M+H-Cl]+.  These peaks are the highest mass peaks that have been 
clearly resolved on the instrument used in this study. 
 
2-9-6: Generic Ibuprofen 
Figure 2- 10 shows the mass spectrum of an individual particle generated from a single 
tablet containing ibuprofen (200 mg).  Although 999 spectra were obtained to ensure the 
Figure 2- 9: Single particle aerosol mass spectrum of an individual loratadine particle 
(aerodynamic diameter 3.95 µm).  Inset shows high mass peaks due to loratadine dimers. 
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consistency of the data recorded, the single particle spectrum is representative of the data 
obtained and was randomly selected. 
 
 
The average aerodynamic diameter of the 999 particles was 1.83 µm (RSD 65.3%), again 
with the large size distribution due to the method of particle formation.  The aerodynamic 
diameter of the particle displayed was 1.21 µm.  The negative ion spectrum is dominated 
by peaks at m/z -205 and -161, due to [M-H]- and [M-COOH]-, respectively.20, 26, 31  A 
peak at m/z -411 is attributed to the deprotonated dimer, [2M-H]-, also seen by Williams 
and Scribens using DESI with a quadrupole-TOFMS.26  The positive ion spectrum 
contains many peaks, including those due to the [M]+ ion as well as peaks due to the loss 
of -OH, and -COOH21 (m/z +206, +189, +161). A slight peak due to the [M+H]+ ion is 
also seen in some mass spectra; however the [M]+ ion does dwarf this peak in all the 
spectra.  The pseudomolecular ion of ibuprofen was also not seen in studies using LC-
ESI-MS for the analysis of several drug samples.  The presence of the [M]+ and [M-H]- 
peaks allows for the simple identification of ibuprofen in the sample using either the 
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Figure 2- 10: Single particle aerosol mass spectrum of a randomly selected individual 
ibuprofen particle (aerodynamic diameter 1.21 µm).  Note the presence of the [M]+ and 
[M-H]- peaks to allow for simple identification. 
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positive or negative ion spectrum; the dual-polarity nature of the data provides additional 
confirmation of the active ingredient. 
 
2-9-7: Generic Pseudoephedrine and Phenylephrine  
Several decongestant tablets were analyzed using SPAMS.  Pseudoephedrine is a 
decongestant commonly sold under the brand name of Sudafed™.  Since the enactment 
of the Combat Methamphetamine Epidemic Act of 2005, the quantity of pseudoephedrine 
purchased by an individual has been restricted to no more than 3.6 g per day and no more 
than 9 g in any 30 day period due to its use as a starting material for methamphetamine 
synthesis.56  This legislation has increased the promotion and availability of alternative 
decongestants, such as phenylephrine (commonly sold as Sudafed PE™).  Figure 2- 11 
shows a mass spectrum of a single particle generated from (a) a pseudoephedrine (30 mg) 
containing tablet and (b) a phenylephrine (10 mg) containing tablet. 
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Molecular masses of pseudoephedrine and phenylephrine are 165.23 and 167.21 Da, 
respectively.  The average aerodynamic diameter of 999 particles of each drug was 1.81 
µm (69.5% RSD) for pseudoephedrine and 1.23 µm (58.0% RSD) for phenylephrine.  
The positive ion spectra of the two substances show similar fragment ions and losses 
owing to the similar structures of the compounds.  Peaks corresponding to the base peaks 
in the NIST standard mass spectra of pseudoephedrine ([CH3NHC2H5]+, m/z 58) and 
phenylephrine ([CH3NHCH2]+, m/z 44) are present in high yield in the current spectra; 
however, peaks assigned to [M+H]+ and [M-OH]+ are also seen in both drug samples, 
have been previously reported,57-60 and provide more confirmatory identification of the 
drug.  Pseudoephedrine also shows evidence of dimer formation with [2M+H]+ (m/z 
+331).  The negative ion spectra of these two compounds again show similarities.  Peaks 
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Figure 2- 11: (a) Single particle aerosol mass spectrum of an individual pseudoephedrine 
particle (aerodynamic diameter 1.08 µm) and (b) an individual phenylephrine particle 
(aerodynamic diameter 0.96 µm).  Although similar in structure and mass, these two 
compounds can be differentiated using SPAMS based on molecular and fragment ion 
species. 
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due to [M+Cl]- are seen in both compounds, as well as peaks attributed to [C3H7NO]- 
(m/z -73) and [CN]- (m/z -26).  Several other fragments are also present that contribute to 
the signature of each drug. 
 
2-9-8: Bayer™ Aspirin versus Certified™ Aspirin 
SPAMS can also be used to identify differences between brands of tablets containing a 
single drug.  Although intended to have the same medicinal effects, differences in 
manufacturing processes, equipment, and inactive ingredients in the tablets impart a 
different chemical signature to the tablets.  Figure 2- 12 compares three regions of the 
mass spectra obtained from two tablets containing aspirin: the average mass spectrum of 
999 particles dislodged from a Bayer™ brand tablet (325 mg aspirin) and a Certified™ 
brand tablet (81 mg aspirin). 
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Figure 2- 12: Average mass spectra of 1000 particles of Bayer™ brand aspirin (a,c,e) 
and Certified™ brand aspirin (b,d,f) in three separate mass regions.  Note the presence
of additional peaks in the Certified™ Brand aspirin, attributed to fillers and impurities in 
the sample that can be used to distinguish the two brands. 
37 
 
The peaks previously discussed (Figure 2- 5) as being indicative of aspirin are present in 
both spectra; however other features in the spectra differ.  The labeled peaks in the figure 
indicate peaks (S/N≥5) present only in the Certified™ brand tablet.  In fact, these peaks 
are not present even in single particle spectra of the Bayer™ brand aspirin sorted for that 
particular mass.  Although small in amplitude, the presence of these peaks can be used to 
qualitatively distinguish between these two brands of aspirin.  These peaks are 
hypothesized to be due to fragments originating from an unknown filler material in the 
tablets. 
 
2-9-9: Tylenol Extra Strength™ (Acetaminophen) 
Many varieties of tablets can be analyzed using SPAMS.  Tablets with a harder shell 
coating to slow tablet dissolution may take a longer analysis time, as the active ingredient 
may or may not be present in this shell.  Several over the counter and prescription 
medications are coated with an enteric coating to aid in digestion and to ensure the tablet 
reaches the appropriate body compartment before releasing the active ingredient (e.g. 
stomach or small intestine).  If this coating does not contain the active ingredient, 
analysis may take a longer time; particles containing the active ingredient must be 
dislodged from the tablet, so many spectra may be obtained that do not contain the active 
ingredient, formed from this coating.  One such medication studied was Tylenol Extra 
Strength™ (EX) geltabs, containing 500 mg acetaminophen.  Figure 2- 13shows (a) the 
average mass spectrum obtained from 799 particles (da=2.33 µm, RSD 52.7%) dislodged 
from a Tylenol EX™ tablet and (b) the average mass spectrum obtained from the 50 
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particles having the highest mass spectral signal at m/z 152, corresponding to the [M+H]+ 
ion of acetaminophen. 
 
 
Although peaks due to the active ingredient are seen in the averaged spectrum (n=799), 
the intensity is low, impeding the facile identification of the substance.  However, after 
sorting the spectra for a particular peak known to be caused by acetaminophen, the active 
ingredient is easily distinguished from the background material.  Thus, even coated 
tablets can be analyzed successfully with SPAMS.  Other ions indicative of 
acetaminophen are also seen in the spectra.  The sodiated ion, [M+Na]+ is seen at m/z 
174, as well as the fragment [M+H-CH3C(O)]+, caused by cleavage of the C-N bond, at 
m/z 109, [CH3C(O)NH]+ at m/z 58, is assigned as a fragment from the acetamide group, 
and, and [C2H3]+ at m/z 27 is likely a fragment of the aromatic ring.  The negative ion 
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Figure 2- 13: Average mass spectrum from 50 particles dislodged from a Tylenol EX 
tablet.  The 50 particles shown were selected by sorting 799 particles for the highest peak 
area at m/z 152. 
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mass spectrum also has identifying peaks: [M-H]-, [M-OH]-, [M-O-CH3]-, [M-CH3C(O)]-, 
and [C4]- at m/z -150, -134, -120, -108, and -48, respectively. Other peaks, attributed to 
anionic carbon clusters (Cn
-), are seen in the negative spectrum at -96, -84, -72, -60, -48, 
and -36. 
 
2-9-10: Tylenol Cold™ (Acetaminophen + Diphenhydramine) 
SPAMS can also be used to identify multiple ingredients in a single tablet.  Several 
multicomponent tablets were analyzed and presented below.  Figure 2- 14b shows the 
average mass spectrum obtained from 999 particles (da= 1.57 µm, RSD 44.9%) dislodged 
from a Tylenol Cold™ tablet. 
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Tylenol Cold™ contains 500 mg of acetaminophen and 12.5 mg of diphenhydramine.  
Diphenhydramine is the active ingredient in Benadryl™, so the average mass spectrum of 
999 particles from a Benadryl™ tablet is shown (Figure 2- 14a) as well as the average 
mass spectrum of 25 particles from a Tylenol EX™ tablet (Figure 2- 14c).  Dashed lines 
indicate the peaks in the Tylenol Cold™ spectrum that have been attributed to either 
diphenhydramine or acetaminophen.  Numerous peaks are present due to each compound; 
especially of note are the [M+H]+ ions from each drug, at m/z 152 for acetaminophen, 
and m/z 256 for diphenhydramine.  The presence of two active ingredients does not affect 
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Figure 2- 14: Average mass spectra of particles dislodged from a.) a Benadryl tablet 
containing diphenhydramine (n=999), b.) a Tylenol Cold tablet containing 
acetaminophen and diphenhydramine (n=999), and c.) a Tylenol EX tablet containing 
acetaminophen (n=25).  Dashed lines indicate peaks in the Tylenol Cold sample that can 
be attributed to either acetaminophen or diphenhydramine. 
41 
 
the ability to identify these substances.  The acetaminophen alarm file identified 953 
particles as containing acetaminophen. Other peaks are also seen in the Tylenol Cold 
spectrum that cannot be attributed to either active ingredient.  These peaks are 
hypothesized to be due to the additional filler compounds in the tablet. 
 
2-9-11: Tylenol PM™ – Caplet versus Tablet (Acetaminophen + Diphenhydramine) 
Figure 2- 15 shows mass spectra obtained from two varieties of Tylenol PM – a caplet 
and a tablet. 
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Figure 2- 15: Average mass spectra obtained from 997 particles dislodged from a.) a 
Tylenol PM caplet and b.) a Tylenol PM tablet.  While many peaks indicative of the 
active ingredients, acetaminophen and diphenhydramine, are seen, other peaks are also 
present in either sample, allowing differentiation between the two formulations. 
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Both formulations also contain both acetaminophen (500 mg) and diphenhydramine (25 
mg).  Again, peaks attributed to the acetaminophen: [M+Na]+, [M+H]+, [M-OH]+, [M+H-
CH3O]+, [CH3C(O)NH]+, [CH3CO]-, [M+CH3CO]-, [M-CH3-O]-, [M-OH]-, [M-H]- and 
[M-H+CH2C(O)]- are seen at m/z 174, 152, 134, 109, 58, -48, -108, -120, -134, -150, and 
-192 respectively and those attributed to diphenhydramine, [D+K]+, [D+H]+, [D-
(CH3)2N(CH2)2O]+, [(CH3)2N(CH2)2O]+, [(CH3)2N(CH2)2]+, [(CH3)2NCH2]+, and [D-H]-, 
at m/z 294, 256, 167, 88, 72, 58, -254, and -271, respectively are seen in both samples.  
The tablet formulation also contains peaks at m/z -271 attributed to [D+O]-, -208 
unattributed, and -93, which is also unattributed but also seen in a Benadryl tablet, 
containing only diphenhydramine.  The caplet formulation contains additional peaks at 
m/z -264, -72, and -60 which were also seen in the Tylenol EX sample attributed to 
acetaminophen and m/z 310, which was seen in the Benadryl tablet.  This variation in 
peaks present allows the different formulations of the same drug produced by a single 
brand to be distinguished, highlighting another ability of SPAMS.   The alarm files for 
both acetaminophen and diphenhydramine were run again all particles.  853 particles in 
the caplet were identified as containing acetaminophen, and 390 were identified as 
containing diphenhydramine.  In the tablet, 898 particles were identified as containing 
acetaminophen, while 584 particles were identified as containing diphenhydramine.  
Thus, many particles must contain both drug components. 
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2-9-12: Advil Cold and Sinus™ (Ibuprofen + Pseudoephedrine) 
Figure 2- 16 shows an average mass spectrum of 50 particles from a multicomponent 
tablet, Advil Cold and Sinus™.  This tablet contains 200 mg ibuprofen and 30 mg 
pseudoephedrine.  The 50 particles shown were chosen by sorting 797 particles (da=1.68 
µm, RSD 48.6%) by peak area at m/z 166, and selecting the top 50 particles.  While 
many peaks have been attributed to either ibuprofen (I) or pseudoephedrine (P), including 
[I]+, [P+H]+, and [I-H]- at m/z 206, 166, and -205, many additional peaks are seen that 
have not been attributed.  Again, these peaks, such as those at m/z -264, -97, 56, and 64 
are thought to be due to the unknown filler compounds in the tablet. 
 
 
2-9-13: Tylenol Severe Congestion™ (Acetaminophen + Dextromethorphan + 
Guaifenesin + Pseudoephedrine) 
A single Tylenol Severe Congestion™ tablet containing four active ingredients: 
acetaminophen (325 mg), dextromethorphan (15 mg), guaifenesin (200 mg), and 
pseudoephedrine (30 mg), was analyzed.  Figure 2- 17a shows the average dual-polarity 
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Figure 2- 16: Average mass spectrum obtained from 50 particles dislodged from an Advil 
Cold and Sinus tablet.  The 50 particles were selected by sorting 797 particles for the 
highest mass area at m/z 166. 
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mass spectrum obtained from 1000 particles (da= 1.46 µm, RSD 49.0%) from this tablet. 
Figure 2- 17b-e show spectra of the individual components for comparison. 
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Figure 2- 17: a) Average mass spectrum of 1000 particles dislodged from a single 
Tylenol Severe Congestion tablet containing pseudoephedrine, acetaminophen, 
dextromethorphan, and guaifenesin as the active ingredients, b-c) mass spectra obtained 
from a single particle dislodged from a tablet containing only pseudoephedrine or 
acetaminophen, respectively, as the active ingredient, d-e) concatenated standard NIST 
mass spectra of dextromethorphan and guaifenesin, respectively.  Single component 
tablets containing these ingredients were not readily available. 
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A tablet containing pseudoephedrine as the active ingredient as well as a tablet containing 
acetaminophen as the active ingredient were analyzed to create the spectra shown in 
Figure 2- 17b-c; Single component tablets containing dextromethorphan or guaifenesin 
were not available during the study, therefore standard 70 eV electron ionization (EI) 
spectra from the NIST reference library are shown (Figure 2- 17d-e), and concatenated to 
display all ions as potentially-formed positive and negative ions.  Note that peaks 
attributed to the molecular or fragment ions of each component are present in the average 
(Figure 2- 17a).  Pseudomolecular ions of each compound are present and indicated by 
the arrows: [M-H]- and [M+H]+ for acetaminophen, [M+H]+ for dextromethorphan, 
[M+H]+ and M- for guaifenesin, and [M+H]+ for pseudoephedrine.  After analysis of 
1000 particles, the mass of the tablet was reduced by only 0.025%, and all markings were 
clearly visible on the tablet. 
The 1000 particles were then processed through the rules trees for all the drug 
compounds in this study.  953 particles produced a positive identification for 
acetaminophen, 571 for pseudoephedrine, 907 for dextromethorphan, and 804 for 
guaifenesin.  No false positives were obtained for aspirin, loratadine, phenylephrine, 
ibuprofen, or chloroquine.  This averages to 3.2 drug compounds per particle.  The 
heterogeneous nature of this multi-ingredient tablet allowed for varying combinations of 
drug compounds to be detected in single particles and demonstrates that the ingredients 
of such a heterogeneous tablet can be rapidly identified using SPAMS. 
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2-9-14: Multiple Tablets: Phenylephrine and Aspirin 
Next, SPAMS was tested to determine if multiple tablets could be simultaneously 
analyzed.  A single phenylephrine tablet (10 mg) and a single generic aspirin tablet (81 
mg) were placed in a single vial and introduced to the SPAMS system.  Figure 2- 18 
shows the average of 798 mass spectra obtained from this sample (Figure 2- 18b) and a 
spectrum from 249 particles of phenylephrine alone (Figure 2- 18a) and aspirin alone 
(Figure 2- 18c). 
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Figure 2- 18: Average mass spectrum obtained from a.) 249 particles dislodged from a 
phenylephrine tablet, b.) 798 particles dislodged from a single phenylephrine tablet and a 
single aspirin tablet placed in the same glass vial and sampled simultaneously, c.) 249 
particles dislodged from a single aspirin tablet.  Note that both phenylephrine and 
aspirin peaks are seen in the mixed tablet spectrum. 
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The presence of each component is seen in peaks attributed to the molecular and 
fragment ions of each compound, all of which have been previously identified and are 
indicated by the dashed lines.  When the data are analyzed on a particle by particle basis, 
most particles can be identified as containing only one drug, but approximately 5% are 
identified by the rules trees as containing both compounds.  It is thought that these are 
indeed individual single particles formed by a collision inside of the glass vial and are not 
due to several particles being concurrently desorbed/ionized in a single pulse, as the 
probability of more than one particle being present in the D/I laser beam when it is fired 
is 0.5%, based on a sample containing 1000 particles/mL and  sampling rate of 1 L/min.61  
This hypothesis is addressed further in Section 2-9-15.  Visual analysis of the tablets after 
sampling reveals small particles present on the outside of the tablets, thought to be 
residual particles from the other tablet in sample.  Particles formed during tablet-tablet 
collisions may contain fragments from both tablets. 
 
2-9-15: Multiple Tablets – Separate Vials: Phenylephrine and Aspirin 
In order to test the hypothesis of tablet-tablet collisions causing the multi-component 
particles, 2 tablets were simultaneously introduced to the instrument using 2 separate 
sampling vials.  A single tablet of loratadine was placed in a modified glass vial, while a 
single tablet of pseudoephedrine was placed in a second vial.  Both vials were connected 
to the SPAMS inlet using a y-shaped connector for the conductive tubing.  By placing the 
tablets in separate vials, tablet collisions are eliminated as a source of this phenomenon, 
while maintaining all other parameters as consistent.  Mass spectra were collected for 498 
particles using this setup, and analyzed on a particle by particle basis.  No spectra were 
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seen that containing peaks indicative of both drugs, which supports the hypothesis of 
mixed drug particles forming within the sampling vial.  
 
2-9-16: Multiple Tablets: Phenylephrine, Aspirin, Ibuprofen, Loratadine, 
Pseudoephedrine 
It is also important to ensure that drug components in a bulk sample containing more than 
1 or 2 types of tablets could be accurately detected and identified.  Thus, a greater 
number of tablets, 5, were placed in a single vial: aspirin (81 mg), ibuprofen (200 mg), 
loratadine (10 mg), phenylephrine (10 mg), and pseudoephedrine (30 mg) and 
simultaneously analyzed.  Figure 2- 19a shows the average dual-polarity mass spectrum 
of 799 particles. 
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Figure 2- 19: a) average mass spectrum obtained from 799 particles introduced from a 
complex sample containing 5 single active ingredient tablets including aspirin, ibuprofen, 
loratadine, phenylephrine, and pseudoephedrine, b-f) single particles selected from the 
799 particles collected that were identified as containing primarily pseudoephedrine, 
ibuprofen, loratadine, phenylephrine, or aspirin, respectively. 
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The presence of each component is seen in peaks attributed to the parent and fragment 
ions of each compound, all of which have been previously identified.  Figure 2- 19b-f 
shows single particles of the 799 particles analyzed. These particles were selected as 
representative of each drug component.  Again, many particles do contain only one drug, 
but many others seem to contain remnants of several of the drug tablets.  This is again 
hypothesized to be due to the tablet-tablet collisions forming mixed component particles. 
The alarm algorithm also successfully identified the components of this drug mixture.  
534 particles were identified as containing aspirin, 606 as loratadine, 13 as 
phenylephrine, 581 as pseudoephedrine, and 206 as ibuprofen.  No false positives were 
detected for dextromethorphan, guaifenesin, acetaminophen, or chloroquine.  This 
averages to 2.4 identified components per particle, thought to be due to the tablet 
collisions. 
 
2-9-17: Emptied Vial 
The prior contents of a vial can also be detected with this system.  After analysis, the five 
tablets were removed from the sampling vial, and the empty vial reanalyzed.  While the 
number of residual particles dislodged from the empty vial was limited, over 500 
particles were analyzed.  Figure 2- 20b shows the resulting average mass spectrum from 
500 particles.  Figure 2- 20a shows 500 randomly selected particles from the vial 
containing the five tablets for comparison.  Although the ion abundances vary, all the 
identifying peaks are still detected for each drug tablet.  328, 348, 7, 353, and 155 
particles were identified as containing aspirin, loratadine, phenylephrine, 
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pseudoephedrine, or ibuprofen, respectively, with no false positives, again, indicating 
formation of multi-component particles. 
 
 
2-9-18: In Situ Sampling: Chloroquine Diphosphate and Loratadine 
The SPAMS technique is also successful when used to sample tablets in situ, i.e. in their 
actual commercial bottle.  11 chloroquine phosphate tablets remaining in their original 
bottle were sampled by taping the modified vial cap to the opening of the jar.  Mass 
spectra of 100 particles dislodged from these 11 tablets were analyzed in 64 seconds 
(fluence=2.4 nJ/µm2); all spectra were equivalent to those shown in Figure 2- 6 and all 
particles were identified by the rules trees as only containing chloroquine, with no false 
positives.  Finally, a single loratadine tablet was added to the eleven chloroquine 
phosphate tablets in this container to simulate the presence of a single illicit tablet in a 
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Figure 2- 20: a) average mass spectrum of 500 particles introduced from the complex 
sample containing 5 single active ingredient tablets including aspirin, ibuprofen, 
loratadine, phenylephrine, and pseudoephedrine, b) average mass spectrum of 500 
residual particles introduced from the emptied sampling vial. 
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container of licit materials.  The loratadine tablet accounted for 1.2% of the weight of the 
tablets in the container.  Using this same sampling method, particles were again identified 
as chloroquine, with mass spectra matching those in Figure 2- 6.  However, a particle 
identified as loratadine was detected 117 seconds after sampling began.  Figure 2- 21a 
shows the mass spectrum obtained from this single loratadine particle and Figure 2- 21b 
shows the averaged mass spectrum previously obtained from 100 loratadine particles 
sampled from a single tablet for comparison.  All identifying peaks are present, especially 
the [M-H]- and [M+H]+ ions which greatly facilitate identification.  The rules tree for 
loratadine identified this single particle, with no false identifications for the other drugs 
studied. 
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Figure 2- 21: a) Mass spectrum of a single particle of loratadine detected in an original 
bottle containing 11 chloroquine phosphate tablets, b) average mass spectrum of 100 
loratadine particles previously collected for comparison. 
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2-10: Conclusions 
As a technique that has previously proven successful for the detection of biological, 
explosive, and chemical warfare agent samples, it was hypothesized that SPAMS would 
also be an ideal detection system for drugs.  A novel sample formation and introduction 
system had to be developed for this application; the modified glass vial was an efficient, 
simple, and effective method for creating particles from solid samples due to their 
collisions with each other and the sides of the glass vial, and the slight vacuum of the 
SPAMS system allowed for the particles to be pulled into the system with no additional 
power requirements.  Many single component over-the-counter medications were 
analyzed and effectively characterized using SPAMS, including acetaminophen, aspirin, 
clemastine, diphenhydramine, ibuprofen, loratadine, phenylephrine, and 
pseudoephedrine.  These tablets were analyzed without destroying other forensically 
useful information, such as their shape, color, and markings.  Chloroquine was also 
identified in tablets, demonstrating the ability of SPAMS to be used for the identification 
of counterfeit drugs.  Additionally, multi-component medications were also analyzed, 
showing indicative peaks from all active ingredients.  These studies also included 
chlorpheniramine, dextromethorphan, and guaifenesin.  Multiple single component 
tablets were then simultaneously analyzed to show the ability of SPAMS to serve as a 
general screening device.  While many particles analyzed contained one drug, many also 
contained multiple drugs, and further experiments showed that this was caused by tablet-
tablet collisions in the glass vial, and not by multiple particles being simultaneously 
desorbed/ionized in the source region.  The study also highlights the ability of SPAMS to 
detect drug compounds even after they have been removed from the container.  This has 
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forensic applications to situations in which a suspected drug sample was discarded before 
seizure, leaving only the emptied container as possible evidence.  Enough residual 
particles were present in the emptied vial to allow for the collection and analysis of over 
500 particles.  Proof of concept in situ analysis experiments were performed by attaching 
the modified glass vial cap to a commercial chloroquine bottle.  The chloroquine was still 
effectively sampled and analyzed, reducing consumables and analysis time.  Finally, a 
single loratadine tablet placed in a bottle with multiple chloroquine tablets was 
successfully detected, even though it only made up 1.2% weight of the sample, 
demonstrating that SPAMS is a useful technique for detecting a single illicit tablet in a 
large batch of licit materials.  SPAMS has been successfully demonstrated as a useful and 
effective drug detection technique with over-the-counter medications, and it is 
hypothesized that it will also be an effective system for sensitive and rapid illicit drug 
detection. As such, SPAMS may be a powerful tool for border control and customs 
applications to provide almost instantaneous identifying information about the 
components in drug tablets. 
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CHAPTER 3: Breath Analysis – Method Developments 
3-1: Motivations and Introduction 
Although breathing is an involuntary action of the human body that often occurs 
unnoticed, it is one of the ways that the human body interacts with the world.  Gas 
exchange occurs each second, with oxygen being inhaled from the air, into the lung, 
transferring into the blood, and being delivered to muscles and organs throughout the 
body.  Carbon dioxide is then removed from the body in the reverse action.  However, 
more than O2-CO2 exchange is occurring at this blood-air barrier.  Other compounds, 
both volatile and non-volatile, are constantly being brought into and expelled from the 
body.  These compounds may range from being inhaled and exhaled with no interaction 
with the body, or may be inhaled, interact with the body and then be exhaled, or they may 
even be inhaled and metabolized before elimination.  Some compounds are also produced 
in the body and subsequently exhaled.  These compounds may provide insight into the 
processes regularly occurring in the body, from metabolism to oxidation. 
The non-invasive nature of breath analysis has generated significant interest in using 
profiles of breath constituents to derive information about physiological functions and 
interactions with the environment.  Applications including medical diagnostics, 
assessment of environmental contamination, and physiological monitoring are common 
interests in the breath analysis community.62  Homeland security applications of breath 
analysis have been suggested.62, 63  Investigation of whether breath analysis could be used 
to detect the prior activity of an individual, or even biometric applications have gained 
momentum recently. 
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Whatever the targeted application of breath analysis, fundamental studies are necessary to 
ensure the reliability of data obtained from breath analysis in such applications.  These 
fundamental studies must identify the problems and weaknesses in breath analysis, with 
the aim of solving some of these problems.  This chapter will describe efforts made to 
develop a breath analysis scheme capable of breath sampling, preconcentration, analysis, 
and interpretation.  Each of these segments of the scheme present individual challenges 
and options, many of which are addressed.  Several breath collection modifications are 
presented, and several detection challenges are discussed.  The next chapter will address 
more applications of breath analysis once a reliable system and method is established 
herein.   
 
3-2: Background on Breath Analysis 
Breath analysis has existed in a qualitative form for thousands of years.  Hippocrates 
described the process of diagnosing disease based on the odor of the breath of patients in 
the 4th century B.C..64 In the 18th century, the French scientist Antoine Lavoisier and 
colleagues measured the breath of guinea pigs to discover the presence of carbon dioxide 
in exhaled breath using a precipitation reaction.64, 65  The 19th century brought additional 
information on exhaled breath, as colorimetric tests were used to detect acetone in the 
breath of a diabetic patient and alcohol in the breath of a subject after consumption.65  
The detection of alcohol in breath grew in the 20th century, as the automotive industry 
boomed and impaired driving became an issue.  Bogen’s work in 1927 to quantify the 
ethanol in the blood by measuring the ethanol in the breath began the development of 
breathalyzers for legal and medical purposes.66  The larger scale application of breath 
63 
 
analysis garnered renewed interest with the work of Pauling in 1971.  In this work, 
Pauling et al. described that several hundred volatile organic compounds (VOCs) were 
present in breath in low, but measurable quantities.67   Since this work, these VOCs have 
been the subject of much research in medical and environmental realms. 
From a medical perspective breath analysis is appealing owing to the non-invasive 
diagnostic nature of the technique. Thus far, over 3000 VOCs have been detected in 
human breath,68 and variations in particular markers have been studied in relation to 
asthma,69-73 chronic obstructive pulmonary disease,74, 75 breast cancer,76-78 lung cancer,79-
85 lung infection,73, 86, 87 transplant rejection,88-90 and diabetes.91, 92  Breath samples are 
easily collected, and have been simplified to the point that the subjects can collect the 
breath privately in their own homes.93    From an environmental perspective, breath 
analysis has focused on detecting exposure to pollutants and industrial chemicals.94-101  
Several Environmental Protection Agency (EPA) studies have measured the breath of 
subjects throughout the United States, documenting exposure to chemicals such as 
automotive exhaust and cigarette smoke.97, 100-103 
No matter what the application, breath analysis relies on the principle that the lung 
alveolar air can be treated as the headspace of the blood stream, given the constant 
partitioning of volatile organic compounds (VOCs) between the two compartments via 
the alveolar pulmonary membrane (Figure 3- 1).68, 104 
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For medical diagnostics, the compounds of interest are the endogenous compounds in 
breath that are formed by metabolic processes taking place in vivo.68, 105  For 
environmental applications the other compounds present in breath, including exogenous 
compounds that are inhaled, are of interest.  Once inhaled, these compounds can be 
passed across the alveolar membrane and be distributed throughout the body via the 
bloodstream.  These compounds can then be cleared via many pathways, including 
respiration.  Breath analysis therefore presents an interesting and non-invasive method of 
detecting chemical exposure as well as monitoring the clearance of such chemicals. 
 
  
Alveolar 
Pulmonary 
Membrane
Capillary
Alveolus
Figure 3- 1: Diagram of the alveolar-capillary interface.  Alveolar air sacks within the 
bronchioles of the lung are in close contact with the blood stream via the alveolar-
pulmonary membrane.  Oxygen and carbon dioxide, as well as VOCs, partition across 
this membrane, making the alveolar air function as a headspace of the blood. (Image 
originally in color) 
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3-3: Breath Collection Methods 
Several commercial and laboratory-based devices have been used for breath collection.  
The RTube™ (Respiratory Research, Inc., Charlottesville, VA) is one such device, a 
commercially available, FDA approved, disposable exhaled breath condensate (EBC) 
collection system (Figure 3- 2).  The RTube™ consists of a polypropylene tube fitted to a 
polyethylene mouthpiece.  The subject inhales through the mouthpiece via a one-way 
valve (valve A) fitted with a saliva trap to prevent sample contamination.  The subject 
then exhales through the mouthpiece into a polypropylene collection tube via a second 
one-way valve (valve B).  The polypropylene collection tube is placed inside an 
aluminum sleeve cooled in a freezer (-20 or -80 ºC) prior to collection (not shown).  In 
this configuration, breath passing through the collection tube condenses and collects at 
the base of polypropylene tube. 
 
 
Valve A
Valve B
Figure 3- 2: Picture of the RTube™.  The RTube™ is used for EBC collection and can be 
chilled with a previously frozen aluminum sleeve. (Image originally in color) 
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The ECoScreen II (VIASYS Healthcare, Yorba Linda, CA) is a third generation EBC 
collection system that also incorporates a spirometer to control either volume or time 
during collection (Figure 3- 3).  The subject exhales through the mouthpiece into a 
pneumotachograph, where the rate of airflow is measured, and the breath is then passed 
into a polyethylene collector, stored in a temperature-controlled unit.  A unique feature of 
the ECoScreen II is the optional use of a second collector, thus allowing separation of 
alveolar air from dead space air.  A portable version is also available, the ECoScreen 
Turbo, which uses a Peltier cooler to maintain the temperature of the breath collectors. 
 
Summa canisters are also used for breath collection.  A Summa canister is a stainless 
steel container whose inner surfaces are passivated by electropolishing with chemical 
deactivation.  Summa canisters are held under vacuum before sample collection, so they 
Figure 3- 3: Diagram of the ECoScreen II.  This device is used to collect EBC and can 
also control the volume or time of sample collection. (Image originally in color) 
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may be stored for up to 30 days before use.  These canisters were used for the extensive 
experiments of the EPA’s environmental studies.98, 100-102, 106-109 
 
3-4: Volatile and Non-Volatile Components 
Breath analysis has focused on both the volatile and non-volatile components in breath.  
Though they have various sources, both classes of components provide interesting 
information about the subject.  The volatile components in breath range from oxygen, 
nitrogen, and carbon dioxide, which compose over 99% of inhaled air, to the low 
concentrations (ppbv and below) of acetone, methanol, and many alkanes and methylated 
alkanes.  The non-volatile components of breath are often proteins, oxidation or nitration 
products, cytokines, eicosanoids, and mediators.110  One of the most abundant 
constituents of breath is water, which is exhaled in the form of respiratory droplets; 
aerosol particles can become trapped in these droplets, allowing them to be expelled.111  
Most breath analysis techniques focus on either the volatile or non-volatile components.  
Work by Zenobi et al. is of interest because the extractive electrospray ionization used 
with mass spectrometry allows the detection of volatile and non-volatile components 
simultaneously from the same breath of air.112 
 
3-5: Breath Analysis Techniques 
Many techniques have been pursued for analysis of exhaled breath including enzyme-
linked immunosorbent assay (ELISA),113, 114 colorimetric tests,115, 116optical 
spectroscopy,116, 117 high performance liquid chromatography, 72, 116 ion mobility 
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spectrometry,87 liquid chromatography-mass spectrometry (LC-MS),72, 74, 75 GC with 
flame ionization detection (GC-FID),19, 118-120 and GC-MS.68, 76, 79-84, 86, 88, 89, 92, 99, 100, 105, 
120-127  Ekips Technologies has developed a system approved by the FDA for research 
studies called the Breathmeter.70  The Breathmeter uses tunable diode later spectroscopy 
to detect both organic and inorganic components in breath.  The mid-IR absorption of 
many compounds allows for internal calibration and wide-range detection with laser 
tuning.  Aerocine Inc. markets the first FDA-approved system called NIOX Flex which 
uses chemiluminescence to monitor NO in exhaled breath with a detection limit of 2 
ppb.128  Toda et al. developed a breath isoprene detection system based on its 
chemiluminescence after reaction with ozone with a limit of detection of 0.6 ppbv.129  
Plodinec and Wang used cavity ring-down spectroscopy for the detection of breath 
acetone in a single breath.130  Amirav et al. demonstrated the use of gas chromatography 
– electrolyzer-fed FID (GC-EFID) for breath detection of ethanol, isoprene, pentane, and 
acetone.131  This system generated its own combustion gases from water and thus was gas 
cylinder-free making it more field-portable.131  Sacks et al. used GC-GC for breath 
detection, achieving limits of detection in the ppt range.132  The most common breath 
detection system currently used is gas chromatography-mass spectrometry (GC-MS). 
Gas chromatography-mass spectrometry (GC-MS) has shown great potential for breath 
analysis, due to its selectivity and sensitivity.68, 76, 79-84, 86, 88, 89, 92, 99, 100, 104, 120-127  Indeed, a 
breath analysis apparatus using GC-MS, Heartsbreath, developed by Menssana Research, 
Inc. has recently been approved by the FDA as a test for heart transplant rejection.89  
Chemical exposure has also been detected using GC-MS.100-102, 125, 133  Sofia et al. studied 
toluene in the exhaled breath condensate (EBC) of individuals exposed to the chemical 
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via inhalation.99  A relationship between concentration in the environment and EBC was 
determined, and the toluene concentration in the EBC decreased with time after the 
exposure ended.99  However, no efforts were made to ensure that additional exposure, e.g. 
from clothing, did not inadvertently occur during sampling. 
 
3-6: Issues in Breath Analysis 
3-6-1: Preconcentration 
A major difficulty in accurate breath analysis is the low concentrations of the VOCs that 
are present in breath samples (ppbv and below).  This issue is compounded by issues 
including the dilution of VOCs by extraneous air as well as loss of VOCs during 
condensation if EBC is to be collected.  To circumvent this issue, several techniques have 
been developed to preconcentrate a breath sample before analysis.  Gordin and Amirav 
have developed the ‘Snifprobe’ as a novel preconcentration method.134  The Snifprobe 
consists of a small length of capillary or porous layer open tubular (PLOT) column that 
preconcentrates the sample.  Breath was sampled for 5 s through the Snifprobe, after 
which the entire column segment was placed inside a direct/dirty sample introduction 
device (DSI) which was then inserted into the GC injector for thermal desorption.134  A 
limit of detection for ethanol was stated in the low ppb (v/v) level.134  Several researchers 
have also used a sorbent material to sample from a bag or chamber containing a breath 
sample.19, 81, 83, 100, 118, 127, 129  In this manner, preconcentration takes place after breath 
collection.  Other groups have created in-line preconcentration methods.100, 122, 125, 126, 135, 
136  Phillips, for example, has developed a breath collection apparatus (BCA) which 
incorporates a sorbent trap in-line with the breath flow so that VOCs are preconcentrated 
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as the breath sample is collected.68, 76, 79, 80, 82, 86, 89, 92, 122-124   Several generations of this 
instrument have been developed, the latest being the BCA 6.0 (Menssana Research, 
Inc.).137  A promising tool for breath VOC preconcentration is solid phase 
microextraction (SPME) which was included in a recent review.94 
SPME was developed in 1989 by Belardi and Pawliszyn138 as a method to quickly, 
inexpensively, and easily preconcentrate chemicals of interest.  The SPME fiber is 
typically an inch-long piece of fused silica coated with various polymeric materials 
depending on the target compounds for preconcentration.  The SPME fiber is housed in a 
standard injection needle, so introduction to the GC is simple, and desorption occurs in 
the heated injection port.  Compounds are absorbed or adsorbed to the fiber from the 
sample.  The SPME fiber can be directly exposed to a liquid sample, where the analyte 
will partition between the liquid phase of the sample and the liquid phase of the SPME 
fiber coating, or exposed in the headspace of a sample, where the analyte partitions 
between the sample, the gaseous phase above the sample, and the SPME fiber coating.  
SPME can be used quantitatively as the amount of analyte absorbed/adsorbed to the fiber 
is proportional to the concentration of the analyte in the sample. 
An analyte partitions into a SPME fiber according to Equation 3- 1:139, 140 
sVhVhsfVfs
oCsVfVfs
fn 



 
Equation 3- 1: Equation describing the partitioning of an analyte into a SPME fiber 
coating. 
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Where nf is the amount of analyte extracted into the SPME fiber, κfs is the distribution 
constant of the analyte between the liquid sample and the SPME coating, Vf is the 
volume of the SPME coating, Vs is the volume of the liquid sample, Co is the 
concentration of the analyte in the sample, κhs is the distribution constant of the analyte 
between the gaseous phase and the SPME coating, Vh is the gas volume of the vial, and 
Vs is the volume of the liquid sample. 
SPME sampling can be passive, where a breath sample is obtained and later exposed to a 
SPME fiber, or active, where a breath sample is exposed to a SPME fiber as it is 
obtained.105  Wang et al. used passive sampling to preconcentrate breath samples 
obtained in Tedlar® sampling bags, obtaining sub ng/mL detection limits for many 
VOCs.119  Mutti et al. used a similar technique, collecting breath samples into Teflon 
bulbs into which a SPME fiber was inserted for preconcentration, with limits of detection 
on the order of 10-12 M.84  Grote and Pawliszyn have used SPME for active breath 
sampling.141  The SPME fiber was inserted into an inert tube serving as a mouthpiece, 
and acetone, isoprene, and ethanol were analyzed using GC-MS.141 
 
3-6-2: Contamination 
Because of the influence of exogenous VOCs on the air exhaled by a subject, some 
emphasis has been placed on ensuring the inhaled air supply of a subject is clean.  One 
solution is to provide a closed source of air for the subject.81, 83, 96, 127, 142, 143  Although 
effective, this method is reagent consuming and makes the testing apparatus importable.  
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Others have required subjects to sit in the sampling environment for a set period of time 
to allow equilibration with the environmental air.92, 119, 124  This is very time consuming 
for the subjects and requires a single sampling location to compare groups of subjects.  
Others still have attempted to clean the ambient air using charcoal filters133, 143  Many 
studies do not cleanse the inhaled air supply;19, 72, 75, 85, 87, 113, 116, 118-120, 129, 136, 144-147 
commonly a background sample of the ambient air is sampled at the same time as the 
subject who has reached equilibrium with the room air donates a breath sample and 
calculation of the alveolar gradient (concentration in the breath – concentration in the 
ambient air) is thought to eliminate any effects of contaminated inhaled air.68, 76, 79, 80, 82, 86, 
89, 92, 122, 123, 126 124, 148  A positive alveolar gradient suggests that VOC was manufactured 
in the body while a negative alveolar gradient indicates the source of the VOC is external 
to the body.149  While this technique has advantages in the determination of kinetics and 
metabolomics, it does require that equilibrium exists for all VOCs in the body and the 
ambient air – a condition that may be difficult to achieve in select situations.  Also, 
important information about occupational and incidental chemical exposure can be 
gained by studying the real-time exposure of a subject. 
This work presents the use of a commercial respirator cartridge or PVC tubing for 
purifying the inhaled air.  This reduces the amount and concentration of exogenous 
substances a subject inhales during sample collection, but can also reduce exposure via 
clothing or skin after exposure. 
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3-7: Background of Gas Chromatography-Mass Spectrometry 
Gas Chromatography-Mass Spectrometry (GC-MS) is an orthogonal detection technique 
that combines the separation ability of chromatography with the specificity of mass 
spectrometry.  GC is used to separate complex mixtures into more simple or pure 
components as a method of sample clean-up and/or to prepare more pure materials for 
sample analysis.  The comparison of the retention time of a compound on 2 columns of 
differing polarities with that of an unknown sample is a presumptive method of 
compound identification.  Mass spectrometry is used to analyze the components in a 
sample, allowing identification based on the fragmentation patterns of the analyte.  Gas 
chromatography was first coupled to mass spectrometry in 1958 and has evolved over the 
last 5 decades into a common bench-top technique used in many standard operating 
procedures in environmental, forensic, and research laboratories.150 
 
3-7-1: Gas Chromatography Theory 
Gas chromatography was first described by Martin and Synge in 1941 and demonstrated 
in 1952 by Martin and James.151, 152  Gas chromatography, or gas-liquid chromatography, 
relies on a gaseous mobile phase carrying an analyte through a column fitted with a liquid 
stationary phase supported by a solid material. Gas-solid chromatography has also been 
described, but has not garnered as much success or attention as gas-liquid 
chromatography.  As the solute passes through the column, it partitions between the 
stationary and mobile phases.  The equilibrium constant of this process, KD, depends on 
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the solute, the stationary phase, and the temperature, and can be relate to the partition 
ratio (k) and phase ratio (β) of the separation according to Equation 3- 2. 
 
 
k
phasegasmobile
phaseliquidstationary
DK  )(
)(
 
 
The partition ratio is a measure of how long an analyte spends in the stationary phase, 
and is related to the retention time, tR, which is the time an analyte spends in the column 
before elution.  The standard compound, methane, is used as a comparison for partition 
ratios, since methane is considered to not be retained by a stationary phase, and spends all 
the time in the column in the mobile phase, and thus has the minimum retention time 
possible in a column.  Thus, 
Mt
Rt
Mt
MtRtk
'


  
where k is the partition ratio, tR is the retention time of the analyte, tM is the retention 
time of methane and tR’ is the time an analyte spends in the mobile phase.  The phase 
ratio (β) can be defined as the ratio between the volume of gas in the column and the 
volume of the liquid stationary phase, 
Equation 3- 2: Description of the equilibrium constant of an analyte as it partitions 
between the stationary and mobile phases during separation. 
Equation 3- 3: Relationship between the partition ratio and retention time. 
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r
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where r is the radius of the column and df is the thickness of the film of the stationary 
phase. 
The efficiency of a chromatographic column can be expressed in terms of theoretical 
plates, or effective theoretical plates.  The use of the term ‘theoretical plates’ refers to the 
early fractionating distillation columns which indeed had discrete plates to perform the 
separation; chromatographic columns of today do not have discrete plates, so ‘theoretical 
plates’ is used to describe the efficiency in a relative manner.  Theoretical plates (n) were 
originally used to define efficiency: 
2
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with WH being the width at half height of a peak.    Effective theoretical plates (N) are 
used to describe the actual time that an analyte is in the mobile phase of the column, thus 
modifying Equation 3- 5 to be: 
Equation 3- 4: Definition of the phase ratio. 
 
Equation 3- 5: Definition of the number of theoretical plates. 
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3-7-2: Mass Spectrometry Theory 
The roots of mass spectrometry are based in the late 19th century with the analysis of 
positive ions using magnetic deflection by Wien.150  Although there are many types of 
mass spectrometry, all mass spectrometers detect ions, positive or negative.  A sample 
must be introduced to the system (sample introduction), ions must be formed (ionization 
region), separated (mass analyzer), and detected (detector), and the data must be 
processed and output into an understandable form (readout). 
There are a variety of sample introduction methods, all requiring introduction of a sample 
to the mass spectrometer in the gas phase, which must be held under high vacuum in 
order to reduce ion-molecule collisions.  These collisions may cause the ions to lose their 
charge, thus losing their ability to be detected, cause ions to undergo reactions, or deflect 
ion trajectories.  Therefore to reduce these ion collisions, the mean free path of an ion is 
important.  The mean free path (L, cm), is defined as: 
22
1
pn
L   
Equation 3- 6: Definition of the effective number of theoretical plates. 
Equation 3- 7: Definition of the mean free path of an ion. 
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where p is the pressure (Pa), n is the number of moles per cm3 and σ is the collision 
diameter (cm).  The mean free path of an ion should be at least 1 m in most mass 
spectrometry applications, which requires a pressure of 66 nbar or lower as shown in 
Equation 3- 8: 
L
p
66.0
  
approximated for 300 K and σ =3.8x10-10 molecules/cm3.  Often chromatographic 
methods are used for sample introduction as they allow for compound separation and 
sample cleanup.  Other options include bleeding a gaseous sample into the ionization 
region, or novel methods such as Direct Electrospray Ionization (DESI) or Direct 
Analysis in Real Time (DART) that combine the sample introduction, gasification, and 
ionization steps. 
The ionization region produces ions from the sample for analysis.  Several ionization 
sources are available, most commonly electron ionization (EI) or chemical ionization (CI) 
are used in GC-MS, but other ionization sources exist for other applications.  In electron 
ionization, the sample is ionized by interactions with electrons.  The electrons are 
produced by heating a filament, and accelerated towards an anodic plate.  As the 
electrons travel through the source, they encounter the gaseous sample, and if the 
wavelength of the electron approaches the bond length of the molecules in the sample, 
energy transfer may occur, and an electron is expelled from the molecule, creating a 
Equation 3- 8: Approximation of the mean free path of an ion at 300 K and 3.8x10-10
molecules/cm3. 
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positive ion.  Typical electron energy of 70 eV is used for the ionization of organic 
molecules, which maximizes the ionization efficiency to ~0.1% on average because of 
the similar de Broglie wavelength of the electrons and bond length of the organic 
molecules (~ 0.14 nm).  Only the positive molecular ion is formed using EI, as the energy 
of the electrons is too high for electron capture to occur.  Fragmentation of the molecule 
is common using EI, creating fragment ions which are also detected. 
Another common ionization method is chemical ionization (CI) which involves the 
introduction of a reagent gas, such as methane, which is ionized using electron ionization.  
The ions produced will then collide and react with other molecules of reagent gas, 
creating a series of ions in the source region.  These reagent gas ions will then react with 
the sample molecules, ionizing them in a ‘soft’ ionization process that causes minimal 
fragmentation.  Deposition of energy into analyte ions is much less than for EI because it 
depends on the thermodynamics of the ion-molecule reaction. 
After ions are produced they must be separated before detection.  This separation occurs 
in the mass analyzer, which is commonly a quadrupole mass analyzer for GC-MS and is 
the mass analyzer used in the instruments used in these experiments.  A quadrupole mass 
analyzer consists of 4 parallel hyperbolic rods, although circular rods are more commonly 
used.  An electric field consisting of a quadrupolar oscillating field superimposed on a 
constant electric field exists in the center of the analyzer, following: 
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where Φ0 is the potential applied to the rods, ω is the angular frequency, and U is the 
constant potential and V is the peak amplitude of the RF voltage.  The angular frequency 
is related to the frequency of the RF field by Equation 3- 10: 
f 2  
 
where f is the frequency of the RF field.  Ions created in the source region are accelerated 
along the z-axis via focusing lenses into the space between the rods.  The electric field 
induces forces on the ions in the x and y directions, causing the ion to move away from 
and towards the rods.  If the ion does not change directions quickly enough with the 
oscillation of the RF field, it will collide with the rod and be discharged.  If the ion 
direction oscillates with the RF field the entire time it is within the rods, it will pass 
through to the detector with its charge intact.  Thus, by modifying the electric field, i.e. 
controlling U and V, ions of a specified mass-to-charge ratio can be selectively passed 
through to the detector.  For detection of a wide range of m/z, U and V must be scanned 
to allow ions of successive m/z to be passed through the mass analyzer.  Generally, the 
U/V ratio is kept constant to allow this successive detection. 
Equation 3- 9: Equations describing the electric field formed in the center of a 
quadrupole mass analyzer. 
 
Equation 3- 10: Relationship between angular frequency and RF field frequency. 
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The ions that pass through the mass analyzer are converted to electrons by collisions with 
a conversion dynode, and these secondary electrons are detected using an electron 
multiplier, typically a continuous dynode electron multiplier.  In an electron multiplier, 
the charged particle collides with a metal or lead oxide coated surface of low work 
function, inducing the emission of 1-3 electrons.  These electrons are then accelerated 
onto another plate, inducing an additional 1-3 electrons each.  This process is repeated 
numerous times until a gain in signal of about 105 is realized.  The current induced in this 
process is measured as a voltage drop across a resistor, and this voltage is converted to a 
digital value and stored on a computer.  A mass calibration function assigns m/z values to 
each ion based on the U and V potentials that are applied coincident with the arrival time 
of each ion. 
 
3-7-3: GC-MS Description 
A schematic of a GC-MS instrument used at LLNL is shown in Figure 3- 4. 
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The sample is introduced to the instrument through a temperature controlled injection 
port using a syringe (liquid samples) or a solid phase microextraction (SPME) fiber, 
discussed previously, where a solid preconcentrating material is injected via syringe 
needle and the adsorbed sample  is thermally desorbed from the material.  The sample is 
vaporized and carried onto the capillary column by a flow of carrier gas, typically helium.  
The column is stored in a temperature controlled oven, and the initial temperature is 
typically held at a point lower than that of the injection port, causing the vaporized 
sample to condense at the head of the column.  The carrier gas carries the sample through 
the column and the analytes partition between the mobile (carrier gas) and stationary 
phases (column coating) to different extents.  Compounds that partition more into the 
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Figure 3- 4: Schematic of a gas chromatograph-mass spectrometer (GC-MS).  A sample 
is injected onto a capillary column held inside a temperature programmed oven.  As the 
sample passes through the column, components separate based on partitioning between 
the mobile and stationary phases of the column, aided by the temperature ramp in the 
oven.  The components exit the column directly into the source region of the mass 
spectrometer, where they are ionized, fragmented, and pass into the mass analyzer, 
where the fragments are detected.  The resulting data includes a chromatogram with a 
corresponding mass spectrum for each time point. (Image originally in color) 
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mobile phase are transported through the column faster than compounds retained more in 
the stationary phase, causing the separation to occur.  The temperature of the oven is 
often increased with time, aiding volatilization of less volatile analytes.  The end of the 
column is positioned inside the ionization chamber of the mass spectrometer, where the 
pressure is held in the range of 10-6-10-5 Torr.  Each analyte is ionized via electron 
ionization (EI) as it elutes from the column.  The resulting ions are accelerated through 
the quadrupole mass analyzer and are detected by the electron multiplier.  The signal is 
digitized and the data readout provided through the commercial software that also 
operates the instrument. 
The current study demonstrates an in-house modification of a standard exhaled breath 
condensate collection device, the RTube™ (Respiratory Research, Inc., Charlottesville, 
VA).  This modification reduces the time of analysis from sampling to results to 27 
minutes, as well as eliminates the need for a freezer, making the sampling device more 
field-friendly, and increases the sensitivity.  This study also shows the need for 
purification of inhaled air in some cases and describes additional RTube™ modifications 
that meet this need. 
 
3-8: Instrument Description 
3-8-1: Agilent System 
An Agilent (Santa Clara, CA) 6890N GC equipped with a SPME inlet sleeve and an 
Agilent J&W DB-5MS column (30 m x 0.25 mm x 0.25 µm, equivalent to 5% phenyl, 
95% methylpolysiloxane) was used for the separation of all compounds.  Helium 
(99.999%, Praxair, Inc., Danbury, CT) was used as a carrier gas and the GC was operated 
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in constant pressure mode (10 psi).  The injector temperature was held at 250 ºC, and the 
oven temperature was held at 40ºC for 1 min, then ramped at 20ºC/min to 300ºC, where it 
was held for 3 min.  Detection was carried out with an Agilent 5973 MS detector (Santa 
Clara, CA), using 70 eV electron ionization and operated in scan mode (m/z 40 – 450) at 
3.54 scans/s, with the source held at 230ºC and the mass analyzer (quadrupole) held at 
150ºC.  ChemStation software was used for data collection and analysis. 
 
3-8-2: Shimadzu System 
A Shimadzu (Pleasanton, CA) QP2010 with a SPME inlet sleeve and fitted with an 
Agilent J&W DB-5MS column was used.  The same method was used as in the Agilent 
system.  GCMS Solutions software was used for data collection and analysis. 
Compounds were identified based on comparison of their mass spectra with those in the 
NIST Mass Spectral Library (RMatch >700, NIST MS Search 2.0, NIST, Gaithersburg, 
MD) as well as mass spectra published in the literature, and comparison of retention time 
with pure chemicals when available. 
 
3-9: Materials 
Frozen lemonade concentrate (Safeway/Vons Lemonade, Safeway, Inc., Pleasanton, CA) 
was purchased from a local supermarket and reconstituted according the manufacturer’s 
instructions.  Samples were used the day of reconstitution after reaching room 
temperature (24 ºC).  Nail Polish (ORLY Nail Color, Orly International, Inc., Los 
Angeles, CA) was obtained from commercial sources and used as is.  Gasoline (89 octane 
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automotive grade) was obtained from a local gas station.  D-Camphor was obtained from 
J.T. Baker, Inc. (Phillipsburg, NJ).  A 65.3 mM solution was made in a 1:4 solution of 
H2O:methanol and stored in a glass vial.  (1S)-(-)-β-pinene (99%) was obtained from Alfa 
Aesar (Ward Hill, MA) and +/- α-limonene (95%) was obtained from TCI America, Inc. 
(Portland, OR). 
 
3-10: Subjects 
Fourteen healthy adults were recruited as subjects for this study.  All subjects had no 
known respiratory ailments and did not report any routine chemical exposure on a 
questionnaire.  The Institutional Review Board (IRB) at Lawrence Livermore National 
Laboratory (LLNL) as well as the IRB at Michigan State University approved the study 
and formal written informed consent was obtained from each subject prior to 
participation. 
 
3-11: Original Sample Collection (EBC) 
Exhaled breath condensate (EBC) was originally collected as per the RTube™ 
manufacturer’s instructions.  The aluminum sleeve was cooled in a -80ºC freezer 
overnight, and then placed in the insulating sleeve on the RTube™ body.  The subject 
held the RTube™ and inhaled and exhaled through the mouthpiece, causing the exhaled 
breath to condense on the walls of the cooled polypropylene tube.  Breath samples were 
collected for 10 minutes, after which the mouthpiece apparatus was removed from the 
RTube™, and the polypropylene tube placed on a plunger which caused the liquid 
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condensate to be collected in a small volume area of the tube.  The liquid was then 
divided into 500 µL aliquots in microcentrifuge vials and the excess vials refrigerated.  A 
single EBC aliquot was sampled using a SPME fiber under direct exposure for 10 
minutes which was then injected into the GC-MS.  The SPME fiber was predesorbed 
during a ‘blank’ GC-MS run each morning before any breath sampling occurred.  After 
collection the RTube™ was washed with methanol followed by water, followed by D.I. 
water and dried before reuse.  Studies demonstrated there was no carryover effect from 
reusing the RTube™ after cleaning. 
 
3-12: GC-MS Method Development 
3-12-1: GC Method Optimization 
Experiments were performed to optimize the GC-MS method used for analysis.  Mass 
spectra were acquired over m/z 40-450.  The temperature ramp of the GC oven was 
modified to create different methods to optimize the separation of a breath sample.  EBC 
was used in order to have a single sample that could be analyzed using each method.  
Four methods were created and are shown in Table 3- 1.  A single EBC sample was 
collected from the subject, and split into 4 0.5 mL aliquots.  A SPME fiber was directly 
exposed to the liquid condensate for 10 min.  Figure 3- 5 shows total ion chromatograms 
obtained using each method.  Overall peak area is consistent throughout methods 1-3, 
with 8.3% RSD for the total integrated area under the curve; however, the total area 
under the curve for method 4 was approximately 3 times larger than for the other 
methods..  The peak area for the peak attributed to acetone, at approximately 1.4 min, 
revealed an RSD of only 4.9% across all 4 methods.  Integration using the ChemStation 
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Software (RTE Integrator, 6000 count area minimum) identified 61, 48, 52, and 11 peaks, 
respectively for each method.  Method 1 was therefore selected to provide an optimal 
separation method based on number of peaks detected and time of analysis. 
  
Table 3- 1: Description of method parameters for methods tested to optimize the 
separation of breath samples. 
 Method 1 Method 2 Method 3 Method 4 
Starting Temp 40ºC (1 min) 40ºC (1 min) 40ºC (1 min) 40ºC (1 min) 
Ramp Rate 20ºC/min 15ºC/min 10ºC/min 1ºC/min 
Final Temp 300 (5 min) 300 (5 min) 300 (5 min) 300 (5 min) 
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Figure 3- 5: GC-MS total ion chromatograms obtained from a single breath sample 
analyzed with the 4 methods shown in Table 3- 1.   Method 1 was selected as the 
optimal detection method. 
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3-12-2: SPME Exposure Time Optimization 
The SPME PDMS/DVB fiber coating was selected based on the literature using SPME 
for breath analysis141, 153  and the need to preconcentrate mostly semi-volatile compounds, 
and was confirmed based on conversations with other researchers in the breath analysis 
field.154  The exposure time was optimized in two sets of experiments, one using EBC 
and one using EBV.  Figure 3- 6 shows the peak area of three peaks detected in EBV 
collected for 0.5, 1, 2, 5, and 10 min.  These compounds, an unidentified branched alkane 
(RT=7.83 min), decanal (RT=7.29 min), and an unidentified alcohol (RT=10.67 min), 
were selected to represent an alkane, an aldehyde, and an alcohol, respectively.  Data 
points are the average of 3 replicates taken in a single day.  A sampling time of 10 min 
was optimal and used for the remainder of the experiments.155 
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Figure 3- 6: Comparison of TIC peak area to exposure time of SPME fiber.  The 
exposure time of the SPME fiber is equivalent to the breath collection time for these EBV 
samples. (Image originally in color) 
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3-13: Comparison of Breath to Background Air 
It is important to understand the source of inhaled air to determine whether a compound 
detected on breath is exogenous or endogenous.  The inhaled air was measured by 
exposing a SPME fiber for 10 minutes on a desk in the room where breath samples were 
obtained.  This SPME fiber was then analyzed using the standard GC-MS method.  
Figure 3- 7a shows the chromatogram obtained after exposure to room air.  There are 
several peaks present in the sample. Table 3- 2 shows the tentative identification as well 
as retention time of these peaks.  Figure 3- 7b shows a representative breath sample 
(EBC) collected from a single subject.  Figure 3- 7c shows this same sample with the 
contribution from the room air subtracted.  While many peaks in the room air and seen in 
the breath, the concentration is much larger in breath. 
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Figure 3- 7: Chromatograms obtained from (a) 10 minute exposure of the SPME fiber to 
the ambient room air at the collection site, (b) a representative breath sample (EBC), and 
(c) the difference between the chromatograms in a and b.  Note that the majority of peaks 
in breath are in much greater concentration than those in the room air. 
91 
 
Peak Compound  RT   Peak  Compound  RT  
1 Carbon dioxide 1.33   14 3-ethyl-Benzaldehyde  7.01  
2 Dimethyl silanediol  2.35  15 4-ethyl-Benzaldehyde  7.17  
3 Butanoic acid, ethyl ester  3.42   16 Decanal  7.30  
4 Hexamethyl 
cyclotricyloxane  
3.55   17 2,4-diisocyanato-1-methyl-
benzene  
8.52  
5 Unidentified aromatic  4.29   18 1,3-dihydro-5-methyl-2H-
benzimidazol-2-one  
8.91  
6 Benzaldehyde  5.12   19 1,3-dihydro-5-methyl-2H-
benzimidazol-2-one  
8.95  
7 Octamethyl 
Cylcotetrasiloxane  
5.18   20 Unidentified compound  9.04  
8 6-methyl-5-Hepten-2-one  5.28   21 1-tridecanol  9.35  
9 Hexanoic acid, ethyl ester  5.40   22 6-undecylamine  12.00 
10 2-(2-ethoxyethoxy)-
ethanol  
5.43   23 Bisphenol A  13.59 
11 Benzyl alcohol  5.79   24 Unidentified Compound  16.19 
12 Nonanal  6.42   25 2-hydroxy-1-(hydroxymethyl) 
ethyl ester-octadecanoic acid  
16.43 
13 Decamethyl-
cyclopentasiloxane  
6.58      
 
  
Table 3- 2: Compounds and corresponding retention times tentatively identified in a 
SPME sample of room air. 
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3-14: Reproducibility Studies 
3-14-1: Repeatability of Measurement 
A study was undertaken to determine the injection to injection repeatability of the 
measurement.  Since breath itself is a variable matrix, sensitive to storage and the activity 
of each subject, a standard of diethyl ethylphosphonate (DEEP) was spiked into samples 
for measurement; thus, the matrix effects of breath were still present.  In order to generate 
a larger volume of sample, EBC was simultaneously collected from two subjects, and 
combined for a total of approximately 5.7 mL of EBC.  15 µL of a 0.031 M solution of 
DEEP in methanol was spiked into 5.5 mL of this combined EBC sample.  The sample 
was then divided into eleven, 0.5 µL aliquots, each of which was refrigerated until 
analysis by GC-MS.  Samples were analyzed 19, 79, 139, 199, 260, and 441 minutes, as 
well as 24.3, 48.9, 49.3, 72.9, and 96.1 hours after sample collection.  Chromatograms 
obtained from the samples at 48.9 and 72.9 hours after exposure were eliminated because 
the SPME fiber was exposed to the sample longer than intended.  Peak areas were 
calculated by manually integrating the area of the peak at 6.23 min due to DEEP in each 
sample.  The relative standard deviation (RSD) was determined to be 11.7%.  This 
measurement includes error in sample dilution, SPME fiber exposure time, and 
instrument variation.   
 
3-14-2: Single Subject, Single Day 
Intra-subject variation is a concern when developing an analytical method relying on 
biological samples.  Natural variation between samples may cause a false positive or false 
negative test if it is not understood.  This variation may occur on a short time scale, being 
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present within multiple samples collected in a single day, or on a longer time scale, being 
present within samples collected over the course of weeks or months.  In order to study 
the short-term variation, EBV samples were collected from a single subject throughout 
the day. 19 samples were analyzed using the standard GC-MS method immediately after 
collection.  The GC-MS data files were processed using MarkerLynx, which extracts XIC 
peak areas for nontargeted analytes, in this case extracting an integrated area for a single 
m/z from each detected peak.  Method parameters for XIC peak area extraction are 
shown in Table 3- 3. 
Retention Time Window 0-17 min 
Mass Range 40-450 Da 
Mass Tolerance 0.30 Da 
Use Relative Retention Time No 
Peak Width at 5% Height 1 s (automatic) 
Peak-to-Peak Baseline Noise 0 (automatic) 
Masses per Retention Time 1 
Minimum Intensity 1% of base peak intensity 
Mass Window 0.3 
Retention Time Window 0.2 
Noise Elimination Level 0 
Deisotope Data No 
Peak Area Normalization None 
Peak Area Scaling None 
 
Markers at m/z 45, 73, 77, and 207 were excluded as they arise from septum and column 
bleed, and m/z 93 was also excluded as this is the major m/z peak in terpenes, which the 
Table 3- 3: MarkerLynx method parameters for peak area extraction 
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subject consumed in lemonade the day of sampling.  Ninety marker compounds were 
reported.  The standard error of the mean (SEM) of the raw peak area of each marker for 
the 19 samples was calculated.  27.8% (25) of the markers had a SEM of <5%, 8.9% (8) 
had an SEM between 5% and 10%, 10.0%  (9) had an SEM between 10% and 15%,  
5.6% (5) had an SEM between 15-20%, 7.8%  (7) had an SEM between 20-25%, and 
21.1% (19) had an SEM >50%.  Of the markers with an SEM <5%, 72.0% (18) had an 
SEM <1%.  These results show that the intra-subject variation during a single day is less 
than 25% for the majority of markers.  The variance is lower for those markers with 
lower average peak areas, with those with an SEM<1% ranging from 0.157-2.31 a.u., 
those with SEM<5% ranging from 3.61-5.69 a.u., SEM<10% ranging from 6.59-298 a.u., 
SEM<15% ranging from 11.5-364 a.u., SEM<20% ranging from 29.5-45.8 a.u., 
SEM<25%ranging from 33.8-564 a.u., and SEM>50% ranging from 93.0-11800 a.u.. 
 
3-14-3: Single Subject, Multiple Days 
Intra-subject variation is not only caused by the variation in the breath composition 
throughout a single day, but also by the long-term variation in the breath.  This type of 
variation could be caused by more major lifestyle changes, including diet, exercise, 
environment, and stress.155 This long-term variation was studied by collecting 25 EBV 
samples from a single subject over the course of 1 month.  Samples were analyzed using 
the standard GC-MS method immediately after collection and analyzed using 
MarkerLynx as described in section 3-14-2 and Table 3- 3 with the exclusion of only the 
markers at m/z 45, 73, 77, and 207.  The software reported data for 233 markers.  The 
standard error of the mean (SEM) for the raw peak areas of 25 samples was calculated for 
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each marker.  43.8% (102) of the markers had a SEM of <5%, 9.4% (22) had an SEM 
between 5% and 10%, 6.4% (15) had an SEM between 10% and 15%,  3.0% (7) had an 
SEM between 15-20%, 3.86% (9) had an SEM between 20-25%, and 20.2% (47) had an 
SEM >50%.  Of the 102 markers with an SEM <5%, 58.8% (60) had an SEM <1%; 
however, these 60 markers had very small average peak areas, the maximum being 0.28 
a.u., and they were not present in all samples, so they may be meaningless as markers.  
These results show that the intra-subject variation over a period of a month is minimal for 
the majority of markers. 
 
3-15: Optimization of Breath Sample Collection 
3-15-1: Exhaled Breath Condensate (EBC) and Exhaled Breath Vapor at -80ºC (EBV-
80ºC) Collection 
The RTube™ was slightly modified to allow for simultaneous vapor collection above the 
EBC.  A plastic fitting was constructed from a second RTube™ (Figure 3- 8b) which 
attached directly to the top of the RTube™ and served as a mount for a SPME sampler.  
A SPME fiber (65 µm PDMS/DVB Stableflex fiber, Sigma-Aldrich, St. Louis, MO), 
previously thermally conditioned in the GC injection port per manufacturer’s 
instructions, was fitted into this mount and extended into the polypropylene tube, the end 
of the fiber extending approximately 3.7 cm into the tube.   The subjects breathed at 
normal frequency and tidal volume through the mouthpiece for 10 or 15 min, typically 
yielding 0.7-2.5 mL of EBC. After collection, the exhaled breath vapor (EBV-80ºC) 
collected on the SPME fiber was analyzed immediately by GC-MS, and a standard 
volume, 0.5 mL, of EBC was aliquoted into a disposable polypropylene microcentrifuge 
tube (Fisher Scientific, Pittsburgh, PA).  After analysis of the EBV-80ºC was complete, 
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the SPME fiber was directly inserted into the aliquot of EBC for 10 minutes (direct 
exposure), followed by injection into the GC-MS. 
 
 
3-15-2: Exhaled Breath Vapor – Room Temperature (EBV-RT) Collection 
EBV-RT was collected using the modified RTube™ (Figure 3- 8b) at room temperature, 
using no aluminum condenser.  The subject breathed at a normal frequency and tidal 
c.)a.) b.)
Valve A
Valve B
SPME 
Fiber 
Housing
2nd
Valve B
Figure 3- 8: Exhaled breath condensate (EBC) and vapor (EBV) collection devices. a.) 
the commercially available RTube™; b.) the RTube™ was modified for EBV collection 
by the addition of a plastic fitting to hold a SPME fiber for active sampling; c.) the 
additional modification of the RTube™ to provide an enclosed environment for SPME 
sampling as well as the addition of a respirator to purify inhaled air. (Image originally in 
color) 
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volume through the mouthpiece of the RTube™ for 10 min while the SPME fiber was 
exposed inside the polypropylene tube.  After collection, the sample was immediately 
analyzed. 
 
3-15-3: Comparison of Collection Methods 
Breath samples were successfully collected from all subjects (n=4) yielding EBC (-80 ºC 
condenser), EBV-80ºC (vapor collection while using -80 ºC condenser), and EBV-RT 
(vapor collection at room temperature).  To reduce confounding effects such as diet, 
ambient intake air, and activity, all samples were obtained from each subject within one 
hour.  All EBV-80ºC and EBV-RT samples were analyzed immediately after collection; 
all EBC samples were sampled using SPME shortly after collection and then immediately 
injected.  Noticeable warming of the aluminum condenser occurred during sampling, as 
has been previously documented.114  A typical EBC collection yielded 0.7-2.5 mL EBC 
during the 10 minute collection time.  EBV-RT collection typically yielded < 200 µL 
condensate which was discarded.  Figure 3- 9 shows example total ion chromatograms 
(TIC) from breath samples of a single subject collected using EBC, EBV-80 ºC, and 
EBV-RT. 
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The EBV-RT samples yielded an average of 23% more peaks than the EBC samples from 
the same subject using the same integration parameters, several of which are indicated by 
the arrows.  Table 3- 4 shows a list of observed compounds and their retention times 
tentatively identified in EBV-RT breath samples. 
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Figure 3- 9: Total ion chromatograms of breath samples from a single subject.  Samples 
were obtained using several collection methods: EBC with a -80 ºC condenser (black 
trace, bottom), EBV-80ºC (green trace, middle), and EBV-RT (red trace, top). Arrows 
indicate several peaks with increased signal in the EBV samples compared to the EBC 
sample. Chromatograms are offset for clarity. (Image originally in color) 
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Peak Compound RT  Peak Compound RT 
1 Carbon dioxide 1.3  38 α-terpinene 6.3 
2 Acetone 1.54  39 α-p-dimethylstyrene 6.34 
3 Acetic acid 1.85  40 Nonanal 6.43 
4 Allyl methyl sulfide 2.5  41 D-fenchyl alcohol 6.64 
5 Unidentified Compound 2.63  42 4,7,7-Trimethylbicyclo 
[4.1.0]heptan-3-ol   
6.76 
6 (Z)-1-(methylthio)-1-propene 2.82  43 L-isopulegol 6.89 
7 Methyl isobutyl ketone 2.86  44 Camphor 6.92 
8 Formic acid 3.0  45 Menthone 6.96 
9 Toluene 3.13  46 Isopregol 7.0 
10 4,4-dimethyl-2-pentene 3.4  47 Ethyl benzoate 7.05 
11 Butyl ester acetic acid 3.55  48 4-isopropyl-1-
methylcyclohexanol 
7.13 
12 3-furaldehyde 3.77  49 4-terpineol 7.18 
13 4-hydroxy-4-methyl-2-pentanone 3.86  50 α-terpineol 7.29 
14 2-furanmethanol 3.97  51 4-ethyl octane 7.35 
15 o-xylene 4.08  52 5-hydroxymethylfurfural 7.43 
16 p-xylene 4.18  53 Undecane 7.58 
17 Unidentified Aromatic 4.31  54 3-methyl-dodecane 7.67 
18 Styrene 4.4  55 Tridecane 7.75 
19 Ethylene glycol monoisobutyl ether 4.49  56 2,6,10-trimethyl-dodecane 7.82 
20 2-methyl-bicyclo[3.1.0]hex-2-ene 4.75  57 Unidentified Alkane 7.85 
21 6,6-dimethyl-2-
methylenebicyclo[3.1.1]heptane 
4.84  58 Isomenthol acetate 8.02 
22 Benzaldehyde 5.13  59 Unidentified Alkane 8.54 
23 Phenol 5.19  60 Unidentified Alkane 8.6 
24 6-methyl-5-hepten-2-one 5.29  61 Unidentified Alkane 8.63 
25 Cyclofenchene 5.30  62 Unidentified Alkane 8.81 
26 beta-pinene 5.34  63 Unidentified Alkane 8.9 
27 Isopentyl ether 5.46  64 Dihydropseudoionone 9.18 
28 alpha-terpinene 5.66  65 2,6-dimethyl heptadecane 9.25 
29 2-ethyl-1-hexanol 5.7  66 1-dodecanol 9.35 
30 o-cymene 5.73  67 Unidentified Compound 9.48 
31 α-limonene 5.78  68 Hexyloctylether 9.53 
32 Eucalyptol 5.83  69 Butylated hydroxytoluene 9.62 
33 2-methyl tridecane 5.96  70 Diethyl phthalate 10.1
8 34 4,6-dimethyl-undecane 6.01  71 Heptadecane 10.2
4 35 gamma-terpinene 6.04  72 2,2-dimethyl-3-octanone 10.8
8 36 Isooctylvinyl ether 6.16  73 2,2-dimethyl-4-Octen-3-ol 11.1
6 37 2,5-furandicarboxaldehyde 6.19     
Table 3- 4: Breath VOCs and corresponding retention times tentatively identified in a 
typical EBV-RT sample (no known exposure). 
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The vapor samples also provided increased peak areas for many peaks.  For example, α-
limonene showed a ten-fold increase in peak area when a vapor phase sample was 
collected and analyzed.  The area increase of several such peaks is shown in Table 3- 5.  
Thus, for many compounds, vapor phase collection of exhaled breath provides increased 
signal and increased information. 
  Factor Increase in Measured 
Peak Area vs. EBC-80ºC 
Compound R.T. (min) EBV-80ºC EBV-RT 
Allyl methyl sulfide 2.50 5.0 2.1 
(Z)-1-(methylthio)-1-propene 2.82 9.9 3.7 
α-Limonene 5.78 6.8 10.2 
Ethyl benzoate 7.05 1.6 4.6 
Tridecane 7.75 2.0 8.4 
Unidentified Alkane 7.85 2.1 9.0 
Butylated Hydroxytoluene 9.62 4.9 8.4 
 
 
3-16: Efforts to Control the Inhaled Air of a Subject 
3-16-1: RTube™ Modification with PVC Tubing 
A method to provide clean air to a subject was developed using approximately twelve 
feet of FDA-approved clear PVC tubing (0.5 in I.D., 0.75 in O.D., VWR, Inc., West 
Chester, PA) fitted to the base of valve A on the modified RTube™ (Figure 3- 8b) using 
Table 3- 5: Peak area of several compounds tentatively identified in total ion current 
chromatograms of breath samples collected as EBV-80ºC or EBV-RT versus peak area of 
EBC total ion current chromatograms.  These peaks are indicated by the arrows in 
Figure 3- 9. 
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a plastic fitting.  Tubing was stretched into a different room (air space) than that in which 
the samples were obtained.  This provided inhaled air free from contamination from the 
skin or clothing of the individual, and eliminated contamination by the localized 
environment of the subject.  The subject breathed at normal frequency and tidal volume 
through the mouthpiece while holding their nose for 10 min. After collection, the EBV-
RT collected on the SPME fiber was analyzed immediately. 
The headspace of the plastic tubing was sampled using SPME in order to understand any 
background that may be present in the tubing.  A SPME fiber was placed inside the 
tubing for 10 minutes, and analyzed using GC-MS.  The major compounds detected were 
2-ethyl-1-hexanol, and butylated hydroxytoluene, a solvent and stabilizer used in the 
production of plastics, respectively.  An increase in the peak area of these compounds in 
chromatograms obtained using the plastic tubing to provide inhaled air relative to 
samples obtained without the tubing was found, but both compounds are present in many 
products that an individual is exposed to on a daily basis; thus they are normally found in 
breath obtained with or without the tubing.  These peak areas decrease over time as more 
air is passed through the plastic tube, thus, the tube was flushed with compressed air 
before use. 
  
3-16-2: Nail Salon Inhalation with PVC Tubing 
Breath samples (EBC) from a single subject with a fresh manicure were obtained at 
regular intervals over the course of a single day (7 hours) using the RTube™ modified 
with PVC tubing.  Immediately after the manicure, the concentration of several 
compounds, tentatively identified as isopropyl alcohol, camphor, and diacetone alcohol, 
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increased and then exponentially decayed with time (data not shown).  Isopropyl alcohol 
and camphor were listed as ingredients on the nail polish used; diacetone alcohol was not 
a listed ingredient, but is commonly formed via an aldol condensation of acetone,156 
which was a listed ingredient.  The breath sample obtained 215 minutes after the 
manicure showed minimal detectable signal from these compounds.  An additional 
sample was then taken 317 minutes post-manicure using an unmodified RTube™ (no 
tubing).  This chromatogram again showed the increased concentrations of isopropyl 
alcohol, camphor, and diacetone alcohol.  Extracted ion chromatograms for each of these 
peaks are shown in Figure 3- 10. 
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Figure 3- 10: Extracted ion chromatograms (XIC) of breath samples from a single 
subject (EBC).  One sample was collected 215 minutes after the subject received a 
manicure with an RTube™ modified with PVC tubing which provided inhaled air from a 
separate room (black trace, bottom).  Another sample was obtained 317 minutes after 
receiving the manicure, and was obtained with the standard unmodified RTube™ (red 
trace, top).  a.) the XIC of m/z 45, identified as a major fragment ion from isopropyl 
alcohol, b.) the XIC of m/z 43, corresponding to a major fragment ion from diacetone 
alcohol, and c.) the XIC of m/z 152 corresponding to the molecular ion of camphor.
(Image originally in color) 
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By holding the RTube™ to obtain the breath sample, the subject’s hands (i.e. painted 
fingernails) were in close proximity to the mouth/nose, inadvertently causing the subject 
to inhale a higher concentration of compounds directly from the nail polish.  The use of 
the PVC tubing to provide an air source removed from the subject’s person eliminated 
these localized situational effects. 
Alveolar gradients were calculated for isopropyl alcohol, camphor, and diacetone alcohol 
in both breath samples.  The breath sample collected using the traditional RTube™ 
method (317 min after exposure) yielded positive values for all three compounds, 
implying that they were manufactured inside the body.122, 124, 149  However, the sample 
obtained using the RTube™ modified with PVC tubing (215 min after exposure) yielded 
negative alveolar gradient values for camphor and diacetone alcohol, indicating they were 
not synthesized in the body.  The alveolar gradient for isopropyl alcohol remained 
positive, but was 96.3% smaller than in the contaminated sample. 
 
3-16-3: RTube™ Modification with Respirator Cartridge 
A commercial organic vapor respirator cartridge with a P100 Particulate Filter (99.97% 
minimum filter efficiency, Lab Safety Supply Inc., Janesville, WI) was fitted to the 
plastic fitting holding valve A via a Viton® o-ring (approximately 2.5 cm diameter) and a 
machined brass fitting.  Plastic caps, the polypropylene tube, and valve B from a second 
RTube™ were used to isolate the SPME fiber from the outside air as shown in Figure 3- 
8c. The subject breathed at normal frequency and tidal volume through the mouthpiece 
while holding their nose for 10 min. After collection, the EBV-RT collected on the SPME 
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fiber was analyzed immediately.  A second respirator can also be attached in series to 
provide additional filtration in selected studies described below. 
 
3-16-4: Nail Polish Inhalation with Respirator Cartridge 
Breath samples were then collected from a single subject while painting a standardized 
1.5 in x 1.5 in cardboard square covered in packaging tape with nail polish.  The 
cardboard was used to simulate a fingernail while preventing the possibility of dermal 
absorption of the compounds.  Breath samples (EBV-RT) were obtained i) with no 
modification to the inhaled air, ii) with the inhaled air passing through an organic vapor 
respirator, and iii) with the inhaled air passing through PVC tubing from a separate room.  
Figure 3- 11 shows the chromatograms obtained in each case. 
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Figure 3- 11: Total ion current chromatograms of breath samples from a single subject 
(EBV-RT) collected using a variety of inhaled air sources: ambient air (red trace, top), 
ambient air through a respirator (blue trace, middle), and ambient air from a separate 
room than sampling (green trace, bottom).   The subject painted a simulated fingernail 
with commercial nail polish during sampling.  Compounds labeled are listed ingredients 
of the nail polish or byproducts of ingredients. Chromatograms are offset for clarity.
(Image originally in color) 
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It is immediately apparent that many foreign compounds are present in the breath 
samples.  The ingredients of the nail polish used were listed as butyl acetate, ethyl 
acetate, toluene, nitrocellulose, tosylamide/formaldehyde resin, dibutyl phthalate, 
isopropyl alcohol, stearalkonium hectorite, camphor, phthalic anhydride/trimellitic 
anhydride/glycols copolymer, benzophenone-1, and guanine; many of these compounds 
are seen in the chromatograms.  Table 3- 6 shows the relative reduction in XIC peak area 
of several compounds caused by the use of the respirator or PVC tubing. 
  Peak Area Reduction (%) 
Compound Extracted Ion (m/z) With Respirator With Tubing 
Isopropyl Alcohol 45 90 96 
Ethyl Acetate 88 92 94 
Diisopropoxy methane 73 89 96 
Toluene 91 94 98 
Mesityl oxide 83 94 99 
Butyl acetate 56 92 98 
Diacetone alcohol 43 96 94 
Camphor (1) 152 95 100 
Camphor (2) 152 97 99 
 
There is a trend that compounds with a higher vapor pressure are less effectively removed 
from the intake air by the respirator (e.g. VP of isopropyl alcohol = 30.75 torr; VP of 
Table 3- 6: Reduction in peak area for several ingredients of nail polish detected in 
human breath obtained with respirator or PVC tubing.  Peak areas were calculated by 
integration of the XIC for each compound, and are displayed relative to the XIC peak 
area value obtained without modifying the inhaled air source. 
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camphor = 0.15 torr)157, 158.  The large reductions in peak area (> 90%) demonstrate the 
advantages of controlling the inhaled air of a subject.  Two additional subjects repeated 
the experiment using a respirator with similar results (peak area reduction RSD 0-17%). 
 
3-16-5: Lemonade Inhalation with Respirator Cartridge 
Figure 3- 12 shows the extracted ion chromatograms (m/z 93) of breath samples obtained 
from a single subject inhaling directly above a glass containing approximately 125 mL of 
room temperature lemonade, which contains many flavor and aroma compounds.  Breath 
samples were obtained with and without the use of a respirator to cleanse the inhaled air. 
 
 
A large reduction in peak area is seen for all compounds present.  The peak area percent 
reduction relative to the sample without the respirator is shown in Table 3- 7.   These data 
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Figure 3- 12: Extracted ion chromatograms (XIC m/z 93) of breath samples from a single 
subject (EBV-RT).  One sample was collected over 4 oz. of lemonade with no 
modification to the inhaled air (red trace, top) and another sample was collected over 4 
oz. of lemonade using a respirator (blue trace, bottom).  Peaks labeled are identified as 
monoterpenes and monoterpene alcohols, flavor ingredients present in lemonade. (Image 
originally in color) 
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show the effectiveness of the respirator for removing naturally-derived compounds, such 
as monoterpenes, from the inhaled air. 
Compound Peak Area Reduction (%) With Respirator Compound 
Peak Area Reduction (%) 
With Respirator 
α-pinene 82 3-carene 91 
β-pinene 93 γ-terpinene 98 
β-myrcene 95 Terpinolene 98 
α-terpinene 96 4-terpineol 100 
α-limonene 97 α-terpineol 99 
 
 
3-16-6: Gasoline Inhalation with Respirator Cartridge and Synthetic Lung Substitute 
Development 
Tests were then performed to determine the efficiency of the respirator-modified 
RTube™ when obtaining breath samples in a very dirty environment.  Automobile-grade 
gasoline was used to simulate dirty sampling conditions.  To prevent unnecessary 
exposure to harmful chemicals a human subject was not used to collect these data; a 
polyethylene synthetic lung substitute was developed to simulate human respiration.  The 
synthetic lung substitute was fabricated to approximate adult tidal volume (500 mL)159 
and was pumped to simulate the inhalation and exhalation of a normal adult respiratory 
pattern over the gasoline and through an RTube™. 
Table 3- 7: Reduction in peak area for the monoterpenes detected in EBV-RT samples 
obtained over lemonade.  Peak areas were calculated by integration of the XIC for each 
compound, and are displayed relative to the peak area value obtained without modifying 
the inhaled air source. 
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Figure 3- 13 shows a portion of the total ion chromatogram of this synthetic breath 
sample obtained using the synthetic lung substitute at a constant and steady respiration 
rate.  Many peaks are present in this chromatogram – numerous compounds have been 
tentatively identified in Table 3- 8. 
 
 
Additional synthetic breath samples were obtained by attaching a single respirator 
cartridge to the intake valve of the RTube™ and repeating the synthetic lung substitute’s 
respiration over gasoline, as well as attaching two respirator cartridges in series by 
removing the particulate filter from one cartridge in order to attach the second.  These 
chromatograms are also shown in Figure 3- 13.  The percent reduction in peak area of the 
compounds detected in the sample obtained with one respirator cartridge versus no 
respirator cartridge is shown in Table 3- 8. The peak area was reduced by 56-98% when a 
single respirator is used, specifically with a greater decrease in peak area for smaller 
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Figure 3- 13: Total ion current chromatograms of ‘breath’ samples obtained using a 
synthetic lung substitute over gasoline (EBV-RT).  One sample was collected with no 
modification to the inhaled air (red trace, top), a second sample was collected using a 
single respirator (blue trace, middle), and a final sample was collected using two 
respirators in series (green trace, bottom) Chromatograms are offset for clarity. (Image 
originally in color) 
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molecular weight compounds.  With the addition of the second respirator cartridge, 
additional reductions in peak areas were determined versus the sample obtained with one 
respirator cartridge (Table 3- 8). 
 
RT Compound Area Reduction (%) One Respirator 
Additional Area Reduction (%) 
Two vs. One Respirator 
1.44 Ethanol 93 86 
1.48 Unidentified compound 97 82 
1.51 2-methylbutane 97 102 
1.56 Pentane 96 82 
1.61 2-methyl-2-butene 94 94 
1.65 2,2-dimethylbutane 91 95 
1.72 2-methylpentane 97 59 
1.75 2,3-dimethylbutane 97 60 
1.77 Unidentified alkane 98 100 
1.81 3-methylpentane 98 59 
1.85 2,2-dimethylheptane 98 34 
1.88 Hexane 97 52 
1.91 2,3-dimethyl-2-butene 97 68 
2.03 2-cyclopropylpropane 98 22 
2.05 Methylcyclopentane 97 70 
2.18 1-methylcyclopentene 96 49 
2.27 Unidentified alkane 96 42 
2.30 2,3-dimethylpentane 96 70 
2.34 3-methylhexane 87 81 
2.44 2,2,3,3-tetramethylbutane 95 68 
2.52 Heptane 90 61 
2.76 Methylcyclohexane 92 50 
2.78 3-methylheptane 91 109 
2.84 Ethylcyclopentane 93 69 
2.90 1,2,4-Trimethylcyclopentane 92 77 
2.97 2,3,4-Trimethylpentane 91 68 
3.04 2,3,3-Trimethylpentane 90 68 
Table 3- 8: Reduction in peak area for the tentatively identified compounds detected in 
EBV-RT samples generated with a synthetic lung substitute respirated over gasoline.  
Peak areas were calculated by integration of the TIC for each compound, and are 
displayed relative to the peak area value obtained without modifying the inhaled air 
source.  The additional peak area reduction demonstrated by the use of two respirators 
was calculated compared to those values when using one respirator to demonstrate the 
additional benefit of the respirator series. 
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Table 3-8 (cont’d). 
3.15 Toluene 77 60 
3.25 3,5,5-trimethyl-1-hexene 86 64 
3.28 1,3-dimethylcyclohexane 87 75 
3.36 1-ethyl-3-methylcyclopentane 83 56 
3.38 
(2,2-Dimethyl 
propylidene)cyclopropane 81 72 
3.43 n-octane 68 66 
3.79 2,5-dimethylheptane 71 71 
4.10 o-xylene 61 66 
4.29 m-xylene 68 79 
4.43 p-xylene 58 70 
4.73 Isopropylbenzene 64 75 
5.04 Propylbenzene 59 74 
5.07 4-methylnonane 56 59 
 
Depending on the concentration of contaminants in the ambient air, the respirator is 
useful in reducing the amount of carryover of the contamination into a breath sample, and 
more than one can be used in extremely dirty environments.  While not a perfect solution 
to entirely eliminating background components from a breath sample, this method allows 
for fast and facile sampling and analysis, with no power (freezer) requirements. 
 
3-17: Conclusions 
The data from this study demonstrate that real-time sampling of EBV is an effective and 
advantageous method for breath analysis.  As an active sampling method, collection is 
fast; because sampling and preconcentration occur concurrently, the overall  collection 
and analysis time of a breath sample is reduced ~30% compared to EBC collection.  
Sampling and SPME exposure time were optimized to yield the highest signal from the 
GC-MS.  Comparisons were made between the traditional EBC collection at -80ºC, EBV 
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collection at -80ºC, and EBV collection at room temperature.  This study has shown that 
EBV is more sensitive than EBC, yielding 23% more compounds than traditionally 
collected EBC, as well as up to a 10-fold increase in peak area for many compounds.  
This modification is simple and thus maintains the disposable and inexpensive nature of 
the RTube™.  The sampling technique is field portable as it requires minimal user 
training and has zero power requirements or need for a frozen condenser.  Also 
demonstrated herein was the need to control the quality and cleanliness of inhaled air 
when collecting a breath sample in a dirty environment.  The use of PVC tubing or a 
respirator cartridge was established as a simple and effective method of providing inhaled 
air yielding breath samples with 89-100% reduction in peak area for compounds inhaled 
from nail polish, and 82-100% reduction in peak are for terpenes inhaled from lemonade.    
The use of multiple respirator cartridges was also demonstrated, showing an additional 
reduction in peak area of 22-109% when a simulated breath sample was obtained over 
gasoline.  Caution must be paid to the localized situational environment created at a 
subject’s point of inhalation; compounds may be inadvertently inhaled at concentrations 
greater than that in the general ambient air causing error in alveolar gradient calculations. 
Collection and analysis of EBV using the methods described in this study will provide 
valuable information for future breath analysis. 
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CHAPTER 4: Measuring Chemical Exposure using Breath Analysis 
4-1: Motivations and Introduction 
Human exposure to environmental chemicals is a reality; the presence of chemicals in the 
work place, in food, and in association with common human activities, such as visiting a 
gas station, or using moth balls for clothing storage, puts all humans in contact with many 
chemicals.  While exposure to some of these chemicals may be harmless, some 
compounds elicit toxicity in individuals exposed to high doses.  Rapid assessment and 
monitoring of chemical exposure is important in order to diagnose the exposure and 
select the appropriate medical treatment to minimize its physiological effects.  The ideal 
technique would provide instantaneous identification of the chemical in question, provide 
information on its concentration within the subject, monitor the rise and fall of this 
concentration, provide information about the route of exposure, and monitor the subject 
to ensure no further exposure is occurring.  If the chemical of interest is toxic, this 
information can be used to determine the appropriate treatment plan for the subject; if the 
chemical is non-toxic, it is still useful to monitor its uptake and elimination in the body in 
order to learn about metabolic and excretion processes.  If the substance is a chemical of 
interest for forensic and homeland security applications, the presence of the chemical 
documents that exposure has occurred.  However, it would also be useful to gain some 
information about the time and extent of exposure.  Detection of chemicals unique to a 
particular environment may also provide information on the prior location of an 
individual and could be used to place a subject at a particular location for forensic 
purposes. 
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This chapter will describe several studies designed to test the abilities of breath analysis 
for use as a means to detect chemical exposure.  This chemical exposure is targeted in an 
effort to document occupational exposure, determine the chemical signature of unique 
locations, or determine the prior location or activity of an individual.  These experiments 
will demonstrate that breath analysis is an effective technique for all of these purposes, 
and the implications of sensitive analysis of breath constituents will also be discussed in 
regards to a field study for the detection of industrial chemicals. 
 
4-2: Background 
Regardless of the exposure route (e.g. dermal, inhalation, oral), breath analysis provides 
an alternative method of monitoring exposure of humans to chemicals.  The non-invasive 
nature of breath sampling allows a greater number of samples to be collected from a 
subject owing to the higher tolerance of subjects to the collection method compared to 
subject willingness to provide blood samples, which is commonly painful.  Another 
advantage of breath collection is that the biological waste is limited.  Research at the US 
Environmental Protection Agency (EPA) has shown that exhaled breath can be an 
accurate surrogate for blood analysis when monitoring chemical exposure to 
trichloroethene.1  Exhaled breath comes from the lungs, where the inspired air diffuses 
through tissues and into the blood.  Chemicals in the blood strive for equilibrium between 
the alveolar air and the capillaries in the lung, passing through the pulmonary alveolar 
membrane in order to achieve this.  Therefore, volatile compounds that are in circulation 
in the bloodstream can be detected by sampling exhaled breath. 
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Breath analysis has been extensively reported in the literature for medical applications, 
but additional studies focused on the exogenous compounds in breath – specifically those 
due to a chemical exposure,2-9 have been reviewed by Wallace.10  Many studies of 
chemical exposure focus on the dermal and inhalation routes of exposure.  Raymer et al. 
studied the effect of inhalation exposure in several microenvironments, including 
common work places including a woodworking shop; 21 VOCs were monitored and their 
elimination from the body was described by a two-compartment model of the body.11  
Work at the US EPA has focused on methods development for monitoring inhalation 
exposures in several microenvironments in part through the Total Exposure Assessment 
Methodology (TEAM) program12, 13 and in part through controlled exposures.12-17  The 
TEAM program developed breath sampling methods to analyze the VOCs in human 
breath of subjects in various cities in the United States, testing levels of VOCs in their 
normal environments as well as after exposure in several environments or to several 
household products, and again fit the acquired data of elimination using a two-
compartment model of the body.13  Dermal exposure was also probed in these studies, for 
example, comparisons were made between the levels of chloroform in breath samples 
collected while the subjects showered with and without rubber suits, isolating inhalation 
exposure versus inhalation and dermal exposure, where the levels detected were twice 
that detected while the rubber suits were worn.12  Several studies have also researched 
trihalomethane exposure from sources such as chlorinated water in showers or swimming 
pools and modeled the uptake and decay of such compounds with a 3-compartment 
model.1, 6, 18, 19  These studies provided insight into the VOCs detected in breath, common 
environmental sources of exposure, as well as common routes of exposure. 
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4-2-1: Industrial/Commercial Exposure 
One example of industrial chemical exposure occurs in the nail salon.  Nail salons are 
poorly regulated, and safety procedures are recommended, but not enforced, and there is 
a general lack of concern of chemical exposure by salon technicians.20  Chemical 
exposure in the nail salon can occur from the nail polish, nail polish remover, acrylic 
nails and other sources.  Workers in the salon may wear a mask, but generally not one 
that would seal against the face and prevent inhalation exposure.  During the application 
of acrylic nails, ethyl methacrylate and silica exposure can be high for the technicians, 
whose breathing zone is 6-12 in from the fingernails.  The filing and sanding of such 
nails can produce much dust containing acrylic monomers, fiberglass, and silica.  
Exposure to such chemicals has been shown to cause asthma, contact dermatitis, and 
even silicosis.21, 22  A study by the Illinois Department of Public Health assessed 
exposures of several nail technicians in salons throughout Illinois.  In this study, none of 
the subjects exceeded the National Institute for Occupational Safety and Health (NIOSH) 
Recommended Exposure Limits (REL) or the Occupational Safety and Health 
Administration (OSHA) Permissible Exposure Limits (PEL) for respirable silica dust 
exposures,23 but the proximity of the technician to the chemicals as well as an intense 
smell of ethyl methacrylate was noted. 
The EPA has also issued comments about the health and chemical exposures of nail salon 
technicians.  They identify acetone, benzoyl peroxide, butyl acetate, butyl methacrylate, 
camphor, dibutyl phthalate, ethyl acetate, ethyl cyanoacrylate, ethyl methacrylate, 
formalin, hydroquinone, isobutyl methacrylate, methacrylic acid, 4-methoxyphenol, 
methyl ethyl ketone, methyl methacrylate, poly (ethyl/methyl methacrylate), titanium 
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dioxide, toluene, and tosylamide formaldehyde resin as common ingredients in nail care 
products.24  Exposure may occur through inhalation or absorption via the skin and 
fingernails, and may cause medical trouble including asthma, cancer, lung fibrosis, or 
shortness of breath.  Monitoring exposure to such chemicals would provide valuable 
information about the risks posed to the health of the subject, as well as the amount of 
time spent in a particular location. 
Other industrial and commercial locations also pose the risk of dangerous chemical 
exposure.  Manufacturing plants and well as retailers of chemicals may present high 
levels of solvents in vapor or liquid form.  These locations are regulated by OSHA and 
NIOSH, but chemical signatures unique to these locations may be present and may 
provide information on the prior location of an individual if detected on breath. 
 
4-2-2: Exposure via Ingestion – Terpenes and Terpenoid Compounds 
Terpenoid compounds are natural organic compounds, which are derived from several 
isoprene building blocks, (C5H8)n.  Terpenoids and terpenes are present in many natural 
products, including fruit oils, flowers, and turpentine.  Several studies have described the 
elimination of monoterpenes from the human body after exposure to these compounds.    
Levin et al. showed that 8% of inhaled α-pinene was eliminated unmetabolized in 
exhaled breath, with less than 0.001% excreted via the kidneys, thus leaving the majority 
of inhaled α-pinene stored in the body or excreted as a metabolite.25  Falk-Fillipson 
reported that the respiratory clearance of 3-carene was significantly higher when the 
subject was exposed to the pure monoterpene, rather than a mixture of monoterpenes in 
turpentine.26  The decay of three monoterpenes in blood was also fit to a 3-compartment 
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model.26  Such a model describes how the organs and processes of the body are 
simplified; a 1-compartment model assumes that a substance is uniformly distributed 
throughout the body via the same kinetic processes.  A 2-compartment model assumes 
that the organs with highest blood flow form the central compartment and have uniform 
rapid distribution of a substance, then the rest of the body forms the peripheral 
compartment which experiences a slower rate of distribution. Likewise, a 3-compartment 
model assume that the central compartment distributes into two compartments with 
slower, and different, kinetics.27  Wallace et al. fit the decay of signal in exhaled breath 
after inhalation exposure to α-limonene to a 3-compartment model, but were unable to 
gather information on the first compartment decay due to its short half-life.14  Few studies 
have described the pharmacokinetics of monoterpenes and terpenoid compounds after 
oral ingestion, especially after consumption of a mixture of compounds.  When orally 
dosed, first-pass metabolism in the liver affects the amount of unmetabolized compound 
present in the bloodstream.27  Chen et al. orally dosed rates with α-limonene, fitting the 
resulting decay curve in blood to a biexponential model.28  It has been reported that 
although the monoterpenes are metabolized in the body, these metabolites were detected 
only in the urine and only the original monoterpenes were detected in the blood.29 
 
4-2-3: Research Directions 
Due to the ubiquitous nature of VOCs in several environments, detection of these VOCs 
in the breath of a subject may provide insight into their prior location or activities.  
Although visiting a nail salon or hardware store is not an activity of forensic interest, 
these systems may be used as surrogates for exposure to VOCs in more illicit 
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environments, or to more toxic VOCs.  The accessible nature of these environments 
makes them ideal to study the presence and elimination of such VOCs in the breath of a 
subject.  The results from these studies can then be used to predict the uptake and 
elimination of other VOCs of interest in the breath of subjects that have been exposed.  
Similarly, while the detection of terpenes in breath is not indicative of any criminal 
activity, these compounds are easily accessible and provide further insight into the uptake 
and elimination of VOCs in breath.  As presented below, the detection of terpenes in 
breath allows many data points to be acquired during the elimination of the compounds 
from the body, allowing greater information on the half-lives and elimination processes 
of these chemicals in breath to be elucidated.  
 
4-3: Materials and Methods 
4-3-1: Materials 
D-Camphor was obtained from J.T. Baker, Inc. (Phillipsburg, NJ).  A 65.3 mM solution 
was made in a 1:4 (v:v) solution of H2O:methanol and stored in a glass vial.  Hexamine 
(hexamethylenetetramine) was obtained from Chem Service, Inc. (West Chester, PA).  
Frozen lemonade concentrate (Safeway/Vons Lemonade, Safeway, Inc., Pleasanton, CA) 
was purchased from local sources.  Original lemonade was mixed according to the 
manufacturer’s instructions.  Concentrated lemonade was mixed using half the water 
required by the manufacturer’s instructions.  Mediterranean lemonade was made by 
mixing 10 thinly sliced lemons, 2 cups of sugar, and 5 cups of water.  (1S)-(-)-β-pinene 
(99%) was obtained from Alfa Aesar (Ward Hill, MA) and +/- α-limonene (95%) was 
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obtained from TCI America, Inc. (Portland, OR).  Serial dilutions of both compounds 
were made using deionized water. 
 
4-3-2: Methods 
The RTube™ (Respiratory Research, Inc., Charlottesville, VA), was used to collect all 
breath samples.  The subject inhales via a mouthpiece through a one-way valve that 
prevents salivary contamination of the EBC or EBV sample.  The subject then exhales 
through the same mouthpiece via a second one-way valve at the base of a polypropylene 
tube which serves as the EBC or EBV collection media.  The polypropylene tube is used 
at room temperature (EBV) or cooled by a previously frozen (-80 C) aluminum sleeve 
(EBC).  The subject breathes at a normal tidal volume and frequency though the 
RTube™. Subjects in the environmental exposure study held their nose during collection. 
When EBC is collected, 0.5 mL of EBC was aliquoted into a disposable polypropylene 
microcentrifuge tube (Fisher Scientific, Pittsburgh, PA).  A previously thermally 
conditioned SPME fiber (65 µm PDMS/DVB Stableflex fiber, Sigma-Aldrich, St. Louis, 
MO), was inserted directly into this aliquot of EBC for 10 minutes, followed by injection 
into the GC-MS.  When EBV is studied, the breath sample is simultaneously collected 
and preconcentrated on the SPME fiber, which is then injected into the GC-MS. 
An Agilent (Santa Clara, CA) 6890N GC with an Agilent 5973N mass spectrometer 
(Santa Clara, CA), or a Shimadzu (Pleasanton, CA) QP2010 GC-MS were used for 
analysis.  In both instruments, the Helium carrier gas was held at a flow rate of 1.3 L min-
1 (99.999%, Praxair, Inc., Danbury, CT).  Both instruments were operated using 70 eV 
128 
 
electron ionization, 3.54 scans s-1, operated in scan mode (m/z 40 – 450).  ChemStation 
software was used for data collection and analysis with the Agilent system; GCMS 
Solutions software was used with the Shimadzu system for data processing.  An Agilent 
J&W DB-5MS column (30 m x 0.25 mm x 0.25 µm, equivalent to 5% phenyl, 95% 
methylpolysiloxane) was used for all experiments. 
Compounds were identified by comparing mass spectra obtained in these experiments 
with those found in the NIST Mass Spectral Library (RMatch >700, NIST MS Search 
2.0, NIST, Gaithersburg, MD) and the literature, as well as comparison of retention time 
and mass spectra obtained from pure chemicals when available. 
 
4-4: Subjects 
Thirteen healthy adults with no known respiratory ailments were recruited for this study.  
Subjects were asked to report any chemical exposure (none) and gave formal written 
consent prior to sample collection.  The Institutional Review Boards (IRB) at Lawrence 
Livermore National Laboratory (LLNL) and Michigan State University approved 
experimental protocols used for this study. 
 
4-5: Nail Salon Study 
In order to provide an isolated inhaled air source and prevent contamination from 
localized chemical exposures (i.e. chemical residues remaining on clothing or 
skin/fingernails), the RTube™ was modified as follows.  Approximately twelve feet of 
FDA-approved plastic tubing (0.5 in I.D., 0.75 in O.D., VWR, Inc., West Chester, PA) 
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was attached to the base of the intake valve on the RTube™ using a plastic fitting.  This 
tubing was extended into a different air space (room) than that in which the subject 
donated a breath sample.  The breath sample (EBC) was obtained using the standard 
procedure with the aluminum sleeve cooled to -80 C, or EBV was obtained using the 
modified procedure with no aluminum sleeve. 
A 10 minute breath sample was obtained from a subject early in the morning.  The 
subject then visited a nail salon; after approximately 45 minutes in the salon, the subject 
returned to the sampling area and gave additional 10 minute breath samples over a 4 hour 
period.  Figure 4- 1 shows the chromatogram obtained from the breath sample obtained 
before visiting the salon versus that obtained 12 minutes after leaving the salon (inverted 
for comparison).  The majority of peaks observed in the GC-MS total ion chromatograms 
are present in both samples, and are attributed to endogenous compounds in the subject’s 
breath; however additional peaks, such as those highlighted by the arrows, are present in 
the sample obtained after salon exposure. The use of the plastic tubing adapter connected 
to the RTube™ during breath collection provided inhaled air from a different room.  This 
prevented inadvertent chemical exposure of the subject while obtaining a breath sample, 
as chemicals from the nail salon may have absorbed onto the clothing of the subject, as 
well as remained on the fingernails of the subject.  Previous data have shown that this 
approach provides effective prevention of subject inhalation of the local chemical source 
(substances applied to fingernails). 
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Figure 4- 2 shows a narrow retention time window in the chromatograms generated from 
breath samples from a human subject collected before visiting the salon, and 12, 50, 99, 
152, and 214 minutes after leaving the salon.  There is a sharp increase in the total ion 
chromatogram signal in this region immediately after salon exposure, which decays back 
to near baseline over several hours.  The source of this peak was identified as camphor, a 
common ingredient in nail polish, and listed as an ingredient in the particular polish used 
on the subject.  Camphor was also identified in a SPME sample obtained from the 
ambient air in the salon, confirming that the subject’s inhaled air contained this 
compound.  The area of the peak due to camphor was calculated using the extracted ion 
chromatogram (XIC) of m/z 152.  The decay of the peak area can be fit to an exponential 
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Figure 4- 1: GC-MS total ion chromatograms of sampled breath constituents obtained 
before salon exposure (top) and 12 minutes after leaving the salon (bottom).  The signal 
obtained after leaving the salon was inverted for clarity.  Many peaks endogenous to 
breath are present in both samples.  Additional peaks are present in the sample taken 
after the subject left the salon, such as those indicated by the arrows. (Image originally in 
color) 
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(R2=0.999), as is shown in Figure 4- 2b.  The half-life of the decay was calculated to be 
23.5 min.   
 
 
The subject made an additional visit to the nail salon, and a polish without camphor as a 
listed ingredient was applied to the subject’s fingernails.  Breath samples were obtained 
using EBV collection with the plastic tubing supplying inhaled air from a separate 
location than the subject.  A single breath sample was obtained from a subject early in the 
morning.  The subject then visited the nail salon; after approximately 45 minutes in the 
salon, the subject returned to the sampling area and gave additional breath samples over a 
5 hour period.  Figure 4- 3a shows the retention time window in the XICs for m/z 91 
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Figure 4- 2: (a) Selected window of GC-MS total ion chromatograms obtained before 
salon exposure (black), and 12, 50, 99, 152, and 214 minutes after leaving the salon.  The 
source of the peak was identified as a common nail polish ingredient, camphor.  
Chromatograms are slightly offset for clarity.  (b) Exponential decay, R2= 0.999, of the 
area of the peak due to camphor, calculated from the XIC (m/z 152) for the molecular ion 
(chromatogram not shown). (Image originally in color) 
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generated from samples obtained before visiting the salon, and 11, 25, 52, 79, 121, 168, 
222, 285, and 313 minutes after leaving the salon.  There is a sharp increase in signal in 
this region immediately after salon exposure, which decays back to near baseline over 
several hours.  The source of this peak was identified as toluene, which is also a common 
ingredient in nail polish and is listed on the polish used on the subject.  Toluene was also 
seen in the sample obtained from the headspace of the salon.  The area of this peak was 
calculated using the XIC for m/z 91.  The decay of the peak area was fit to an exponential 
(R2=0.960), as is shown in Figure 4- 3b.  The half-life of the decay was calculated to be 
21.4 min.  A small amount of camphor was detected in the sample collected 11 minutes 
after exposure in the salon.  Though it was not a constituent in the polish used, camphor 
was still present in the air of the salon, so the subject was exposed even when care was 
taken to use a polish free of camphor. 
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Figure 4- 3: (a) Selected window of GC-MS XIC for m/z 91showing the peak due to 
toluene in breath before (no peak detected) and, 11, 25, 52, 79, 121, 168, 222, 285, and 
313 minutes after salon exposure. (b)Decay of the area of the peak due to toluene fit to an 
exponential process (R2=0.960). (Image originally in color) 
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4-5-1: Headspace Analysis of Manicured Hands 
In order to support the hypothesis that the subject was being reexposed to the nail salon 
chemicals as they outgassed from the nails and hands, studies were performed to 
determine the composition of the localized headspace surrounding the hands.  At 301 
minutes after exposure at the nail salon, one hand of the subject was placed in a 
resealable plastic bag with a SPME fiber for 5 minutes, allowing the VOCs outgassing 
from the nails and hands to be collected.  The resulting TIC is shown in Figure 4- 4. 
 
Many chemicals were measured in this sample, including toluene, n-butyl acetate, 
diacetone alcohol, 6-methyl-5-hepten-2-one, and camphor, common ingredients in nail 
polish and listed as hazardous ingredients in nail care products by the EPA.24  That these 
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Figure 4- 4: GC-MS total ion chromatogram obtained by exposing a SPME fiber to the 
manicured hand inside a plastic bag 5 hours, 1 minute after salon exposure.  Note that 
chemicals indicative of the nail polish are still present in the headspace of the nails. 
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chemicals remain in the headspace of the fingernails over 5 hours after exposure in the 
salon indicates that the products used in nail salons release numerous VOCs to which nail 
salon workers and clients can be continually exposed, even outside of the salon.  Thus, 
the localized environment from which the inhaled air of a subject giving a breath sample 
is taken is important to consider in studies such as these.  
 
4-6: Hardware Store Study 
The decay in abundance of levels of inhaled volatile chemicals has also been seen post-
exposure in hardware store exposures to VOCs.  Breath samples (EBC) were obtained 
from two human subjects before they spent an hour in a local hardware store.  After 
returning to the sampling area, 3 additional breath samples were obtained from each 
subject over the course of 2 hours.  Samples were obtained from subject A at 18, 70, and 
125 min after leaving the hardware store; samples were obtained from subject B at 4, 28, 
and 37 min after leaving the hardware store.  Figure 4- 5shows a selected area of the XIC 
(m/z 105) obtained from each breath sample of the 2 subjects.  This peak has been 
tentatively identified as 1-methoxyethyl benzoate, an ingredient in furniture stain that is 
sold at the hardware store.  The same compound was detected in a direct SPME sample 
taken of the air inside the hardware store for 10 minutes (data not shown).  Given that the 
compound was present in the air source of the subjects, and the breath of both individuals 
shows a rise and fall in the concentration of this compound, these data show that breath 
analysis using GC-MS is an appropriate way to measure and monitor chemical exposure, 
with detectable signal remaining for hours after exposure.  A small signal was detected in 
135 
 
the breath samples obtained before exposure; however this is not unexpected given the 
ubiquitous nature of furniture stain in an office/laboratory setting. 
 
 
4-7: Lemonade Study 
A control breath sample was taken prior to lemonade consumption and then many 
samples were collected after lemonade consumption.  A breath sample taken before 
lemonade consumption does show a detectable but low-level signal in the GC-MS TIC 
and XIC (m/z 93) from monoterpenes and terpenoid compounds; however, this signal is 
dwarfed by the contribution of these compounds in a post-lemonade sample.  Many of the 
monoterpenes and terpenoids are consumed in food products or inhaled from the ambient 
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Figure 4- 5: (a.) Selected window of XICs (m/z 105) obtained from Subject A before 
exposure (black) in the hardware store and 8, 70, and 125 minutes after leaving the 
hardware store.  (b.) Selected window of XICs (m/z 105) obtained from Subject B before 
exposure (black) and 4, 28, and 37 minutes after leaving the hardware store.  The source 
of the peak was tentatively identified as an ingredient in furniture stain, 1-methoxyethyl 
benzoate.  This chemical was also detected in a SPME sample of the ambient air in the 
hardware store. (Image originally in color) 
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air due to their abundance in the environment from natural and synthetic sources, 
presumably causing this initial signal.  In fact, estimates of the average per capita 
combined exposure of α-limonene, terpinolene, and β-myrcene approach 1.3 mg/day.30  
Figure 4- 6 shows an XIC obtained before consuming original lemonade compared to one 
obtained 3 minutes after lemonade consumption, offset for clarity. 
 
 
The 13 monoterpenes and terpenoid compounds of interest are labeled, and their 
structures, molecular weights, and retention times (RT) are shown in Table 4- 1.  The 
signal post-consumption ranges from 1.6-57 times that seen in the sample before 
consumption.  The inset shows a magnification of the boxed area in the figure.  Although 
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Figure 4- 6: Extracted Ion Chromatograms (XICs) of the m/z 93 ion in breath samples 
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these compounds are present in the sample before consuming lemonade, this background 
contribution to the compounds’ level measured after lemonade consumption is minimal.  
This background contribution is corrected for in peak area calculations for all 
measurements made after lemonade consumption. 
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Compound Structure
RT
(min)
Average Tau
n=5 (min, SEM)
α–Thujene
MW 136.23
4.75 85.9(13.9)
tauabs=1.0
α–Pinene
MW 136.23
4.84 129.1(12.57)
tauabs=2.0
Camphene
MW 136.23
5.03 213.1 (44.6)
tauabs=1.5
β–Phellandrene
MW 136.23
5.23 129.9 (25.7)‡
tauabs=0.1
β–Pinene
MW 136.23
5.30 118.2 (17.6)
tauabs=1.5
β–Myrcene
MW 136.23
5.34 81.3(10.2)
tauabs=0.1
α–Terpinene
MW 136.23
5.66 60.2(13.8)
tauabs=0.1
p–Cymene
MW 134.22
5.73 186.0(25.6)†
tauabs=1.0
α–Limonene
MW 136.23
5.78 86.6 (5.7)
tauabs=0.2
γ–Terpinene
MW 136.23
6.04 62.6 (4.3)
tauabs=0.0
Table 4- 1: Molecular weights, structures, and GC retention times (RT) of 13 terpenes 
and terpenoid compounds studied.  Average decay values, tau, for a single subject (n=5) 
after consumption of original lemonade, modeling compound decay in breath to a single 
phase decay are also shown. 
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Table 4-1 (cont’d). 
 
 
4-7-1: Reproducibility of Single Subject Drinking Original Lemonade 
Figure 4- 7a-b show the XIC region containing the peak identified as α-limonene from 19 
breath samples obtained from a single subject after original lemonade consumption. The 
XIC trace from the pre-consumption sample is also shown. 
Compound Structure
RT
(min)
Average Tau
n=5 (min, SEM)
Terpinolene
MW 136.23
6.30 56.1(12.1)
tauabs=0.0
4–Terpineol
MW 154.25
7.17 12.3(2.9)
tauabs=0.0
α–Terpineol
MW 154.25
7.29 8.6 (01.7)
tauabs=0.2OH
OH
†n=4, ‡n=3
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In the sample obtained 3 minutes after lemonade consumption, a 77-fold increase in the 
peak area above background level is observed.   An additional experiment in which the 
subject gargled with lemonade without swallowing and completed the described rinsing 
procedure demonstrated that a minimal amount of this increase is due to residuals in the 
mouth and/or throat.  Figure 4- 7c shows the α-limonene peak area from each time point.  
α-Limonene, as well as α-pinene and β-pinene, has previously been shown to follow a 
triphasic elimination, with a short half life immediately after exposure and longer half 
lives as the elimination processes progress.26, 31, 32  This slow elimination is thought to be 
caused by the high lipophilicity of the compounds which causes the compounds to 
preferentially partition in fatty tissue, assuming they are not first metabolized.26, 33  
Indeed, previous reports have shown that metabolic products of monoterpenes excreted 
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Figure 4- 7: (a) XICs (m/z 93) of peak identified as α-limonene in breath samples 
obtained before and 3-1368 minutes after original lemonade consumption. (b.) Magnified 
view of XICs shown in (a) obtained 247-1368 minutes after original lemonade 
consumption, c) Area of peak due to α-limonene corrected for initial area before 
lemonade consumption plotted versus time after ingestion.  These data are fit to a single 
phase exponential uptake and decay model. (Image originally in color) 
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through the kidneys reach maximum levels approximately 5 days after exposure, even 
after hemoperfusion, suggesting storage and slow metabolism in the fatty tissues.29  
While many studies have fit terpene data to a two- or three- component exponential decay 
process,11, 28 the data presented in this study do not reveal the first phase of elimination in 
the α-limonene data as the reported half-life of this phase is 3 min,34 and the initial breath 
sample in this study was obtained from 3-13 minutes after exposure.  The current data fits 
most accurately to a model including a single exponential rise (absorption) and a single 
exponential decay (elimination) model: 
)/(
1
)/(
1
1 abstauxtaux
o eAeAyy
   
 
where yo is the offset of the fit, A1 is the concentration remaining in the body, tau1 is the 
half-life of the decay, and tauabs is the half-life of the absorption process.  tauabs was held 
constant at 0.2 min for the fit, yielding a half-life (tau1) of 86.6 min for α-limonene. 
Figure 4- 8a-b shows the XIC region for the peak identified as containing γ-terpinene 
from the same breath samples previously discussed.  The pre-consumption sample 
contained only a trace amount of γ-terpinene, so the sample obtained 3 minutes after 
consumption showed a 149-fold increase in peak area compared to this value.  Figure 4- 
8c shows the decay in peak area for this peak fit to a single exponential rise and decay 
(Equation 4- 1).  The half-life of absorption was held constant at 0 min, and the half-life 
Equation 4- 1: Exponential rise and decay with a y-offset 
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of elimination was determined to be 62.6 minutes.  Similar curve peak area analysis and 
curve fitting was performed for all peaks (See Appendix B). 
 
 
Calculated half-lives are shown in Table 4- 1 for 5 replicates of a single subject except 
where noted.  The standard error of the mean (SEM) is surprisingly low for many of the 
monoterpenes and terpenoids monitored.  This particular subject had a consistent exercise 
and diet schedule during the study which was thought to affect the consistency of the 
data.  The half-lives of the monoterpene alcohols were determined to be significantly 
lower than those of the other monoterpenes and terpenoids using Welch’s t-test 
(p<0.001).  This may be due to the higher water solubility and lower saturated vapor 
pressure of the alcohols,35-38 causing them to quickly partition into the water vapor that 
dominates the components in human breath.  The monocyclic monoterpenes’ half-lives 
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Figure 4- 8: (a) GC-MS XICs (m/z 93) of peak identified as γ-terpinene in breath samples 
obtained before and 3-1368 minutes after original lemonade consumption, (b) Magnified 
view of XICs shown in Figure 4a obtained 247-1368 minutes after original lemonade 
consumption, (c) Area of peak due to γ-terpinene versus time after ingestion.  These data 
are fit to a single phase exponential uptake and decay model. (Image originally in color) 
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were also significantly lower than those of the bicyclic monoterpenes (p< 0.001), and the 
aromatic monoterpene, p-cymene (0.001<p<0.01).  The linear monoterpene’s half-life 
was also significantly different from that of the aromatic monoterpene (0.01<p<0.02, 
Student’s t-test), which may also be due to the different solubilities of the compounds.36, 
37, 39  Table 4- 2 shows the tau values calculated for 3 subjects after drinking original 
lemonade.  Similar relative values for half-lives of the different compounds were 
observed for data obtained from 3 subjects after consumption of original lemonade. 
   Tau (n=3 subjects)  
Compound  Average  SEM  
α - Thujene  62.5  26.4  
α - Pinene  56.0  29.5  
Camphene  76.3  34.7  
β - Phellandrene  43.4 27.9  
β - Pinene  47.7 31.2  
β - Myrcene  39.6 20.7  
α - Terpinene  35.7 18.8  
p - Cymene  105.7 10.4  
α - Limonene  43.6 22.9  
γ - Terpinene  32.5 15.6  
Terpinolene  32.6 15.1  
4 - Terpineol  12.5 2.3  
α - Terpineol  15.6 3.6  
 
  
Table 4- 2: Half-lives (tau) for single exponential decay of 13 terpenes and terpenoid 
compounds in breath after original lemonade consumption by 3 subjects. 
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4-7-2: Concentration Dependence of Terpene Signal in Breath 
Other concentrations and types of lemonade were also used to analyze the uptake and 
decay kinetics of the terpenes and terpenoid compounds.  Concentrated lemonade was 
prepared from the same lot of frozen lemonade concentrate as the original lemonade but 
with less dilution.  Mediterranean lemonade was made from fresh lemons in an effort to 
further increase the terpene and terpenoid concentration consumed.  Figure 4- 9 shows 
the α-limonene XIC peak area (m/z 93) versus time after consumption of each type of 
lemonade for a single subject.  The highest XIC peak area reached in a sample increases 
linearly with the α-limonene concentration measured in each lemonade sample: 0.696 
mM, 1.93 mM and 5.96 mM for the original, concentrated, and Mediterranean varieties, 
respectively (R2=0.993), previously seen with monoterpenes.25, 31  This trend is also 
apparent in the other monoterpenes and terpenoid compounds. 
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The maximum peak area of each terpene and terpenoid compound measured in breath 
after consumption of each lemonade sample was normalized to the maximum peak area 
measured in breath after consumption of the original lemonade for comparison.  
Similarly, the peak area of each terpene and terpenoid compound in the actual (neat) 
lemonade samples was normalized to its area in the original lemonade.  Figure 4- 10 
shows these relative peak areas for the 13 compounds monitored in the actual (neat) 
lemonade samples (Figure 4- 10a) as well as the maximum peak area measured in breath 
after consumption of each type of lemonade (Figure 4- 10b).  All terpene analytes show a 
Figure 4- 9: α-Limonene peak area versus time after consumption for original, 
concentrated, and Mediterranean lemonade.  Note the higher tmax for higher lemonade 
concentrations as well as the appearance of the uptake curve of the α-limonene. (Image 
originally in color) 
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significant increase in peak area in breath as the concentration of the lemonade consumed 
increases, similar to the peak area increase of the terpenes measured in the neat lemonade 
samples of increasing concentrations.  The only exception is the terpene alcohols, 4-
terpineol and α-terpineol, where no significant increase in signal in breath samples with 
increasing concentration of lemonade consumed is seen; this is possibly due to the quick 
elimination of terpene alcohols from the body. 
 
 
More information about the uptake of the monoterpenes and terpenoids is gleaned when 
higher concentrations of lemonade are consumed.  Figure 4- 9 also demonstrates that the 
maximum peak area, thus, concentration in breath, is reached at later times when the 
terpene concentrations in lemonade are greater.  This finding also supports the conclusion 
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Figure 4- 10: Relative peak areas of 13 terpene and terpenoid compounds in (a) neat 
samples of original, concentrated, and Mediterranean lemonade, and (b) breath samples 
after consumption of original, concentrated, and Mediterranean lemonade.  Peak areas 
are normalized to the original lemonade peak area for each compound, and the breath 
sample obtained at tmax was used. (Image originally in color) 
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that residual compounds in the mouth are not causing the signal seen in the breath 
samples as the signal continues to rise long after consumption.  In the original lemonade, 
the initial breath sample taken 3 minutes after consumption (tmax) yielded the highest α-
limonene concentration.  In the concentrated lemonade this tmax was not reached until 52 
minutes after consumption, and in the Mediterranean lemonade, 73 minutes after 
consumption.  After exposure, a chemical is first distributed through the body, and then 
eliminated.  These processes are not exclusive of each other; elimination begins while the 
chemical is still being distributed.  In the experiment presented, chemical exposure 
proceeds through ingestion, so the kinetics of an additional absorption step must be 
considered.  The terpenes and terpenoids are first absorbed through the digestive tract, 
passed into the blood and distributed to various tissues based on their lipid and water 
solubilities.40  Absorption and distribution also occur concurrently. The terpenes and 
terpenoids pass from the blood into the lung via the alveolar pulmonary membrane and 
attempt to establish equilibrium between the two compartments.  Exhalation pushes the 
compounds out of the lung, which are subsequently replaced through the constant shift 
towards equilibrium.  The higher the concentration of lemonade consumed, the longer it 
takes for the absorption and distribution processes to occur, yielding a rise followed by 
the decay of the peak area due to monoterpenes and terpenoid compounds as previously 
described.28  With higher concentration of monoterpenes and terpenoids, absorption and 
distribution take a longer time, yielding the increased tmax, and describing that the 
absorption or distribution processes have been saturated, and that further terpenes cannot 
be absorbed until elimination has removed some from circulation.  The extended time 
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period before elimination becomes the primary process in the uptake and decay of the 
monoterpenes and terpenoid compounds after consumption of Mediterranean lemonade 
allows the compound uptake to become more apparent in the data, as several data points 
were obtained before tmax was reached.  The data from the consumption of the 
Mediterranean lemonade was fit to Equation 4- 1, and is shown in Figure 4- 11.  Fit 
parameters are shown in Table 4- 3. 
 
 
Because of the deviation seen in this fit, the data from consumption of the Mediterranean 
lemonade was fit to a higher order model using the method of residuals (Figure 4- 12).27  
The data was fit to the following equation which describes the first order uptake, and 
triphasic decay of α-limonene:  
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Figure 4- 11: Uptake and decay of α-limonene after consumption of Mediterranean 
lemonade fit to Equation 4- 1.Equation 4- 2 Fit parameters are shown in Table 4- 3. 
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where y is the peak area of the compound detected in breath, A1, A2, A3, and U are the 
constants of the three phases of decay and uptake, respectively, tauabs is the half-life of 
the first order absorption process, and tau1, tau2, and tau3 are the first order fast, medium, 
and slow elimination half-lives.  These fit values are also shown in Table 4- 3.  Neither 
Equation 4- 1 nor Equation 4- 2 describe the data in an acceptable manner.  It is thought 
that these data require a much more complicated fit, which may be pursued in the future. 
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Equation 4- 2: Model of uptake and triphasic decay for monoterpenes and terpenoids 
Figure 4- 12: Uptake and decay of α-limonene after consumption of Mediterranean 
lemonade fit to Equation 4- 2 using the method of residuals. Fit parameters are shown in 
Table 4- 3 
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A deviation from exponential decay is seen for many of the monoterpenes and terpenoids 
across all subjects.  Approximately 5 hours after lemonade consumption, the peak area of 
the terpenes and terpenoids in breath plateaus or increases slightly, rather than continuing 
to decrease exponentially (see Figure 4- 9 and Appendix B).  After approximately 1 hour, 
peak areas measured in breath samples return to the exponential decay.  This is thought to 
be a real effect, as all samples were analyzed using the same GC-MS method and the 
deviation is consistently observed for all terpenes and across subjects.  A similar plateau 
phenomenon has been previously reported for several VOCs measured in breath, 
specifically 1,1,1-trichloroethane,11 and was thought to be due to changes in activity, 
Fit to Equation 4-1
A tauabs tau1
3.70 x 108 57.0 120
Fit to Equation 4-2
Uptake Decay
U tauabs A1 tau1
3.54 x 108 55.2 1.10 x 107 968
A2 tau2
1.93 x 108 171
A3 tau3
1.28 x 108 365
Table 4- 3: Coefficients and half-lives obtained after fitting the uptake and decay of α-
limonene in breath after consumption of Mediterranean lemonade to Equation 4- 1 and 
Equation 4- 2. 
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blood flow, or diet.  Several subjects in this study fasted while participating, eliminating 
immediate effects of diet variation as a cause of this effect, however changes in activity, 
blood flow, or changes in metabolism due to fasting are viable possibilities and will be 
considered further in the future. 
 
4-8: Drug Studies 
4-8-1: Sudafed 
Studies were performed to determine if oral ingestion of an OTC drug would be 
detectable on breath.  If so, this method may have applications to drug testing, or even 
diagnostics in an emergency room setting where a patient may have overdosed on an 
unknown drug.  Two subjects participated in this study.  A breath sample was collected in 
the morning, followed by the subject consuming two 30 mg pseudoephedrine tablets.  
Breath samples were then collected at several times after ingestion.  Breath samples were 
analyzed using Selected Ion Monitoring (SIM) mode of the GC-MS, monitoring m/z 58, 
the ion corresponding to the base peak in the mass spectrum of pseudoephedrine.  For 
retention time and mass spectral confirmation, a pseudoephedrine tablet was crushed and 
26.6 mg of the powder was dissolved in 5 mL of water.  A SPME fiber was directly 
exposed to the water for 1 min, and analyzed using the method previously described and 
well as in scan mode.  The mass spectrum obtained was consistent with that in the NIST 
mass spectral database, and the retention time was determined to be 8.61 min. 
Results were variable across subjects and even between different exposures of a single 
subject.  Figure 4- 13 shows the ‘best case’ data of exposure of a single subject.  Figure 
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4- 13a shows the chromatographic peak attributed to pseudoephedrine in breath samples 
obtained before and at eight intervals after ingestion.  Figure 4- 13b shows the same data, 
without the 10 min after consumption sample, for clarity.  A significant increase in peak 
area is seen in the breath sample obtained 10 minutes after pseudoephedrine consumption 
relative to that seen in the breath sample obtained before consumption.  Over several 
hours, the area of this peak decays to values near that seen in the sample obtained before 
consumption.  The decay can be fit to an exponential model (R2=0.9989) with a half-life 
of 13.4 minutes.  This is a preliminary experiment, and the reproducibility of the rise and 
decay of the pseudoephedrine peak after consumption has not been determined.  In 
repeated experiments, the pseudoephedrine peak area in a breath sample obtained 
approximately 10 minutes after consumption was lower than that shown below, and is not 
seen in samples obtained approximately an hour after consumption, thus preventing study 
of the decay of the compound in these additional experiments.  This could be due to 
variation in diet of the subject as it was not regulated, illness of the subject as medication 
was only taken when symptoms were present, or other variation in metabolism and 
digestion. 
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The signal seen in the chromatograms obtained from breath after consumption of 
pseudoephedrine is 4 orders of magnitude less than that previously observed for terpenes 
after lemonade consumption.  The amount consumed is actually higher; 60 mg of 
pseudoephedrine were consumed in this study while ~45 mg of α-limonene were 
consumed in the original lemonade sample.  The vapor pressure of limonene at 25 ºC is 
20 torr,41 much higher than that of pseudoephedrine, which is listed as a non-volatile 
solid.42  Indeed, pseudoephedrine is typically derivatized prior to GC-MS analysis in 
order to increase its volatility.  In order for the pseudoephedrine to be detected in breath, 
it must be absorbed and distributed into the blood which then passes by the alveolar 
pulmonary membrane, where the pseudoephedrine must partition into the alveolar air and 
be exhaled.  With a low vapor pressure, partitioning into the alveolar air would be slight; 
whereas the higher vapor pressure of limonene would allow significant partitioning 
across the membrane.  A recent study has used breath analysis to monitor levels of 
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Figure 4- 13: Selected window of the m/z 58 chromatogram obtained in SIM mode before 
and after ingestion of 60 mg of pseudoephedrine.  The peak has been identified as 
pseudoephedrine.  (a) shows all breath samples obtained, (b) shows a zoomed in view of 
the samples excluding that obtained 10 min after consumption for clarity. (Image 
originally in color) 
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propofol, an intravenous anesthetic, during surgery by sampling breath directly from the 
endotracheal tube in the patient.43  In this study, exhaled breath was analyzed and the 
propofol signal was correlated to the concentration measured in blood.   Although the 
vapor pressure of propofol is still relatively low (0.142 torr at 20 ºC), it was reported that 
its low water solubility results in a measurable quantity of the drug in the gas phase near 
a hydrophilic solution.43  
Investigation into the detection of ibuprofen ingestion was also pursued, but no signal 
was detected in breath after ingestion.  The vapor pressure of ibuprofen is reported as < 1 
torr.44  Ibuprofen undergoes minimal first pass metabolism in the liver; however, it 
experiences very high binding to plasma proteins.45  It is reported that only 0.3-0.5% of 
ibuprofen remains unbound when a low concentration, as used in this study, is 
consumed.45  A combination of little free ibuprofen being available to partition across the 
alveolar pulmonary membrane, as well as the benefit of derivatizing the molecule for 
GC-MS analysis which was not done in these studies may be responsible for the lack of 
signal in this study. 
 
4-9: Explosive Studies 
4-9-1: Hexamine 
Studies were performed to determine if explosive-related compounds could be detected in 
human breath.  Comparisons were made between samples collected using EBC and EBV.  
A single breath sample was obtained from a subject in the morning.  The subject then 
poured approximately 10 g of hexamine, a common precursor in the synthesis of RDX, 
between 2 100 mL plastic beakers on the laboratory benchtop for 10 min. Subsequent 
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breath samples were then collected.  Samples were analyzed via GC-MS which was 
operated in selected ion monitoring (SIM) mode to specifically detect the m/z 140 and 42 
ions, the molecular ion and base peak in the hexamine mass spectrum, respectively, with 
greater sensitivity. For retention time and mass spectrometric confirmation, a sample of 
vapors from the hexamine powder was obtained by suspending a SPME fiber in the 
headspace of the jar for 1 minute and analyzing for hexamine using the method 
previously described and well as with the GCMS in scan mode.  The mass spectrum 
obtained was consistent with that in the NIST mass spectral database, and the retention 
time was determined to be 7.64 min. 
Figure 4- 14a shows the peak due to hexamine in the m/z 140 XIC for EBC samples 
obtained before and 26 minutes after exposure to hexamine.   Figure 4- 14b shows the 
peak due to hexamine in the m/z 140 XIC for EBV samples obtained before and 30 
minutes after exposure to hexamine from the sample subject.  Note the difference in the 
y-axis for the samples.  Although they both show an increase in signal after exposure to 
hexamine, the signal from the EBV is much higher than that from the EBC.  The 
difference in signal may be partially explained by whether the hexamine is inhaled in 
vapor or aerosol form.  The vapor pressure of hexamine is reported to be 0.0035 mbar,46 
which makes it unlikely that it would be present in the vapor phase.  Aerosol particles of 
hexamine may have been inhaled and then exhaled and collected by the SPME fiber.  
Even a single particle collected in this manner would provide significant signal.  Another 
possible explanation is differences in actual exposure, as the only parameter that was 
controlled was the length of exposure; the actual exposure, breathing rate and depth were 
not easily controlled.  
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A study was then performed to investigate the rate at which hexamine was cleared from 
the body via the breath.  A single EBV sample was again obtained in the morning, and 
the subject poured the hexamine back and forth between plastic beakers.  Breath samples 
were then obtained 1, 30, 61, and 82 minutes after exposure.  Figure 4- 15a shows the 
peak due to hexamine in these samples obtained by monitoring m/z 140 and m/z 42.  
Peak areas were calculated from the XIC of m/z 140.  Figure 4- 15b shows the change in 
peak area versus time after exposure for the samples.  The four samples taken after 
exposure were fit to an exponential decay (R2=0.994), and the half-life was determined to 
be 15.6 minutes.  This provides initial evidence that an RDX precursor can be detected on 
breath, and may remain on breath for a period of time after exposure. 
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Figure 4- 14: (a) Selected window of GC-MS XIC (m/z 140) for breath samples (EBC) 
obtained before (black) and 26 min after (red) exposure to hexamine, (b) Selected 
window of XIC (m/z 140) for breath samples (EBV) obtained before (black) and 30 min 
after (red) exposure to hexamine. (Image originally in color) 
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As 10 minutes of exposure to 10 g of hexamine provides a relatively low exposure level, 
a study was performed to determine if a longer exposure would provide a higher signal 
from the breath samples.  A single EBV breath sample was obtained from a subject in the 
morning.  The subject then poured ~10 g of hexamine between the plastic beakers for 10 
min.  An additional breath sample was collected, and the subject then repeated the 10 min 
hexamine pour on the benchtop.  This procedure was repeated for over 5 hours, resulting 
in 8, 10 min exposures and the collection of 12 breath samples.  All breath samples were 
analyzed using selected ion monitoring of ions at m/z 140 and 42, the molecular ion and 
base peak fragment ion in a mass spectrum of pure hexamine, respectively.  Figure 4- 16 
shows the increase and decay of the area of the hexamine peak in the XIC m/z 140 
chromatograms over time.  The red bars represent the time the subject was exposed to the 
hexamine.  As the subject’s exposure increased, so did the concentration of hexamine on 
the breath.  When exposure ceased, the concentration of hexamine began to decay.  The 
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Figure 4- 15: (a) Selected window of TIC (SIM, m/z 140, 42) from breath samples (EBV) 
of a single subject before and after exposure to hexamine, (b) Exponential decay, R2= 
0.994, of the area of the peak due to hexamine, calculated from the XIC (m/z 140) 
(chromatogram not shown). (Image originally in color) 
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subject in this study was handling only 10 g hexamine in a well-ventilated environment, 
while wearing goggles, nitrile gloves, and a laboratory coat for a combined time of 80 
minutes; it is hypothesized that clandestine synthesis and/or handling of explosives such 
as RDX would involve longer exposures to higher concentrations of the precursors in less 
than ideal environments, allowing for detection on a longer timescale.   
 
 
4-9-2: Field Studies 
In order to demonstrate the real-world ability of this technique to detect exposure to 
industrial chemicals, field studies were performed with six volunteers who participated in 
exercises designed to accurately simulate the clandestine building of devices.  These 
subjects participated in daily activities that included packing, preparing, and transporting 
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Figure 4- 16: Integrated area of GC-MS XIC m/z 140 peak attributed to hexamine at 
RT=7.69 min in chromatograms obtained in SIM mode (m/z 140 and 42) of breath 
samples from a single subject before, during, and after several 10 min exposures (shown 
in red) to hexamine.  Note the increase in hexamine on the breath during exposure and 
the gradual decay after exposure.  Hexamine was still detected on breath 24 hrs after the 
initial exposure. (Image originally in color) 
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the materials.  Breath samples (EBV) were collected from the subjects each morning 
before these activities began, and each afternoon after the simulation was completed.  
Although details of these studies are sensitive and cannot be shared, it was confirmed that 
exposure to these industrial materials can indeed be measured based on signatures 
measured in breath samples. 
 
4-10: Conclusions 
The detection of chemicals for hours after exposure can serve as proof of concept for a 
detection protocol for chemical exposure.  In the data presented here, the presence of key 
chemicals, such as camphor, on the breath of an individual can suggest the prior 
environment of the subject, such as the nail salon.  These data are also important in 
measuring chemical exposures, intentional or accidental, as in the case of a chemical 
spill.  The environment and exposure that occurs in a hardware store are also described, 
which also provides data on the chemicals that could relate an individual to that location.   
Even though these locations may not be of forensic interest, this work demonstrates that 
the prior location of an individual may be determined based on residual signatures of 
VOCs indicative of that location in human breath.  Exposure via ingestion is also 
described in the uptake and elimination of terpenes and terpenoid compounds after oral 
exposure to a mixed terpenoid beverage (lemonade).  The elimination of each compound 
is modeled and fit to an exponential decay in order for comparisons to be made between 
the different compound classes.  The uptake and triphasic decay of α-limonene on breath 
was modeled after consumption of a high concentration lemonade sample.  The effect of 
concentration on the elimination process is also described.  These data support the 
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hypothesis that longer exposures or higher concentration exposures will increase the 
signal of a chemical measured on breath, therefore providing a larger time scale of 
detection. 
The detection of drugs and chemicals used in the synthesis of explosives is also shown, 
allowing for the monitoring of illicit activity.  Field studies presented an opportunity to 
test the breath analysis technique on real-world samples from industrial chemical 
workers, proving the success of the technique and methods that were developed. 
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CHAPTER 5: Conclusions and Thoughts for the Future 
5-1: Conclusions 
5-1-1: Single Particle Aerosol Mass Spectrometry 
This dissertation has presented an evaluation of the performance of Single Particle 
Aerosol Mass Spectrometry (SPAMS) for the detection of active ingredients in over-the-
counter (OTC) drug tablets.  In order to analyze these solid tablets, a sampling vial was 
developed that could create particles from the tablets because of collisions with the vial 
walls or other tablets.  This novel sampling system was coupled easily to SPAMS, and 
benefited from the slight vacuum at the inlet of SPAMS pulling the aerosolized particles 
into the instrument. 
The forensic implications of the current work are vast.  The active ingredients in OTC 
tablets were identified without destroying the identifying marks on the exterior of the 
tablet, and even in the presence of filler materials in the tablets.  The alarm algorithm 
developed for use with SPAMS relies on rules trees alone, and was successful in 
identifying the active ingredients in single ingredient and multi-ingredient tablets, as well 
as a sample containing multiple tablets of different drugs.  The ability for the sampling 
mechanism to be used for in situ sampling out of an original drug bottle is another 
forensic attribute.  This suggests the ease at which a new sample could be presumptively 
screened for the presence of illicit material, without the need for separating each tablet, 
extracting the active ingredient, and testing each one individually.  The active ingredient 
could even be detected from the residual particles left on the walls of a container after it 
had been emptied.  This means that even if a drug sample was discarded in order to 
prevent detection or arrest, identification may still be made. 
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5-1-2: Breath Analysis 
Breath analysis has been developed as a method of detecting chemical exposure based on 
the identification of signature compounds in the breath.  Significant attention was paid to 
developing a method for sampling the breath, testing both exhaled breath condensate 
(EBC) and exhaled breath vapor (EBV) obtained at two different temperatures, using 
GC-MS for analyte detection.  EBV was found to be superior for the analysis of most 
compounds, and thus used for many of the studies.  The importance of the localized 
breathing environment was demonstrated with studies involving chemicals used in a nail 
salon.  The rebreathing of chemicals outgassing from the fingernails was avoided by 
incorporating a respirator cartridge or plastic tubing to remove contaminants from the 
inhaled air, or provide it from a different environment, respectively.  Both methods were 
effective at reducing the contamination by the localized environment. 
Extensive studies were also completed to analyze the breath of a human subject after 
ingestion or inhalation exposure to chemicals, in particular terpenes and terpenoid 
compounds.  An immediate rise in signal, followed by decay back to near baseline over 
several hours was measured for 13 compounds.    This decay was successfully fit to a 
model describing a single exponential uptake and decay.  The effects of different doses of 
compounds on their levels in exhaled breath were then tested by varying the 
concentration of the lemonade consumed in the study.  An increased signal was measured 
for constituents in breath which corresponded to the increase in concentration of each 
compound in the lemonade sample.  Several subjects were sampled, and several 
replicates were obtained from a single subject, providing relatively similar signals over 
time.  When more concentrated forms of lemonade were consumed, the kinetics of the 
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uptake and distribution process of the terpenes and terpenoids could be assessed based on 
levels exhaled in the breath.  Fitting these data to an established model presented 
substantial challenges, but these measurements provide information that can be used to 
assess the exposure of individuals to volatile chemicals. 
Results from this work indicate that the prior location or prior activity of a subject may be 
indicated by the presence of chemicals signatures of a particular environment or activity 
on the breath.  The chemical signatures of volatiles present in a nail salon and hardware 
store were described and detected in breath sampled for several hours after exposure.  
Chemicals indicative of exposure to explosive-related compounds were also detected on 
breath for several hours after even a short exposure.  These results, although preliminary, 
indicate that breath analysis will be a powerful technique for identifying subjects of 
interest when investigating possible criminal and terrorist activities. 
 
5-2: Thoughts for the Future 
5-2-1: Single Particle Aerosol Mass Spectrometry 
Single Particle Aerosol Mass Spectrometry has already been established as a reliable 
detection system capable of identifying biological agents, chemical agents, radiological 
material, and explosives.  Its ability to operate autonomously and sound alarms in the 
presence of a user-defined number of identified particles in time has also been defined.  
The current work has expanded these applications to include the detection of OTC drugs.  
The future of SPAMS shows promise in expanding this drug application also to illicit 
drug testing. 
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The detection of illicit drugs with SPAMS is a natural extension of the current work.  
Forensic laboratories would benefit from this ability.  In the future, illicit drug samples 
could be obtained from the Drug Enforcement Agency and analyzed in small quantities 
using SPAMS.  Alarm files could be created from these data and unknown drug samples 
could be analyzed and characterized using alarm files.  However, cutting agents, filler 
materials, synthetic impurities and byproducts may be present in the ‘real world’ drug 
samples.  These additives are problematic in that they may interfere with the alarm 
identification, but are useful in that they may provide information on the synthetic origin 
of a sample, useful for forensic attribution.1  Therefore, standard cutting agents, 
impurities, and byproducts should also be tested, alarm files created for these compounds, 
and the illicit drug alarm files adjusted to allow identification in these complex matrices.  
Some common cutting materials in illicit drugs include pseudoephedrine, caffeine, 
procaine, baking soda, evaporated milk, and salt, some of which have been previously 
studied with SPAMS. 
Once alarm files are operable, SPAMS could become a powerful tool for drug detection 
in a forensic laboratory.   The National Forensic Laboratory Information System 
(NFLIS), reports that U.S. state and local laboratories analyzed ~1.9 million drug items in 
2006.3 The Census of Publicly Funded Forensic Crime Laboratories reported in 2002 that 
the overwhelming number of requests caused a backlog of 233,000 samples. The fast 
analysis time, as well as the ability to perform in situ analyses of SPAMS would be 
beneficial in reducing this massive caseload. 
Further development of SPAMS may benefit from modification of the solid tablet 
sampling apparatus.  The current device is made from a glass sampling vial; however, the 
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transport efficiency of aerosol particles can be influenced by the charge of the particles 
and interactions of particles with the container.  Thus, a non-glass sample introduction 
device is expected to yield a higher efficiency of particles for SPAMS characterization.  
 
5-2-2: Breath Analysis 
This work was initially approached with a single overarching goal: develop a detection 
scheme that can be used to identify an individual that has been using illicit materials (e.g. 
explosives) based on characteristic compounds in their breath.  This goal was set based 
on the current political climate and needs of the United States military and government to 
protect its citizens, soldiers, and innocent civilians, from terrorist attacks, specifically 
those involving improvised explosive devices (IEDs).  Unfortunately, as fast as science 
and technology evolve on the defense and detection side, so too do they evolve on the 
side of those who wish to use science and technology with malicious intention.  The 
constant battle waged by U.S. government-funded defense science of the 21st century is 
to evolve at a faster pace than the evolution of malicious science.  But evolution speed is 
not the only important factor in such a research project.  A fundamental understanding of 
the processes being studied as well as the analytical thoroughness of the work and its 
place in a larger context are also crucial.  Thus, a technique developed without attention 
to these factors may be doomed to failure in the future if the fundamentals are not also 
studied. 
This work began with a two-fold approach – seek out subjects who may have exposure to 
explosives who can serve to provide initial signatures and proof of concept results to 
determine if breath analysis will be successful at detecting explosive markers on breath, 
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and perform more fundamental studies into what constituents are present in breath, how 
they can best be detected, and what useful results can be obtained from this relatively 
understudied matrix.  This two-fold approach focused on both the speed of evolution and 
the analytical thoroughness in parallel. 
This research has developed and evaluated a breath analysis technique that has been 
proven effective at detecting explosives and explosive-related compounds in human 
breath after exposure to these substances.  The technique uses commercial 
instrumentation which would allow it to be disseminated and used in any lab with a 
standard GC-MS almost instantaneously.  The original goal of the project has therefore 
been met.  But along the way, the dual nature of the scientific approach to this problem 
allowed additional useful information to be discovered from studies involving 
unintentional chemical exposure at nail salons, in hardware stores, and from dietary 
intake, which contributed to the development of a stronger detection method, and added 
more confidence in the results obtained from the exposures to explosives. 
The future of this work must then build upon current results pertinent to explosives 
detection.  In order to advance breath analysis for the detection of explosive makers, 
enhancements to the sampling and detection system should be made to allow for a field-
deployable device.  The constant push for deployable systems requires a smaller size both 
in footprint and weight, low power consumption, higher sensitivity and selectivity, and a 
shorter analysis time.  In order to meet these criteria, significant changes will need to be 
made to the analytical scheme. 
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In order to reduce the size of the device, the detector may need to be changed.  While 
GC-MS is a powerful analytical tool, it does not serve well for miniaturization.  Mini-
GCs have been developed and show remarkable efficiencies and resolving power; 
however, miniaturizing a mass spectrometer has been more challenging.  Although 
miniature mass analyzers have been developed,2-5 it is the remainder of the system, 
including the electronics, power supplies, and vacuum systems that are difficult to 
miniaturize while retaining functionality and the pumping speeds necessary to maintain 
the required vacuum.  GC-GC, and GC-DMS have been successfully miniaturized, and 
may show promise for the future of breath analysis.  Another aspect that will have to be 
miniaturized and incorporated into a hand-held system is the preconcentrating device, 
currently the SPME fiber.  The ideal system would incorporate the preconcentrator in an 
in-line manner, so the sample could be obtained, preconcentrated, and analyzed in a 
single action.  Options for miniaturized preconcentrators are plentiful, as even the 
polymer on the SPME fibers used in the current study could be incorporated in a high-
surface area manner onto different miniaturized structures.  Carbon nanotubes or 
micropore or micropillar technologies are also in development at various laboratories, 
and these technologies may be useful for a future breath analyzer.  The preconcentrator 
may also be adapted to increase the sensitivity and control the selectivity of a future 
instrument by selecting materials that would preferentially absorb the compounds of 
interest.  These preconcentrating materials could perhaps be arranged in a consecutive 
fashion so that multiple materials specific to particular compounds could be used and 
serve as a crude separation step in the analysis. 
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In order to reduce the analysis time, the time of sampling must be reduced.  If this time is 
to be cut, attention must be paid to what part of a breath is sampled. Figure 5- 1 shows a 
typical time capnogram which can be used to describe the respiration pattern of a healthy 
adult.  Carbon dioxide is used as a tracer gas, and the capnogram shows at what points of 
respiration the concentration of CO2 is the highest in the respiratory gas.6   
 
 
The present work sampled breath from all phases of respiration.  It can be seen from the 
figure that the highest concentration of CO2, and therefore other VOCs that diffuse across 
the pulmonary alveolar membrane, occurs during Phase E-3, when the exhalate contains 
primarily alveolar air.  If the time during which a breath sample is obtained is reduced, 
efforts must be made to sample during Phase E-3, and not Phase E-1 or E-2, to ensure the 
sample is collected while the concentrations of VOCs are the highest.  If the sensitivity 
time
PC
O
2
Figure 5- 1: Diagram of a typical time capnogram, which displays the concentration of 
carbon dioxide in respiratory gas. Inhalation is represented by Phase I-0, exhalation is 
represented by Phases E-1, E-2, and E-3, corresponding to exhalation of deadspace (CO2
free) air, a mixture of dead space and alveolar air, and primarily alveolar air, 
respectively.  Adapted from reference 6. 
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and surface area of the preconcentration material is improved, reducing the sampling time 
to this window should still provide enough signal for detection.   Figure 5- 2 shows a 
potential schematic for a future breath analysis device, incorporating all of these 
modifications. 
 
 
This technique should not only be pursued for the detection of explosives on breath.  This 
work demonstrated proof of concept data for the use of breath analysis for detecting the 
prior location of an individual based upon chemical signatures of breath constituents; 
however, this information also demonstrates a non-invasive way to monitor chemical 
exposure.  Another promising avenue of research may be found in the oral exposure 
studies that were pursued.  This presents breath analysis as a method for assessing the 
dynamics of the metabolic processes in an individual.  The ability to visualize the 
absorption and uptake phase of exposure would also provide valuable pharmacokinetic 
Mouthpiece Preconcentration Separation (GC?) Detection (MS?)
Exhaled Breath
Figure 5- 2: Diagram of possible handheld breath analyzer.  Breath is exhaled into the 
mouthpiece where it passes into a thermally controlled preconcentration region.  After a 
predetermined period of time, the temperature of the preconcentrator is quickly ramped, 
desorbing the analytes of interest and allowing them to pass into the separation region, 
possibly a miniaturized GC where separation occurs.  The eluent then passes into a 
detection system, possibly a miniaturized MS where the analytes are identified and a 
signal is reported to the user (signal digitization not shown). 
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data if similar behaviors were measured for other orally ingested drugs or compounds.  
Using breath to monitor intravenous exposure to drugs or chemicals would also present 
potential applications for breath analysis, but would require subjects to already be 
undergoing medical treatment, and may be difficult to justify to an Institutional Review 
Board. 
Several avenues of research should be pursued to improve the breath research field.  
There is no accepted and standardized method for breath collection and analysis.  This 
makes it difficult to compare results with those of another laboratory using a different 
system.  It is hoped that the future will hold some standardization practices and 
recommendations.  This should include the temperature and time of breath collection, 
flow rate of breathing, type of sampling (alveolar versus total air), material of the 
collection device, and preconcentration methods.  The field would also benefit from the 
existence of a breath reference standard.  Figures of merit and analytical method 
performance are difficult to establish without a standard breath, and no two human 
breaths are exactly alike.  Although an EBC standard would not be ideal for experiments 
involving the collection of EBV, condensate may be a more reliable standard, as a real 
breath would contain a mixture of vapor and suspended aerosols that would not be 
amenable to storage, and condensate could be refrigerated or frozen for stability.  In 
whatever form, this standard would have to contain a complex matrix similar to that of 
human breath, resulting in hundreds of compounds being necessary.  Once a standard is 
developed it would be a logical step to spike this breath sample with target compounds to 
determine more reliable limits of detection.  Such fundamental studies would allow data 
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to be more easily compared across research groups, and would improve the possibility of 
successful applications of breath analysis. 
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APPENDIX A – Additional Rules Trees for Drug Identification Using SPAMS 
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Figure A- 1: Rules tree for classification of pseudoephedrine.  The mass vectors probed 
at each branch division are shown, with ‘Y’ indicating a positive response and ‘N’ 
indicating a negative response.  Circles labeled ‘PSE’ indicate a positive identification 
for pseudoephedrine; circles labeled ‘Null’ indicate a negative response. 
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Figure A- 2: Rules tree for classification of Coricidin.  The mass vectors probed at each 
branch division are shown, with ‘Y’ indicating a positive response and ‘N’ indicating a 
negative response.  Circles labeled ‘C’ indicate a positive identification for Coricidin; 
circles labeled ‘Null’ indicate a negative response. 
 
All Particles
m/z
320,321
m/z
286
m/z
286
m/z
-195
Null
Y
Y
Y
Y
N
N
N
m/z
-97
Y
G
m/z
-178
N
Null
Null
N
C
Y
N
m/z
-178
Null
N
m/z
86
C
m/z
-178
Y
Null
N
Y
Null
Y C
m/z
-195
Y
N
Y
CNull
N
Null N
Y
m/z
-79
Null N
m/z
-98
Null Y
N
Null
N
Y
C
Null Y
N
Null
N
Y
C
m/z
-133
m/z
-195
m/z
-178
m/z
-321
m/z
-97
m/z
-35
Y
Y
N
N
All Particles
m/z
280
m/z
245
m/z
217
m/z
245
m/z
217
Null
Null
Null
Y
Y
Y
Y
Y
N
N
N
N
N
Lm/z
266
Y
Lm/z
266
Y
L
m/z
266
Y
Null
N
Null
N
Null
N
Figure A- 3: Rules tree for classification of loratadine.  The mass vectors probed at each 
branch division are shown, with ‘Y’ indicating a positive response and ‘N’ indicating a 
negative response.  Circles labeled ‘L’ indicate a positive identification for loratadine; 
circles labeled ‘Null’ indicate a negative response. 
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Figure A- 4: Rules tree for classification of acetaminophen.  The mass vectors probed at 
each branch division are shown, with ‘Y’ indicating a positive response and ‘N’ 
indicating a negative response.  Circles labeled ‘Ac’ indicate a positive identification for 
acetaminophen; circles labeled ‘Null’ indicate a negative response. 
Figure A- 5: Rules tree for classification of dextromethorphan.  The mass vectors probed 
at each branch division are shown, with ‘Y’ indicating a positive response and ‘N’ 
indicating a negative response.  Circles labeled ‘D’ indicate a positive identification for 
dextromethorphan; circles labeled ‘Null’ indicate a negative response. 
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Figure A- 6: Rules tree for classification of aspirin.  The mass vectors probed at each 
branch division are shown, with ‘Y’ indicating a positive response and ‘N’ indicating a 
negative response.  Circles labeled ‘A’ indicate a positive identification for aspirin; 
circles labeled ‘Null’ indicate a negative response. 
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Figure A- 7: Rules tree for classification of phenylephrine.  The mass vectors probed at 
each branch division are shown, with ‘Y’ indicating a positive response and ‘N’ 
indicating a negative response.  Circles labeled ‘PE’ indicate a positive identification for 
phenylephrine; circles labeled ‘Null’ indicate a negative response. 
Figure A- 8: Rules tree for classification of guaifenesin.  The mass vectors probed at 
each branch division are shown, with ‘Y’ indicating a positive response and ‘N’ 
indicating a negative response.  Circles labeled ‘G’ indicate a positive identification for 
guaifenesin; circles labeled ‘Null’ indicate a negative response. 
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APPENDIX B - Additional Terpene and Terpenoid Data from Lemonade Consumption 
 
Included herein are the data obtained from several subjects after consumption of original, 
concentrated, and Mediterranean lemonade.  Thirteen terpenes and terpenoid compounds 
were monitored; peaks due to each compound in the TIC of each breath sample were 
integrated, and the area plotted versus time after lemonade consumption.  The resulting 
curves were fit to Equation 4-1, describing the rise and decay in each compound.  See 
Chapter 4 for additional information. 
20
15
10
5
Pe
ak
 A
re
a x
10
6
(a
.u
.)
120010008006004002000
Time after Consumption (min)  
  
Figure B- 1: Integrated area of the peak attributed to α-limonene in chromatograms 
obtained from the breath of subject A on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B- 1
for fit parameters.  
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Figure B- 2: Integrated area of the peak attributed to α-limonene in chromatograms 
obtained from the breath of subject A on the second day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B- 1 for fit parameters. 
Figure B- 3: Integrated area of the peak attributed to α-limonene in chromatograms 
obtained from the breath of subject A on the third day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B- 1
for fit parameters. 
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 Figure B- 4: Integrated area of the peak attributed to α-limonene in chromatograms 
obtained from the breath of subject A on the fourth day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B- 1 for fit parameters.  
Figure B- 5: Integrated area of the peak attributed to α-limonene in chromatograms 
obtained from the breath of subject A on the fifth day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1). See Table B- 1
for fit parameters. 
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Figure B- 6: Integrated area of the peak attributed to 4-terpineol in chromatograms 
obtained from the breath of subject A on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B- 1
for fit parameters. 
500
400
300
200
100P
ea
k 
A
re
a 
x1
03
 (a
.u
.)
7006005004003002001000
Time after Consumption (min)  
Figure B- 7: Integrated area of the peak attributed to 4-terpineol in chromatograms 
obtained from the breath of subject A on the second day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B- 1 for fit parameters. 
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Figure B- 8: Integrated area of the peak attributed to 4-terpineol in chromatograms 
obtained from the breath of subject A on the third day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B- 1
for fit parameters. 
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Figure B- 9: Integrated area of the peak attributed to 4-terpineol in chromatograms 
obtained from the breath of subject A on the fourth day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B- 1 for fit parameters. 
   
186 
 
500
400
300
200
100Pe
ak
 A
re
a 
x1
03
 (a
.u
.)
400300200100
Time after Consumption (min)  
 
250
200
150
100
50
Pe
ak
 A
re
a 
x1
03
 (a
.u
.)
400300200100
Time after Consumption (min)  
  
Figure B- 10: Integrated area of the peak attributed to 4-terpineol in chromatograms 
obtained from the breath of subject A on the fifth day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1). See Table B-1 
for fit parameters. 
Figure B- 11: Integrated area of the peak attributed to α-terpineol in chromatograms 
obtained from the breath of subject A on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 12: Integrated area of the peak attributed to α-terpineol in chromatograms 
obtained from the breath of subject A on the second day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
Figure B- 13: Integrated area of the peak attributed to α-terpineol in chromatograms 
obtained from the breath of subject A on the third day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 14: Integrated area of the peak attributed to α-terpineol in chromatograms 
obtained from the breath of subject A on the fourth day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 15: Integrated area of the peak attributed to α-terpineol in chromatograms 
obtained from the breath of subject A on the fifth day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 16: Integrated area of the peak attributed to α-terpinene in chromatograms 
obtained from the breath of subject A on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 17: Integrated area of the peak attributed to α-terpinene in chromatograms 
obtained from the breath of subject A on the second day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 18: Integrated area of the peak attributed to α-terpinene in chromatograms 
obtained from the breath of subject A on the third day of original lemonade consumption.    
See Table B-1 for fit parameters. 
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Figure B- 19: Integrated area of the peak attributed to α-terpinene in chromatograms 
obtained from the breath of subject A on the fourth day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 20: Integrated area of the peak attributed to α-terpinene in chromatograms 
obtained from the breath of subject A on the fifth day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 21: Integrated area of the peak attributed to γ-terpinene in chromatograms 
obtained from the breath of subject A on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 22: Integrated area of the peak attributed to γ-terpinene in chromatograms 
obtained from the breath of subject A on the second day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 23: Integrated area of the peak attributed to γ-terpinene in chromatograms 
obtained from the breath of subject A on the third day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 24: Integrated area of the peak attributed to γ-terpinene in chromatograms 
obtained from the breath of subject A on the fourth day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 25: Integrated area of the peak attributed to γ-terpinene in chromatograms 
obtained from the breath of subject A on the fifth day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 26: Integrated area of the peak attributed to terpinolene in chromatograms 
obtained from the breath of subject A on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 27: Integrated area of the peak attributed to terpinolene in chromatograms 
obtained from the breath of subject A on the second day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 28: Integrated area of the peak attributed to terpinolene in chromatograms 
obtained from the breath of subject A on the third day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1). See Table B-1 
for fit parameters. 
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Figure B- 29: Integrated area of the peak attributed to terpinolene in chromatograms 
obtained from the breath of subject A on the fourth day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 30: Integrated area of the peak attributed to terpinolene in chromatograms 
obtained from the breath of subject A on the fifth day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 31: Integrated area of the peak attributed to camphene in chromatograms 
obtained from the breath of subject A on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 32: Integrated area of the peak attributed to camphene in chromatograms 
obtained from the breath of subject A on the second day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 33: Integrated area of the peak attributed to camphene in chromatograms 
obtained from the breath of subject A on the third day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
   
198 
 
  
3500
3000
2500
2000
1500
1000
500
0
Pe
ak
 A
re
a 
(a
.u
.)
1400120010008006004002000
Time after Consumption (min)  
Figure B- 34: Integrated area of the peak attributed to camphene in chromatograms 
obtained from the breath of subject A on the fourth day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 35: Integrated area of the peak attributed to camphene in chromatograms 
obtained from the breath of subject A on the fifth day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 36: Integrated area of the peak attributed to p-cymene in chromatograms 
obtained from the breath of subject A on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1). See Table B-1 
for fit parameters. 
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Figure B- 37: Integrated area of the peak attributed to p-cymene in chromatograms 
obtained from the breath of subject A on the second day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 38: Integrated area of the peak attributed to p-cymene in chromatograms 
obtained from the breath of subject A on the third day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 39: Integrated area of the peak attributed to p-cymene in chromatograms 
obtained from the breath of subject A on the fourth day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 40: Integrated area of the peak attributed to p-cymene in chromatograms 
obtained from the breath of subject A on the fifth day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1). See Table B-1 
for fit parameters. 
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Figure B- 41: Integrated area of the peak attributed to α-pinene in chromatograms 
obtained from the breath of subject A on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1). See Table B-1 
for fit parameters. 
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Figure B- 42: Integrated area of the peak attributed to α-pinene in chromatograms 
obtained from the breath of subject A on the second day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 43: Integrated area of the peak attributed to α-pinene in chromatograms 
obtained from the breath of subject A on the third day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 44: Integrated area of the peak attributed to α-pinene in chromatograms 
obtained from the breath of subject A on the fourth day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 45: Integrated area of the peak attributed to α-pinene in chromatograms 
obtained from the breath of subject A on the fifth day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 46: Integrated area of the peak attributed to β-pinene in chromatograms 
obtained from the breath of subject A on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1). See Table B-1 
for fit parameters. 
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Figure B- 47: Integrated area of the peak attributed to β-pinene in chromatograms 
obtained from the breath of subject A on the second day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 48: Integrated area of the peak attributed to β-pinene in chromatograms 
obtained from the breath of subject A on the third day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
 
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
Pe
ak
 A
re
a 
x1
06
 (a
.u
.)
1400120010008006004002000
Time after Consumption (min)  
Figure B- 49: Integrated area of the peak attributed to β-pinene in chromatograms 
obtained from the breath of subject A on the fourth day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
   
206 
 
  
1.4
1.2
1.0
0.8
0.6
0.4
Pe
ak
 A
re
a 
x1
06
 (a
.u
.)
400300200100
Time after Consumption (min)  
Figure B- 50: Integrated area of the peak attributed to β-pinene in chromatograms 
obtained from the breath of subject A on the fifth day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 51: Integrated area of the peak attributed to β-phellandrene in chromatograms 
obtained from the breath of subject A on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 52: Integrated area of the peak attributed to β-phellandrene in chromatograms 
obtained from the breath of subject A on the second day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 53: Integrated area of the peak attributed to β-phellandrene in chromatograms 
obtained from the breath of subject A on the third day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 54: Integrated area of the peak attributed to β-phellandrene in chromatograms 
obtained from the breath of subject A on the fourth day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 55: Integrated area of the peak attributed to β-phellandrene in chromatograms 
obtained from the breath of subject A on the fifth day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 56: Integrated area of the peak attributed to α-thujene in chromatograms 
obtained from the breath of subject A on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 57: Integrated area of the peak attributed to α-thujene in chromatograms 
obtained from the breath of subject A on the second day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 58: Integrated area of the peak attributed to α-thujene in chromatograms 
obtained from the breath of subject A on the third day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 59: Integrated area of the peak attributed to α-thujene in chromatograms 
obtained from the breath of subject A on the fourth day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 60: Integrated area of the peak attributed to α-thujene in chromatograms 
obtained from the breath of subject A on the fifth day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 61: Integrated area of the peak attributed to β-myrcene in chromatograms 
obtained from the breath of subject A on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 62: Integrated area of the peak attributed to β-myrcene in chromatograms 
obtained from the breath of subject A on the second day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 63: Integrated area of the peak attributed to β-myrcene in chromatograms 
obtained from the breath of subject A on the third day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 64: Integrated area of the peak attributed to β-myrcene in chromatograms 
obtained from the breath of subject A on the fourth day of original lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 65: Integrated area of the peak attributed to β-myrcene in chromatograms 
obtained from the breath of subject A on the fifth day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 66: Integrated area of the peak attributed to α-limonene in chromatograms 
obtained from the breath of subject B on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 67: Integrated area of the peak attributed to 4-terpineol in chromatograms 
obtained from the breath of subject B on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 68: Integrated area of the peak attributed to α-terpineol in chromatograms 
obtained from the breath of subject B on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 69: Integrated area of the peak attributed to terpinolene in chromatograms 
obtained from the breath of subject B on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 70: Integrated area of the peak attributed to α-terpinene in chromatograms 
obtained from the breath of subject B on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 71: Integrated area of the peak attributed to γ-terpinene in chromatograms 
obtained from the breath of subject B on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1). See Table B-1 
for fit parameters. 
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Figure B- 72: Integrated area of the peak attributed to camphene in chromatograms 
obtained from the breath of subject B on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 73: Integrated area of the peak attributed to p-cymene in chromatograms 
obtained from the breath of subject B on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 74: Integrated area of the peak attributed to α-pinene in chromatograms 
obtained from the breath of subject B on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 75: Integrated area of the peak attributed to β-pinene in chromatograms 
obtained from the breath of subject B on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 76: Integrated area of the peak attributed to β-phellandrene in chromatograms 
obtained from the breath of subject B on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 77: Integrated area of the peak attributed to α-thujene in chromatograms 
obtained from the breath of subject B on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1). See Table B-1 
for fit parameters. 
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Figure B- 78: Integrated area of the peak attributed to β-myrcene in chromatograms 
obtained from the breath of subject B on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 79: Integrated area of the peak attributed to α-limonene in chromatograms 
obtained from the breath of subject C on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 80: Integrated area of the peak attributed to 4-terpineol in chromatograms 
obtained from the breath of subject B on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
Figure B- 81: Integrated area of the peak attributed to α-terpineol in chromatograms 
obtained from the breath of subject C on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 82: Integrated area of the peak attributed to terpinolene in chromatograms 
obtained from the breath of subject C on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
 
Figure B- 83: Integrated area of the peak attributed to α-terpinene in chromatograms 
obtained from the breath of subject C on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1). See Table B-1 
for fit parameters. 
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Figure B- 84: Integrated area of the peak attributed to γ-terpinene in chromatograms 
obtained from the breath of subject C on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1). See Table B-1 
for fit parameters. 
Figure B- 85: Integrated area of the peak attributed to camphene in chromatograms 
obtained from the breath of subject C on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1). See Table B-1 
for fit parameters. 
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Figure B- 86: Integrated area of the peak attributed to p-cymene in chromatograms 
obtained from the breath of subject C on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
 
Figure B- 87: Integrated area of the peak attributed to α-pinene in chromatograms 
obtained from the breath of subject C on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
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Figure B- 88: Integrated area of the peak attributed to β-pinene in chromatograms 
obtained from the breath of subject C on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
Figure B- 89: Integrated area of the peak attributed to β-phellandrene in chromatograms 
obtained from the breath of subject C on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1). See Table B-1 
for fit parameters. 
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Figure B- 90: Integrated area of the peak attributed to α-thujene in chromatograms 
obtained from the breath of subject C on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
Figure B- 91: Integrated area of the peak attributed to β-myrcene in chromatograms 
obtained from the breath of subject C on the first day of original lemonade consumption.  
The data has been fit with an exponential rise and decay (Equation 4-1).  See Table B-1 
for fit parameters. 
   
227 
 
25
20
15
10
5Pe
ak
 A
re
a 
x1
06
  (
a.
u.
)
150010005000
Time after Consumption (min)  
500
400
300
200
100Pe
ak
 A
re
a 
x1
03
  (
a.
u.
)
1400120010008006004002000
Time after Consumption (min)  
  
Figure B- 92: Integrated area of the peak attributed to α-limonene in chromatograms 
obtained from the breath of subject A on the first day of concentrated lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
Figure B- 93: Integrated area of the peak attributed to 4-terpineol in chromatograms 
obtained from the breath of subject A on the first day of concentrated lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 94: Integrated area of the peak attributed to α-terpineol in chromatograms 
obtained from the breath of subject A on the first day of concentrated lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
Figure B- 95: Integrated area of the peak attributed to terpinolene  in chromatograms 
obtained from the breath of subject A on the first day of concentrated lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 96: Integrated area of the peak attributed to α-terpinene in chromatograms 
obtained from the breath of subject A on the first day of concentrated lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
Figure B- 97: Integrated area of the peak attributed to γ-terpinene in chromatograms 
obtained from the breath of subject A on the first day of concentrated lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
   
230 
 
80
70
60
50
40
30
20
Pe
ak
 A
re
a 
x1
03
  (
a.
u.
)
150010005000
Time after Consumption (min)  
1.2
1.0
0.8
0.6
0.4
0.2
Pe
ak
 A
re
a 
x1
06
  (
a.
u.
)
1400120010008006004002000
Time after Consumption (min)  
  
Figure B- 98: Integrated area of the peak attributed to camphene in chromatograms 
obtained from the breath of subject A on the first day of concentrated lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
Figure B- 99: Integrated area of the peak attributed to p-cymene in chromatograms 
obtained from the breath of subject A on the first day of concentrated lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 100: Integrated area of the peak attributed to α-pinene in chromatograms 
obtained from the breath of subject A on the first day of concentrated lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
Figure B- 101: Integrated area of the peak attributed to β-pinene in chromatograms 
obtained from the breath of subject A on the first day of concentrated lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 102: Integrated area of the peak attributed to β-phellandrene in 
chromatograms obtained from the breath of subject A on the first day of concentrated 
lemonade consumption.  The data has been fit with an exponential rise and decay 
(Equation 4-1). See Table B-1 for fit parameters. 
Figure B- 103: Integrated area of the peak attributed to α-thujene in chromatograms 
obtained from the breath of subject A on the first day of concentrated lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
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Figure B- 104: Integrated area of the peak attributed to β-myrcene in chromatograms 
obtained from the breath of subject A on the first day of concentrated lemonade 
consumption.  The data has been fit with an exponential rise and decay (Equation 4-1).  
See Table B-1 for fit parameters. 
 
Figure B- 105: Integrated area of the peak attributed to α-limonene in chromatograms 
obtained from the breath of subject A on the first day of Mediterranean lemonade 
consumption. 
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Figure B- 106: Integrated area of the peak attributed to 4-terpineol in chromatograms 
obtained from the breath of subject an on the first day of Mediterranean lemonade 
consumption. 
Figure B- 107: Integrated area of the peak attributed to α-terpineol in chromatograms 
obtained from the breath of subject A on the first day of Mediterranean lemonade 
consumption. 
500
400
300
200
100P
ea
k 
A
re
a 
x1
03
  (
a.
u.
)
16001400120010008006004002000
Time after Consumption (min)
400
300
200
100Pe
ak
 A
re
a 
x1
03
  (
a.
u.
)
16001400120010008006004002000
Time after Consumption (min)
   
235 
 
 
 
  
Figure B- 108: Integrated area of the peak attributed to terpinolene in chromatograms 
obtained from the breath of subject A on the first day of Mediterranean lemonade 
consumption. 
Figure B- 109: Integrated area of the peak attributed to α-terpinene in chromatograms 
obtained from the breath of subject A on the first day of Mediterranean lemonade 
consumption. 
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Figure B- 110: Integrated area of the peak attributed to γ-terpinene in chromatograms 
obtained from the breath of subject A on the first day of Mediterranean lemonade 
consumption. 
 
 
 
 
Figure B- 111: Integrated area of the peak attributed to camphene in chromatograms 
obtained from the breath of subject A on the first day of Mediterranean lemonade 
consumption. 
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Figure B- 112: Integrated area of the peak attributed to p-cymene in chromatograms 
obtained from the breath of subject A on the first day of Mediterranean lemonade 
consumption. 
Figure B- 113: Integrated area of the peak attributed to α-pinene in chromatograms 
obtained from the breath of subject A on the first day of Mediterranean lemonade 
consumption. 
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Figure B- 114: Integrated area of the peak attributed to β-pinene in chromatograms 
obtained from the breath of subject A on the first day of Mediterranean lemonade 
consumption. 
Figure B- 115: Integrated area of the peak attributed to β-phellandrene in 
chromatograms obtained from the breath of subject A on the first day of Mediterranean 
lemonade consumption. 
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Figure B- 116: Integrated area of the peak attributed to α-thujene in chromatograms 
obtained from the breath of subject A on the first day of Mediterranean lemonade 
consumption. 
Figure B- 117: Integrated area of the peak attributed to β-myrcene in chromatograms 
obtained from the breath of subject A on the first day of Mediterranean lemonade 
consumption. 
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Subject A
Original
First
Subject A
Original
Second
Subject A
Original
Third
Subject A
Original
Fourth
Subject A
Original
Fifth
Subject B
Original
First
Subject C
Original
First
Subject A
Concentrated
First
α-limonene yo 544310 1021000 661590 491670 1089600 3790200 874680 424470
A1 21034000 16377000 10373000 11691000 11822000 109160000 16273000 34604000
tau1 81.564 108.4 74.521 85.105 83.484 12.349 31.422 114.03
tauka 0.2 0.2 0.2 0.2 0.2 0.2 0.2 5
4-terpineol yo 51083 80935 53062 50923 49537 163310 125720 65881
A1 317930 517310 703930 552660 567080 634550 625420 601010
tau1 23.896 9.2733 9.1991 9.9467 8.9428 13.349 15.902 18.076
tauka 0.000001 0.000001 0.000001 0.000001 0.000001 0.000001 1E-07 0.001
α-terpineol yo 56696 87705 88101 85451 89343 170800 154040 77308
A1 252460 767850 1465000 816210 1013100 753710 1212800 542880
tau1 15.268 6.6357 7.985 7.5243 5.6561 12.365 10.641 16.807
tauka 0.01 0.000001 0.000001 0.000001 1 0.01 1E-07 0.2
terpineolene yo 64617 69237 68144 58483 64372 216010 167190 50995
A1 209800 204870 169450 16317 115580 1652000 536590 356460
tau1 78.108 91.896 38.416 31.751 40.248 15.107 34.455 99.715
tauka 0.001 0.001 0.001 0.001 0.001 0.001 0.001 5
α-terpinene yo 36958 51700 46303 44039 44389 110570 67407 35795
A1 131740 99934 68834 14414 41738 1009800 154460 325180
tau1 68.593 103.75 60.344 18.312 50.149 10.478 27.205 106.02
tauka 0.1 0.1 0.1 0.1 0.1 0.1 0.1 5
γ-terpinene yo 141540 193150 139900 129970 216150 507560 176230 115050
A1 3274900 2588000 1674100 1945500 2033800 20981000 2854200 5411600
tau1 63.624 78.745 54.905 60.109 55.548 10.638 24.828 99.381
tauka 0.001 0.001 0.001 0.001 0.001 0.001 0.001 5
Table B- 1: Fit Parameters for the terpenes and terpenoid compounds monitored in 
breath.  The data after lemonade consumption were fit according to Equation 4-1. 
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Table B- 1 (cont’d). 
 
Subject A
Original
First
Subject A
Original
Second
Subject A
Original
Third
Subject A
Original
Fourth
Subject A
Original
Fifth
Subject B
Original
First
Subject C
Original
First
Subject A
Concentrated
First
camphene yo 17514 484.92 189.55 -53.236 -459.81 38904 34352 20197
A1 47217 6917.7 3083.4 3642.6 3792.7 149140 44602 127360
tau1 110.64 143.19 206.24 185.91 349.4 11.6 36.913 102.43
tauka 1.5 1.5 1.5 1.5 1.5 1.5 1.5 20
p-cymene yo 82408 82563 68480 47475 -370770 261000 150230 199970
A1 557820 408760 211550 348540 718880 1936800 589630 1785100
tau1 137.65 250.73 153.15 202.34 1032.7 26.01 58.287 125.94
tauka 1 1 1 1 1 1 1 20
α-pinene yo 93362 189450 137520 101760 103430 213250 148260 179430
A1 867400 942450 409330 446750 377030 3934900 480570 3026700
tau1 98.043 128.98 110.21 137.08 171.21 8.8082 45.438 84.163
tauka 2 2 2 2 2 2 2 20
β-pinene yo 252950 388570 310790 246720 336370 443750 326810 107140
A1 4671600 3229900 1156400 1533400 1178800 21566000 1442200 8452400
tau1 68.442 136.25 85.069 139.58 161.39 9.1774 35.176 132.87
tauka 1.5 1.5 1.5 1.5 1.5 1.5 1.5 5
β-phellandrene yo 35710 26337 46418 25998 62417 69373 48093 49434
A1 24723 29399 4273.9 13625 -21769 89102 1383.9 102570
tau1 38.561 207.12 479.66 144.13 1107.3 1.6004 9.1121 62.239
tauka 0.1 0.1 0.1 0.1 0.1 0.1 0.1 10
α-thujene yo 25208 31416 30556 29669 30051 42818 35280 33511
A1 1.1101 60926 21087 15648 13470 404250 23081 268620
tau1 61.854 131.9 82.485 99.071 54.184 8.4933 17.735 106.93
tauka 1 1 1 1 1 1 1 5
β-myrcene yo 46828 63287 59473 49877 63215 115540 57665 54613
A1 572360 400240 215380 196240 255320 3555100 331510 1098000
tau1 69.242 120.56 66.424 81.517 68.671 9.3712 29.104 88.277
tauka 0.1 0.1 0.1 0.1 0.1 0.1 0.1 10
